<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:ao="http://www.w3.org/ns/oa#"
   xmlns:dailymed="http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/"
   xmlns:dct="http://purl.org/dc/terms/"
   xmlns:dikbD2R="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/"
   xmlns:domeo="http://www.w3.org/ns/domeo#"
   xmlns:foafx="http://xmlns.com/foaf/0.1/"
   xmlns:pav="http://purl.org/pav/"
   xmlns:permissions="http://vocab.deri.ie/cpo#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns:sio="http://semanticscience.org/resource/"
>
  <rdf:Description rdf:about="urn:domeoclient:uuid:984705CF-6418-4362-AA0D-0A0DD15065D1">
    <pav:createdOn>2014-07-15 14:03:06 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:984705CF-6418-4362-AA0D-0A0DD15065D1"/>
    <ao:exact> risperidone</ao:exact>
    <ao:prefix>The clinical effect from</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone [see 12 CLINICAL PHARMACOLOGY]. Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D3E8CE76-944F-40F2-AF66-51EBF76481A9">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <rdfs:label>carbamazepine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1FD70F7A-986E-48F8-93F4-DA3377C3E107">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:2C25A7F3-8A42-4060-A64C-5C2AB24D4675</pav:lineageUri>
    <pav:lastSavedOn>2014-07-09 13:39:37 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-09 13:36:31 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:80304B91-FB8B-4EF5-87EC-80F59A689F2A</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:4CE762A1-3B91-4B51-861E-7CFEE91439CF"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3F6F9929-F258-49DD-AEE9-BEC5C27775EF">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <ao:prefix> 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.</ao:suffix>
    <ao:exact>fluconazole</ao:exact>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-16 15:40:36 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3F6F9929-F258-49DD-AEE9-BEC5C27775EF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D166220A-E6E2-4ECF-B03B-AF573EEAE31B">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix> (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations. Therefore, the slight decrease of sildenafil exposure in the presence of epoprostenol is not considered </ao:suffix>
    <ao:prefix>The mean reduction of </ao:prefix>
    <pav:createdOn>2014-07-10 11:20:24 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D166220A-E6E2-4ECF-B03B-AF573EEAE31B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>sildenafil</ao:exact>
    <domeo:uuid>D166220A-E6E2-4ECF-B03B-AF573EEAE31B</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB645A75-8C80-4DBE-A619-BDD15DFC4DF3">
    <pav:lineageUri>urn:domeoserver:annotation:389FC9FC-6B0A-4B9D-BFD4-2042659879DF</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:719101C7-4FC8-4E56-81FA-58D7AC021659"/>
    <pav:createdOn>2014-07-16 15:40:24 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-16 15:40:55 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E3DA2E5E-FC19-4C22-AF6C-A9CB4B450554</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13602CFC-088D-4008-B42C-EA497E316CB4">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:13602CFC-088D-4008-B42C-EA497E316CB4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <pav:createdOn>2014-07-16 10:22:41 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:455E5E9F-232E-451B-8C43-9687045AD008">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:455E5E9F-232E-451B-8C43-9687045AD008"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-26.txt.html</ao:hasSource>
    <ao:suffix> AUC and Cmax were determined before and after the administration of fluconazole 200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks</ao:suffix>
    <ao:exact>Cyclosporine</ao:exact>
    <pav:createdOn>2014-07-18 13:51:09 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>455E5E9F-232E-451B-8C43-9687045AD008</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0FE2C318-FF67-459F-9092-2EF6E04B1472">
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D1D630F4-743B-425E-8FB2-C96DB1D59EEE"/>
    <pav:lastSavedOn>2014-07-17 15:56:11 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:C94BECCE-E3E9-4B70-AC23-F715B9D3EEFF</pav:lineageUri>
    <pav:createdOn>2014-07-17 15:56:08 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:4E57D817-C3D5-47E5-AECC-169C5A1EF60D</pav:previousVersion>
    <ao:body rdf:nodeID="Nb7458e4454314e1d99e42e0974e37829"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:96BAB4C7-6F7A-4EBA-BAC1-134F746F11FA</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:6DBCB873-26F3-4E6A-9BD4-311369B43736">
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:701FB70F-31F1-4E69-B54F-77820E603E4C"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:7A5B87F1-0D90-49BD-B71F-1710FF095850"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:A5A2521E-A463-45F1-BFC8-4843561F5EFD"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9AA0507C-281E-45C8-9719-03E66F12C069</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:4BDAA007-22DC-4E1D-8BB3-46728661C2F1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-18 17:05:18 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:5280B7DB-AA4C-46FE-AB43-85E58C828264"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0216B801-6401-4E8A-B678-5222EA6AA098"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:95BD0C2B-0FA9-43F6-AC62-608DC7F301DE"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:previousVersion>urn:domeoclient:uuid:E65FF29A-8FE7-4D0E-A93C-4DA8136F4956</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:CFF4DD39-5FB5-46B5-9868-D724A30FB42C"/>
    <pav:createdOn>2014-07-18 14:02:36 -0700</pav:createdOn>
    <permissions:permissions rdf:nodeID="N0daa61040cdc45c8ac598b175b7a935e"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3E83240-5B88-4E8A-9F52-DF6E195AAF5D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:979284A9-B754-4E29-92E7-8BFA59BFC91A</pav:lineageUri>
    <pav:lastSavedOn>2014-07-18 18:26:41 -0400</pav:lastSavedOn>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:94A95C57-5A20-472B-87AE-DD634374AADD"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-18 15:24:32 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:body rdf:nodeID="Na24e8708a58d43cb8b5041c765dc28d9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75978B88-8F19-4550-921C-BCAB17F30E80">
    <domeo:uuid></domeo:uuid>
    <ao:exact>Risperidone</ao:exact>
    <ao:prefix>Excretion: </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-15 14:17:00 -0700</pav:createdOn>
    <ao:suffix> and its metabolites are eliminated via the urine and, to a much lesser extent, via the feces. As illustrated by a mass balance study of a single 1 mg oral dose of 14C-risperidone administered as solution to three healthy male volunteers, total recovery </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:75978B88-8F19-4550-921C-BCAB17F30E80"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC71B917-C3C7-4475-B462-6525E8CEF601">
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdOn>2014-07-15 14:14:54 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:14470CEA-E989-4566-A704-AC9CEFD39B6E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A216BADD-014F-4644-9641-24F03B40257D">
    <pav:createdOn>2014-07-16 10:21:21 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:EABEEB7D-C8D4-4F28-AC7D-F8B20016A4DB</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:8A01C077-1FE2-4DD4-96E1-C475228628A9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-16 10:23:07 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:66EB6B71-8574-4EC7-B3B5-BA3D58493C78">
    <ao:exact>procyclidine</ao:exact>
    <ao:prefix> (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of </ao:prefix>
    <domeo:uuid>66EB6B71-8574-4EC7-B3B5-BA3D58493C78</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-50.txt.html</ao:hasSource>
    <ao:suffix> (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state. If anticholinergic effects are seen, the dose of procyclidine should be reduced.</ao:suffix>
    <pav:createdOn>2014-07-18 14:20:23 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:66EB6B71-8574-4EC7-B3B5-BA3D58493C78"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A77ED33E-10B2-43BE-8BC6-D5F14E2FE208">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-15 14:14:23 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:9AA1C371-A08E-41E5-AC8E-B7624054B9FF"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52C23FEF-CB29-459B-934E-EDA40F63DD1E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:2C25A7F3-8A42-4060-A64C-5C2AB24D4675</pav:lineageUri>
    <pav:lastSavedOn>2014-07-09 13:39:37 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:80304B91-FB8B-4EF5-87EC-80F59A689F2A</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E4FC0A1A-8003-4267-9EC8-5C1F467D2F5F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-09 13:36:40 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196">
    <ao:item rdf:resource="urn:domeoclient:uuid:68AD55C4-223A-46C6-896A-87345A781B61"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:274D4FB3-81D3-46CA-BE6A-31286B260E56"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:24886D93-A995-41A8-9E66-1BF6DF77E9D2"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A77ED33E-10B2-43BE-8BC6-D5F14E2FE208"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D1062598-B310-4CF4-8237-5F8F8F74933F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:99C27DF5-F974-4BCC-AE8D-49CE9212E9D2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7CAB3CEB-53D4-45C0-BDE2-D01D9FD9219C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D707EDCF-5B5D-4AB9-9815-32BDDA05721F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:07B9E40E-C2A9-41CF-9B91-A2A057E2FB86"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C025BBE5-19A7-4D05-9813-E49F4799CB23"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A252FD3C-4309-4CCB-8491-4B23A2848662"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7DF78E91-4010-455D-9300-16EAD7D6AB87"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:79C3BE8E-51D8-473A-AC88-0ADB7AE9D239"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:76E5F11A-7EC2-4412-BCB7-E9B0542040DE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0A8134EE-D8E3-447B-9EB9-2CB597651AB4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A5A82A3B-FE45-46DE-9048-8E85995D8F43"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1453C795-84C1-4C48-AF84-AEEE18ED1682"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AA5B502F-CF57-4C65-81A8-140217111073"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:12CCDE72-9FC0-4264-A3F2-C533F792F613"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4D3BA7C7-A806-41A4-84AC-38A85FF0F9C2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E0EC9718-8100-4840-9F10-BFE3FC7823F2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AAA6478C-E7E4-4D30-9F06-AA094434B620"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A526C161-102B-469E-9242-8D2CB0C94450"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:85B5BEBE-D146-414B-A979-B9CEBE9C57E6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7443907B-C475-4EA4-B081-8C3D55A1EF69"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:446899E9-2BB7-4629-AA6E-75AF9EC38F08"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:29A7AD86-B18C-409C-86E9-985BFF28A757"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:A3DBEE5E-C93B-4DBE-A1E3-317DA19FA203"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BFCAC108-C978-4C7B-A79A-9887A3CA3C6C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:12D5CA7C-401C-4376-A246-03585C5F9AC0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:797BAFBC-5256-4C7D-9ACC-064403D70DDB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BF8175E8-F52D-4CE3-9DE9-BAE3E2CE04A1"/>
    <permissions:permissions rdf:nodeID="N5cac53e0585347c0b0bdd3b1e50e4054"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:51770B89-7CCF-409A-A2E9-D4576F9DB59A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:318D970E-E791-465D-B650-869C74523D2C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:60AE44A7-769C-4774-8E4D-7AF66A2F2EA1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:914C2061-E547-4CFD-9F3C-C0070F56BF90"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ADFEE70E-EDC2-4D08-90AB-0ABAFD52BC6F"/>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:8900088E-395F-4576-960E-1B67ECCA0A65"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6FED0630-F5B3-4A05-892B-CB86D31FD6DF"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:82FFD7F0-AC94-462F-BA86-70CFD849B686"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FDDEE9D3-D4C2-40CB-BC92-305777AFD63E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BED0BB6E-5962-4714-A49A-2DB5A1787334"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6F7C3F13-3AE2-43EA-93D3-9F0AF79252AC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:52926929-04E3-4243-A2C3-5B9100F9FBE1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F87C43FC-DD9B-42FA-953B-C8C25AA48C91"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D1D92634-CB40-4585-8260-1917D2119CC7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BCC5E7E8-854A-4B02-859A-36A9EC807AF5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A1A5580F-53D7-4F22-824E-5430565EDBF1"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:785FFE99-34A3-41C7-A3D5-65DC60E0807D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DDF11329-3CD1-4391-B01E-D821B9E4C7F3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:24229507-32A8-4A26-89C0-59655390DA1A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C66BBCCE-CA43-44FB-8D97-2084E19C48FF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:76294E1F-52C3-4DC1-BB56-4B5DE633DEA3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CA792FCD-C812-49FE-9EDF-15DA0F056A53"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:920B7836-2155-4EE5-9028-A6274B846CBA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F8EED65F-31D9-41A0-9BB4-436FCBA969FA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E3D4514F-8C2B-4E16-B53E-81B363D7FDBE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8F11E81F-1EDB-4EA8-8E4A-47D93E06FFF2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6EB13D46-B414-424C-9D7C-BADA59079327"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C1A443CA-B8D4-4A28-825B-B97ECDEC88D7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4CD0874F-AA43-4C04-958D-6CFBFA68EC61"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E2A636FF-8FE8-44E9-B454-573E4E7470FA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8CA72313-3E32-44D6-A336-EDE69F22975A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:926EB546-FC66-4BEC-B38A-18749E06CCE5"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:7130A96C-7BF2-4DBE-A880-248C420268E9"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:14655D75-DC23-4E82-84C9-F40B702E4B69"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C91DD2D9-B8D7-4C80-85A1-EE73345B059A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DA483938-DFFC-4F6C-85C3-FED68E6D4DE8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DC71B917-C3C7-4475-B462-6525E8CEF601"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:48E274BA-EE97-464C-9512-861F9207381F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:71089688-5934-49A8-BBF4-07B4CAD41AA7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C4D81A7B-4D7D-4EBA-A2C1-0E5AC4A8CE5C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:52A12616-29C9-4323-A81B-949195D51273"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5CE6135C-97A9-4B21-9915-11E87A1697A5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3051A76E-96A2-4A70-91F9-A241566DEFD1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BB6F25A1-6FFC-4CE5-8F5F-AD5806D52477"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C54A1798-BD47-4D4C-89DF-B37F5A3AB9F0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:34A66F13-B248-4FD8-A3CE-7AAAC40B7ACC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5415B79F-FEAF-4999-A78E-2C1039116F7C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9CAD6283-FE79-428D-A3CE-B664A09583CB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AD757AC1-7E10-42A9-A8ED-0BD21ADA30A7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A688F7D2-43BF-4838-A9A1-339829ADA43A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:63FB79CC-576B-4FFD-A109-FF63DAE371C0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DC20D454-AAA8-4A81-915D-03526B8FC40B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2AAEA179-90D2-4661-9105-64A780850DEB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5C0FAFB3-9734-473A-85E5-980D1051DADD"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lastSavedOn>2014-07-18 18:26:08 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:A2215D32-FF99-4DC9-90B9-5C350C098EEB"/>
    <pav:previousVersion>urn:domeoserver:annotationset:21B0E479-04F9-4D66-B396-B773EFE53882</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:A056C491-9BB0-438A-A716-FE909F2281AD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D2174191-CE1D-4EF2-8DD5-03008A9706DE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:312701AC-EC1C-4292-B01F-44DD40979EEA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:90386835-AD59-4BAA-A860-3003ABCAF86C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A4632682-84C0-4DFD-915D-D1C3B235F095"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:65047D28-4B70-4701-B243-A146C45926A7"/>
    <pav:createdOn>2014-07-15 14:02:34 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C51A06F1-DF50-4438-A801-D1307CBA609A">
    <pav:createdOn>2014-07-18 13:49:30 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C51A06F1-DF50-4438-A801-D1307CBA609A"/>
    <ao:suffix>. The absolute magnitude of this interaction is unknown because of the intrinsically nonlinear disposition of phenytoin. (See PRECAUTIONS.</ao:suffix>
    <ao:exact>Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in phenytoin AUC. The mean ± SD increase in phenytoin AUC was 88% ± 68% (range: 16 to 247%)</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>C51A06F1-DF50-4438-A801-D1307CBA609A</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41D4DAFD-01A3-4F08-82F4-AB8B59CEEB2B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:41D4DAFD-01A3-4F08-82F4-AB8B59CEEB2B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-16 10:20:13 -0700</pav:createdOn>
    <ao:prefix>, and </ao:prefix>
    <ao:suffix> plus 9-hydroxyrisperidone are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma concentrations of risperidone occurred at about 1 hour. Peak conce</ao:suffix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8049D373-44B2-4E73-95D6-3445DE0002F8">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-16 14:03:51 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>norethindrone </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8049D373-44B2-4E73-95D6-3445DE0002F8"/>
    <ao:suffix> compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in t</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A8C40C51-0B43-4493-80CC-949EA671E491">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A8C40C51-0B43-4493-80CC-949EA671E491"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix> and </ao:prefix>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:suffix> was decreased, and elimination half-lives were prolonged compared to young healthy subjects. Dosing should be modified accordingly in the elderly patients [see 2 DOSAGE AND ADMINISTRATION].</ao:suffix>
    <pav:createdOn>2014-07-15 14:18:55 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6EB13D46-B414-424C-9D7C-BADA59079327">
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:ECCDA999-8E58-4BD8-9384-5A00E79F147E</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-15 14:04:06 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-15 14:04:04 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:21EAE98A-5FE8-4364-AD53-F77A42DFEE51"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75261373-1FF5-4BA4-8887-FD4548F77DE6">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-16 10:19:56 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:BEEF40B4-6424-4E52-8991-9FA7249F61E5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2FC3C7A5-C738-4ED9-8908-673E98D7C9CB">
    <ao:exact>fluconazole</ao:exact>
    <ao:suffix>. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTI</ao:suffix>
    <domeo:uuid>2FC3C7A5-C738-4ED9-8908-673E98D7C9CB</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2FC3C7A5-C738-4ED9-8908-673E98D7C9CB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>			http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-17 15:59:16 -0700</pav:createdOn>
    <ao:prefix> AUC and a significant increase in apparent oral clearance of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69BEBC8E-741D-4841-BCB0-771651B22677">
    <domeo:uuid></domeo:uuid>
    <ao:exact>Risperidone </ao:exact>
    <pav:createdOn>2014-07-15 14:15:18 -0700</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>could be subject to two kinds of drug-drug interactions. First, inhibitors of CYP 2D6 interfere with conversion of risperidone to 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. This occurs with quinidine, giving essentially all recipients a risperidone </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:69BEBC8E-741D-4841-BCB0-771651B22677"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E3DA2E5E-FC19-4C22-AF6C-A9CB4B450554">
    <ao:item rdf:resource="urn:domeoclient:uuid:B2C03A2F-0DF1-4E82-B58C-1909B3460EAA"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:98DABE9A-9F89-4DF9-9DEE-B6853D1F5CC1</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:2EFDE02B-EB81-4773-A923-937E941963E2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:71649D2A-6308-46A5-9322-DFC56F36E8F3"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3776F388-42AA-4941-B8F9-416DFC230546"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CB645A75-8C80-4DBE-A619-BDD15DFC4DF3"/>
    <pav:lastSavedOn>2014-07-16 18:46:13 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:E97673F8-7E4F-465A-9DDA-320EE8E031C1</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N3e33944b1b3747898ec3a325c6c1ffbe"/>
    <pav:createdOn>2014-07-16 15:39:34 -0700</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:ABA94567-EA53-40B6-AF02-E6FC02E40AD6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F7888D3F-B736-44E1-8FF0-7C578EEDD97E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:887773A9-6D1A-46C3-A7F4-E2255F7FBE67"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9AF357DC-FE46-4BA4-BC30-1C0C4232273D"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4C5E020-24D9-465B-97AB-8A4E6685160F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D4C5E020-24D9-465B-97AB-8A4E6685160F"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> from a tablet is 94% (CV=10%) when compared to a solution.</ao:suffix>
    <ao:prefix> is 70% (CV=25%). The relative oral bioavailability of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-16 10:19:46 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21394BF5-9EBD-45B5-A3E3-29F92CC4E65F">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E0676820-4037-444B-AE4D-9C1ED43E28D9"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B716A719-3E66-4B72-87E0-370D90F3B8F7</pav:lineageUri>
    <pav:createdOn>2014-07-17 15:59:21 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DEBE5AF-B171-4BE8-880B-76A2BEE742A6</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-17 15:59:35 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BAF30A3C-A239-441C-8B34-9AC0EFD5ED8E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BAF30A3C-A239-441C-8B34-9AC0EFD5ED8E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>BAF30A3C-A239-441C-8B34-9AC0EFD5ED8E</domeo:uuid>
    <ao:suffix> (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in phenytoin AUC. The mean ± SD increase in phenytoin AUC was 88% ± 68% (range: 16 to 247%). The absolute magnitude of this interaction is unknown</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:hasSource>
    <ao:exact>fluconazole</ao:exact>
    <pav:createdOn>2014-07-18 13:48:18 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8452517-26D0-419F-88FD-A818925FDE06">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-26.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:F9B8EE58-CE38-4918-9802-C2CBECEEA050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F69E5920-13F7-4233-8E5C-355591D43752"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5975A18C-9750-49AF-9CBD-E13C8DFBA413"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:05FDCD78-BAF2-46D7-9D0F-0636684A6834"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="Nc57ae467ff874feabe54b93742350fa0"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lineageUri>urn:domeoserver:annotationset:5D9E9387-63D8-470C-8657-CFD191EF7563</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:EE1BA765-A716-44E9-BE81-971BDF21154E"/>
    <pav:createdOn>2014-07-18 13:51:09 -0700</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <pav:lastSavedOn>2014-07-18 16:51:47 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:0ED8918B-EAC0-44B8-AA42-B78AD724F7BE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3A31AA07-7919-4161-9DEB-01C06D730BF5">
    <pav:createdOn>2014-07-10 11:10:53 -0700</pav:createdOn>
    <ao:exact>sildenafil</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3A31AA07-7919-4161-9DEB-01C06D730BF5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in </ao:prefix>
    <ao:suffix> systemic exposure (AUC).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9B54FB4-D4A5-4FA0-ABB3-A05CFA1F5934">
    <pav:lastSavedOn>2014-07-16 17:10:58 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-16 14:09:37 -0700</pav:createdOn>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:2B478044-BBD7-4785-9DD7-003991731548</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C</domeo:belongsToSet>
    <ao:body rdf:nodeID="N4f2e2d3050024dbe8dbe521893735c39"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:60698783-AF86-402C-ADB4-1162CCD89EBA"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ABA0CCF3-E252-4C23-B881-D2E2AF418E6C">
    <ao:context rdf:resource="urn:domeoclient:uuid:540A603C-5624-405F-9660-D636865AE01B"/>
    <pav:createdOn>2014-07-10 11:20:15 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C00DD3B-AD96-4229-AD96-9CFE64EA4677">
    <permissions:permissions rdf:nodeID="N3dbb2b829465456a87b87065d29aa30b"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-4.txt.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:BCA6AE93-8F70-41D6-9D04-EEFEAA82A4A2</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2014-07-15 16:58:24 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E38D9228-C97F-4151-9702-C3C8F519D87E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-15 13:56:25 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46F4178C-1487-4F57-A6D9-06D0CE8BE565">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:46F4178C-1487-4F57-A6D9-06D0CE8BE565"/>
    <pav:createdOn>2014-07-10 11:20:21 -0700</pav:createdOn>
    <domeo:uuid>46F4178C-1487-4F57-A6D9-06D0CE8BE565</domeo:uuid>
    <ao:prefix>. The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing). Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of </ao:prefix>
    <ao:exact>sildenafil</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:688A40AF-929E-4DEA-858A-D3762D3C014B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lastSavedOn>2014-07-18 16:59:52 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A3D1C555-823A-42D3-975B-C6C42C41329E"/>
    <ao:body rdf:nodeID="Ne6b5e89703e34cad809c689b3bc9b8fb"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdOn>2014-07-18 13:57:27 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:5A89661F-9824-4844-AED5-7313EED76025</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:99826AC3-3668-4F74-9E9D-DADD1F7098F0</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5692BCB9-DDA3-438D-9E49-F80218BB67C8">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:B716A719-3E66-4B72-87E0-370D90F3B8F7</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DEBE5AF-B171-4BE8-880B-76A2BEE742A6</domeo:belongsToSet>
    <pav:createdOn>2014-07-17 15:59:16 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:2FC3C7A5-C738-4ED9-8908-673E98D7C9CB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-17 15:59:35 -0700</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA979FCE-441A-47D4-9797-5CC727F01663">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-16 14:06:30 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:14EF1296-9281-4C53-B309-5C368E7DBD5D"/>
    <pav:createdOn>2014-07-16 14:03:38 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:BAAEB633-65CB-426D-AD31-0B36CB5F9EE4</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FBE4D752-3492-405C-8C46-E0FAC0507DD3">
    <ao:suffix> </ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FBE4D752-3492-405C-8C46-E0FAC0507DD3"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-16 10:22:00 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EDA5CCDC-B45B-4C9D-9286-2C6331B0DC2E">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-16 10:20:45 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:433EA64F-D83C-4038-880E-456719321D8E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6F7C3F13-3AE2-43EA-93D3-9F0AF79252AC">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:D4B04F76-068F-4446-8605-4EDC1E4CB4F3"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:9B307D8B-D2B0-4795-8850-FAAAAC6B5AF4</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdOn>2014-07-15 14:07:21 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-15 14:07:58 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C">
    <pav:createdOn>2014-07-16 14:03:15 -0700</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:9B234C79-AB11-4626-BB32-A29D819B57BA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CA979FCE-441A-47D4-9797-5CC727F01663"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>urn:domeoserver:annotationset:B3F0B84F-756D-4724-B177-98D0D290D00D</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:A9B54FB4-D4A5-4FA0-ABB3-A05CFA1F5934"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A2FA427B-9D1C-4042-8796-682C2C547E30"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B7CDA6B5-18B6-4EB0-A176-5FA6DF4BD169"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0C9C3F3B-D652-4BC5-8BE9-2D01F09D0D62"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C8EE5491-20E0-446F-BE4F-48D8F8CDCAB9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:05F3AC40-8EB1-409A-9E01-317E8C07400C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F77BE7E4-398E-4B73-9848-3A5055B88BD4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N1b471d49d3eb44f6ba9b021f2038d6c9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DCA6DB56-8ED4-4BF0-9368-16ACBA6F82AE"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:7EF340BC-FC51-443A-B404-48D9728F2E15"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:EB1F59F5-F04B-4836-B1C9-90E20E62B91E"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:73C19DFA-F31A-4286-BFC2-5C8757F59492"/>
    <pav:lastSavedOn>2014-07-16 17:10:58 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:5DCE0D50-99F3-4301-8B36-DE5F9A87ECDD"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:03DD4E8D-1756-4822-B979-A160AAF90F82</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E3D4514F-8C2B-4E16-B53E-81B363D7FDBE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:883587E1-49C1-4EE0-909E-4ADBAE13DD3A</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lastSavedOn>2014-07-15 14:30:47 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-15 14:28:14 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:B7BF01C6-A444-43C9-8592-E7548AF045AB"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:nodeID="Nab58d95e62b24227af3808cbbec530c8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:882C3E53-3401-4418-9864-3D34134F9C86">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In a placebo-controlled trial in normal volunteers, the administration of two doses of sertraline did not significantly alter steady-state lithium levels or the renal clearance of lithium</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>882C3E53-3401-4418-9864-3D34134F9C86</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:882C3E53-3401-4418-9864-3D34134F9C86"/>
    <pav:createdOn>2014-07-09 13:57:34 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-13.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7CD9615A-69D6-4A70-94B2-EF43CF591997">
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DEBE5AF-B171-4BE8-880B-76A2BEE742A6</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:B716A719-3E66-4B72-87E0-370D90F3B8F7</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-17 15:59:35 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-17 15:59:07 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:DB99EE39-D6AF-4C66-A7BF-D1186DCE23D6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21EAE98A-5FE8-4364-AD53-F77A42DFEE51">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>eridon</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>p</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>ris</ao:prefix>
    <pav:createdOn>2014-07-15 14:04:04 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:21EAE98A-5FE8-4364-AD53-F77A42DFEE51"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D975807-A259-49EC-97EB-1E0EC9EB112C">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-16 15:33:03 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:7AE68AC7-9B47-4954-8C65-45A6F0DC80C2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F87EEF0-40A6-43E2-8222-95E7D1335A0B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-16 15:33:06 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:387A1EFC-40FD-4ED2-A90C-E9AE2D14E77B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:914C2061-E547-4CFD-9F3C-C0070F56BF90">
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:5261237F-686F-41D7-B860-16364A944D37"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdOn>2014-07-15 14:16:19 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE892364-BAE9-432B-976E-743B57F2408B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CE892364-BAE9-432B-976E-743B57F2408B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix> results from the combined concentrations of </ao:prefix>
    <pav:createdOn>2014-07-15 14:03:13 -0700</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> and its major metabolite, 9-hydroxyrisperidone [see 12 CLINICAL PHARMACOLOGY]. Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of risperidone.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33ED9F46-26DA-4463-B66D-77E2995BE5C0">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:7AE68AC7-9B47-4954-8C65-45A6F0DC80C2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F87EEF0-40A6-43E2-8222-95E7D1335A0B</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-16 15:33:06 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-16 15:32:37 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:ECDDC20F-1C2B-469E-98F0-C0EB9DA754E2"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A21EC03A-3C43-4CAE-9D75-32F08D9599AA">
    <pav:createdOn>2014-07-16 14:03:39 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A21EC03A-3C43-4CAE-9D75-32F08D9599AA"/>
    <ao:exact>fluconazole </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:suffix>dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 1</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393">
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:43443A66-1162-4BDC-88F9-4CB789CFAF8B"/>
    <pav:createdOn>2014-07-10 10:59:34 -0700</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:91E13B1F-608F-46DC-825E-D1031BD8EE6D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6C376F0E-D7D6-4846-B8E9-1C50742E0CD2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:665D54F7-737F-4E41-85AF-4DB192AB7A15"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:21180C8D-1095-4E2F-9A46-484DCC01879D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:10EA2F12-BD12-4F54-9D90-CD6B3DC5179E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:702BE5BD-B486-4EEB-9B0C-8C790AAA768A"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:C70E2E47-3AA5-4F01-A8A1-711E946726F5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:3E0194D4-524A-4E69-B161-52FB98ED36C2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CD3E95AA-5887-4E3B-B181-8C84F1A4D6C5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B9DE1789-19F9-43BC-B292-659F900EA6EB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3F707B16-9AC0-4A46-A0C5-ED7358D7F764"/>
    <pav:lastSavedOn>2014-07-10 14:25:16 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C9D98AB8-FCA0-4A14-92DD-EBD32CC6776E"/>
    <permissions:permissions rdf:nodeID="Nce83eb0cbafd4be08363841226135913"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F5FD5F49-D620-4FE1-9968-D31A01410DEC"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:025EF8CC-8100-4ED5-A590-368E009133CC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:33374D0E-AF28-4161-ACC9-7713697436CB"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:ABA0CCF3-E252-4C23-B881-D2E2AF418E6C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F4E4C204-187C-449E-9023-BF663418A548"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5A441D1D-CF1A-4E2D-80CF-F79B9D77D232"/>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:C820B82D-AF0E-4A71-9E65-5AB73DFE5206"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:86ABDA54-6350-41E2-93E1-1353431A082D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E5AC3B8B-F69B-4482-815F-54FC3F75312F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:114FB83A-C60C-42F5-AB92-9462558A06FC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C4C14FED-0642-4B44-8AD5-DFA9D02E5B99"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:380253B1-58A2-45B6-B271-96D870E13796"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:94AD2935-8FE6-4D3D-847A-A1AC66E35692"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C4DD997B-59E6-4FDF-944E-0E3151C25851"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A30AACD8-E9A8-4B2C-9DB3-7E44F147751F"/>
    <pav:previousVersion>urn:domeoserver:annotationset:970963DF-8BCE-4936-9DFC-328A36014E1B</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:EFED6610-75EB-4165-827C-237B7D245279"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:32208944-92E0-40BE-AA45-03DC0663A09C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:31F660CD-C617-4D06-85AD-7A9D8F2EDEEC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:977A2BC8-0744-472F-9FA2-CCF897431CA1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:84ED4684-C66A-4CA3-8A17-114128E1557B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:587BEAE7-8AE9-4452-8478-FF400284EBF7">
    <ao:exact>sildenafil</ao:exact>
    <ao:suffix> was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-10 11:10:42 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:587BEAE7-8AE9-4452-8478-FF400284EBF7"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:891ADA8B-FE3B-424C-BA58-775CE8AC2E75">
    <pav:createdOn>2014-07-18 13:43:23 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>891ADA8B-FE3B-424C-BA58-775CE8AC2E75</domeo:uuid>
    <ao:prefix> AUC and a significant increase in apparent oral clearance of </ao:prefix>
    <ao:suffix>. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTI</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <ao:exact>fluconazole</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:891ADA8B-FE3B-424C-BA58-775CE8AC2E75"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EEAF2259-5093-4FDA-A5B5-9FB724127DB0">
    <ao:prefix> is well absorbed. The absolute oral bioavailability of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EEAF2259-5093-4FDA-A5B5-9FB724127DB0"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <ao:suffix> is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-16 10:19:38 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:A7F21A3D-50B3-495E-884A-2C707B40C763">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:372E2DC2-9D30-4E6B-AD72-5B085AE1A42F"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:D8773E33-77FB-4402-ABAD-8048CB22BB84"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E960B89C-B215-4093-9AF7-C100D8D48511"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2014-07-18 16:49:32 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:FCAC7AB3-7719-4C9B-8378-64BF0D2B4AD2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:862041D3-5963-4DC0-966F-207E3A62BA47"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4ACE7F4B-F57E-4417-9D3D-B18148E82D1E"/>
    <permissions:permissions rdf:nodeID="Nbaa1a9bdc6384b75b8d0824504b16b4d"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:748BB253-1066-4977-91B2-35D8C6906790</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2014-07-18 13:48:05 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:53775C4C-7CC4-46EB-9EFC-EDF9D3D264ED</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:D75527AE-44F3-49BF-B7AB-31C1D6E91722"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FC0B6A3C-A2F8-4ACD-9832-BF13C7065BAE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:742BAEF2-5B32-4F05-87AD-ACC7F302B35E"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:433EA64F-D83C-4038-880E-456719321D8E">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> </ao:suffix>
    <pav:createdOn>2014-07-16 10:20:45 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:433EA64F-D83C-4038-880E-456719321D8E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71089688-5934-49A8-BBF4-07B4CAD41AA7">
    <pav:createdOn>2014-07-15 14:13:56 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E8921F3A-7792-4582-AEB4-1956E549C6E3"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2C01868C-4CA4-41F7-878B-4BF3487A2B98">
    <ao:suffix> AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male vol</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2C01868C-4CA4-41F7-878B-4BF3487A2B98"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-18 13:48:05 -0700</pav:createdOn>
    <ao:exact>Phenytoin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>2C01868C-4CA4-41F7-878B-4BF3487A2B98</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07B9E40E-C2A9-41CF-9B91-A2A057E2FB86">
    <pav:createdOn>2014-07-15 14:26:27 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:nodeID="Nad0f4c7de3ab4d7eb27614e2b129af81"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:883587E1-49C1-4EE0-909E-4ADBAE13DD3A</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:ED25013C-406F-45E7-817A-38F31C1C84A1"/>
    <pav:lastSavedOn>2014-07-15 14:30:47 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D0A91F52-6752-4FEC-A801-601958619292">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> is rapidly distributed. The volume of distribution is 1 to 2 L/kg. In plasma, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D0A91F52-6752-4FEC-A801-601958619292"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>risperidone</ao:exact>
    <pav:createdOn>2014-07-15 14:07:38 -0700</pav:createdOn>
    <ao:suffix> is bound to albumin and α1-acid glycoprotein. The plasma protein binding of risperidone is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A056C491-9BB0-438A-A716-FE909F2281AD">
    <pav:lastSavedOn>2014-07-15 14:07:58 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:53F2EA0B-B02F-4D15-A55E-843D837795E4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:9B307D8B-D2B0-4795-8850-FAAAAC6B5AF4</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdOn>2014-07-15 14:06:41 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41C2DB2C-7077-4ABE-8A8A-54A08326A7B8">
    <ao:exact>Risperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:41C2DB2C-7077-4ABE-8A8A-54A08326A7B8"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> decreased by 60% compared to young healthy subjects. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-15 14:18:20 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> doses should be reduced in patients with renal disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21180C8D-1095-4E2F-9A46-484DCC01879D">
    <pav:createdOn>2014-07-10 11:24:33 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:6B2FA09F-EFA4-4175-BB0D-C5E1AA855337</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:3ABC05DD-EC5F-4576-86DC-D8C25A0E287D"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-10 14:25:16 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Ncf9ea80f1b4c494fb4d5b7042d73e55e"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/2440B2BA-E703-439E-9D9D-F871F0C7006D">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <rdfs:label>Fluconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC9D7EB3-FEB5-450C-959B-F7BCBAC26F3C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CC9D7EB3-FEB5-450C-959B-F7BCBAC26F3C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-15 14:04:00 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix>e oral solution is bioequivalent to </ao:prefix>
    <ao:suffix> tablets.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE8D3AAD-5714-40E9-8521-B30676F883D5">
    <pav:createdOn>2014-07-09 13:56:32 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:80304B91-FB8B-4EF5-87EC-80F59A689F2A</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:8B8B88D4-5E42-47CB-9E37-EED59C74FD96</pav:previousVersion>
    <ao:body rdf:nodeID="N963671e9e79045288f7a0196105f6283"/>
    <pav:lastSavedOn>2014-07-09 16:57:52 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:2C25A7F3-8A42-4060-A64C-5C2AB24D4675</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:882C3E53-3401-4418-9864-3D34134F9C86"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F89E37D5-CA53-4C58-B4D2-AE8F0A3FBCE2">
    <pav:createdOn>2014-07-16 10:19:38 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:EEAF2259-5093-4FDA-A5B5-9FB724127DB0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:987C60C7-6D1F-4118-A362-4E5E00057318">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-16 10:22:55 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-16 10:23:07 -0700</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:2B3DD740-D22B-482C-9A75-48DD8B5632A7"/>
    <pav:lineageUri>urn:domeoserver:annotation:FE963564-3A50-43BC-A700-CA59A1CF8371</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C9AAECF8-1252-4F78-95C3-766B0DC2CF93">
    <pav:createdOn>2014-07-17 15:53:34 -0700</pav:createdOn>
    <domeo:uuid>C9AAECF8-1252-4F78-95C3-766B0DC2CF93</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C9AAECF8-1252-4F78-95C3-766B0DC2CF93"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>				http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html																													</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Fluconazole</ao:exact>
    <ao:suffix> 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers. After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A59961D-051E-4238-8A44-2BD5D13E656F">
    <ao:prefix> dose for at least 6 weeks. There was a significant increase in </ao:prefix>
    <ao:suffix> AUC, Cmax, Cmin (24-hour concentration), and a significant reduction in apparent oral clearance following the administration of fluconazole. The mean ± SD increase in AUC was 92% ± 43% (range: 18 to 147%). The Cmax increased 60% ± 48% (range: -5 to 133%</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-18 13:51:33 -0700</pav:createdOn>
    <ao:exact>cyclosporine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-26.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A59961D-051E-4238-8A44-2BD5D13E656F"/>
    <domeo:uuid>7A59961D-051E-4238-8A44-2BD5D13E656F</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC4605E1-BB47-46C6-87EA-F8DDE5BC9868">
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D4C5E020-24D9-465B-97AB-8A4E6685160F"/>
    <pav:createdOn>2014-07-16 10:19:46 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:0F87EEF0-40A6-43E2-8222-95E7D1335A0B">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:8A82BF7D-FCE6-4985-9C4B-E950C1124476"/>
    <permissions:permissions rdf:nodeID="N147c3273815e49bd9a16ba3fe2d02f2e"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:787C8DA7-E4FF-4344-8E03-827399F78206"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:51D42CFA-4CB2-4B55-9EFE-A1109484AC25"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7D975807-A259-49EC-97EB-1E0EC9EB112C"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:33ED9F46-26DA-4463-B66D-77E2995BE5C0"/>
    <pav:createdOn>2014-07-16 15:32:30 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-16 18:38:32 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:5153D183-17EE-480B-9FF3-A9FB70E3CB26"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:5C7A7116-C174-4EB1-933E-3A46CEE71709</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:7838B265-7A04-40B9-A395-37C612A69AEA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5A671621-83D0-48B3-B249-7E1ECC849539"/>
    <pav:lineageUri>urn:domeoserver:annotationset:7AE68AC7-9B47-4954-8C65-45A6F0DC80C2</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F5EA08DB-0874-466C-8ADD-16FB922B834F">
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F5EA08DB-0874-466C-8ADD-16FB922B834F"/>
    <ao:suffix> is well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.</ao:suffix>
    <ao:prefix>Absorption: </ao:prefix>
    <pav:createdOn>2014-07-16 10:19:32 -0700</pav:createdOn>
    <ao:exact>Risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:61EFE295-187A-4B36-B127-C54D8E2D8B4D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:61EFE295-187A-4B36-B127-C54D8E2D8B4D"/>
    <ao:suffix> half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTIONS.)</ao:suffix>
    <domeo:uuid>61EFE295-187A-4B36-B127-C54D8E2D8B4D</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <ao:prefix> increased 32% ± 17% (range: 16 to 72%). </ao:prefix>
    <ao:exact>Fluconazole</ao:exact>
    <pav:createdOn>2014-07-18 13:43:41 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/00222986-6A7D-42B7-950C-C9A90060EA28">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>tolbutamide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10635</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:8DEBE5AF-B171-4BE8-880B-76A2BEE742A6">
    <ao:item rdf:resource="urn:domeoclient:uuid:7CD9615A-69D6-4A70-94B2-EF43CF591997"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ED9173BA-30D7-4181-85F1-37CC30DFF11C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0AE1727A-ACA3-43E1-8A12-B8F0F479A3DF"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:B716A719-3E66-4B72-87E0-370D90F3B8F7</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:025B9C60-3F34-47FE-83EE-A415FB50E5FC"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:B2931C8A-EC31-47B6-AE9D-7EFD2AFC6C76"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5A49ECAF-CE5A-41FF-B8D4-43B060247DBA"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <permissions:permissions rdf:nodeID="Na603c9495bc34faaba77d3cd645dbad8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:21394BF5-9EBD-45B5-A3E3-29F92CC4E65F"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5692BCB9-DDA3-438D-9E49-F80218BB67C8"/>
    <pav:lastSavedOn>2014-07-17 19:00:13 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2014-07-17 15:58:55 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:annotatesResource>			http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:83B2E87D-3732-4699-AA3D-363A6EB95959</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A441D1D-CF1A-4E2D-80CF-F79B9D77D232">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-10 11:20:26 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1C30B0B1-5EC7-4866-B5F3-AA2CB04C9143"/>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3363C787-8AF1-4899-903A-F4812DD65C36">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D2E85468-7CF7-4CD4-BDCA-9028642087EE"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D7826928-4C32-427A-B946-D947EB2451B5">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D7826928-4C32-427A-B946-D947EB2451B5"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:prefix> was co-administered with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>erythromycin</ao:exact>
    <domeo:uuid>D7826928-4C32-427A-B946-D947EB2451B5</domeo:uuid>
    <pav:createdOn>2014-07-10 11:15:15 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A526C161-102B-469E-9242-8D2CB0C94450">
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:27E8BA7E-57CC-48C7-86F6-BFF286EBA6E0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:40507A83-879B-47E6-8AFE-8BF8A6380190</pav:lineageUri>
    <pav:createdOn>2014-07-15 14:10:12 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4F68DB2-7686-4E60-9A9D-F764E3A0DF93">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D4F68DB2-7686-4E60-9A9D-F764E3A0DF93"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of flucon</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fluconazole</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-16 15:40:17 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:27E8BA7E-57CC-48C7-86F6-BFF286EBA6E0">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:suffix>, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug results from the combined concentrations of risperidone plus 9-hydroxyrisperidone.</ao:suffix>
    <pav:createdOn>2014-07-15 14:10:12 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:27E8BA7E-57CC-48C7-86F6-BFF286EBA6E0"/>
    <ao:prefix> by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, </ao:prefix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:31106440-9B03-40EC-87ED-9D0BFE935266">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/78CA8426-F17B-4F98-AB2F-F77F74181051"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/4AF09D72-39A6-4BC4-A512-26DBDD3392E4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76294E1F-52C3-4DC1-BB56-4B5DE633DEA3">
    <pav:lineageUri>urn:domeoserver:annotation:3B7D16AF-4F8C-446D-AE7D-C284C5835FAC</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-15 14:32:08 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-15 14:31:21 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B8F6DECD-B84A-439C-AB5B-FD0E059E3FAC"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4">
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <permissions:permissions rdf:nodeID="N6c1edeae53834f0b85d46ff0eac3ef13"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:34BFAD74-FE4D-4E30-8ACE-10002901EAA2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:785FC8A2-DE5D-4084-8BEC-107690A111CB"/>
    <pav:lastSavedOn>2014-07-18 18:26:38 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:94220E4B-2D94-4374-8F09-2F8CAACF7723"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:75261373-1FF5-4BA4-8887-FD4548F77DE6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EDA5CCDC-B45B-4C9D-9286-2C6331B0DC2E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A216BADD-014F-4644-9641-24F03B40257D"/>
    <pav:previousVersion>urn:domeoserver:annotationset:AAD02A4C-E01E-4C82-BC8A-D0F4639844FA</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:A9E905EC-FD3B-44E6-9603-8C4B7B645A61"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6395774E-A61F-4CC3-AC03-4A9A97F402CB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:069D387B-708F-4C78-BA75-2E62415C81C9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:287EB7AD-1FB2-4E91-A01C-FFE1A2CB547D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AD7753FF-D1E8-489F-B53D-1F96A5C7118D"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6B42267E-6924-4453-B105-2F66C330186C"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:076F37CF-3229-400A-A6F6-EBE2A8FC2F4C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:F89E37D5-CA53-4C58-B4D2-AE8F0A3FBCE2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:18EE2CB9-3D4F-42B6-A49D-245BF6C564CA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F2AF7A08-3EE5-4851-BC7F-4DF99BFE382A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:987C60C7-6D1F-4118-A362-4E5E00057318"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0623A94E-6CBD-441E-92B8-16C280BD8650"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:41134D12-A312-4FDD-ADEA-5285A0740BFA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D3E83240-5B88-4E8A-9F52-DF6E195AAF5D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0C20AD1B-8F9C-472D-A102-E6A1F85BDC4E"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ADF2DC89-FCCE-47DE-8493-BEC599C898E4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:50B64AB9-5E00-4F5D-BE7F-9B8CE91BCF2A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:81DA2C24-D202-4991-9DC6-FFA54776B4D2"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:annotatesResource>
    <pav:createdOn>2014-07-16 10:18:37 -0700</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:AC4605E1-BB47-46C6-87EA-F8DDE5BC9868"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8D0FBEEE-F2C5-4EBC-892B-1E8DE2D584AE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:06A59058-E7B5-4A71-9D10-07FD98051EBF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:03498850-C0AC-4682-B3F3-91FD27180D38">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:03498850-C0AC-4682-B3F3-91FD27180D38"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> was about 21 hours (CV=20%) in extensive metabolizers and 30 hours (CV=25%) in poor metabolizers. The pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, were similar in extensive and poor metabolizers, wi</ao:suffix>
    <pav:createdOn>2014-07-15 14:17:20 -0700</pav:createdOn>
    <ao:prefix> was 3 hours (CV=30%) in extensive metabolizers and 20 hours (CV=40%) in poor metabolizers. The apparent half-life of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F77BE7E4-398E-4B73-9848-3A5055B88BD4">
    <domeo:belongsToSet>urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C</domeo:belongsToSet>
    <pav:createdOn>2014-07-16 14:03:22 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-16 14:06:30 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:172620B0-F20C-491D-A7F8-F2C65B3B75A5</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:316356DA-5EB5-42EB-9878-F3A3E1BDA4E9"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81FD23EC-BBD2-4E95-B296-364F882C43DB">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:81FD23EC-BBD2-4E95-B296-364F882C43DB"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-29.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-18 14:08:08 -0700</pav:createdOn>
    <domeo:uuid>81FD23EC-BBD2-4E95-B296-364F882C43DB</domeo:uuid>
    <ao:suffix>. (See PRECAUTIONS.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In 13 normal male volunteers, there was significant increase in tolbutamide (500 mg single dose) AUC and Cmax following the administration of fluconazole. There was a mean ± SD increase in tolbutamide AUC of 26% ± 9% (range: 12 to 39%). Tolbutamide Cmax increased 11% ± 9% (range: -6 to 27%)</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:785FFE99-34A3-41C7-A3D5-65DC60E0807D">
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdOn>2014-07-15 14:06:32 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-15 14:07:58 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:9B307D8B-D2B0-4795-8850-FAAAAC6B5AF4</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:DD78A8D5-89E1-46CD-BC97-037DB330DF6D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7893705-3CF7-42B9-9C7F-93F25693DB84">
    <pav:createdOn>2014-07-18 13:43:13 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FF76049E-6B2C-46A9-ACF7-CA565C8087F3</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:23BAF555-C96E-4707-8EBA-34BCE14B71F5"/>
    <pav:lastSavedOn>2014-07-18 13:43:48 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C00C2C3C-0648-4779-A135-09D440F1CEA8</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F5FD5F49-D620-4FE1-9968-D31A01410DEC">
    <pav:lineageUri>urn:domeoserver:annotation:357EF864-DD43-4B3D-B0D4-05133DC26F05</pav:lineageUri>
    <pav:createdOn>2014-07-10 11:10:37 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:AF7B07B6-2BD9-490B-95BF-D760C5399474"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-10 11:14:30 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F11CBAD8-E220-415C-81B8-EC30E7A34762">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F11CBAD8-E220-415C-81B8-EC30E7A34762"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-16 14:10:22 -0700</pav:createdOn>
    <domeo:uuid>F11CBAD8-E220-415C-81B8-EC30E7A34762</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>study evaluated the potential interaction of once weekly dosing of fluconazole 300 mg to 21 normal females taking an oral contraceptive containing ethinyl estradiol and norethindrone. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosing. The individual AUC values of norethindrone decreased very slightly (&lt;5%) in 3 of the 21 subjects after fluconazole treatment</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EDA74310-A0B5-4356-940A-7C74749CD2EF">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-20.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EDA74310-A0B5-4356-940A-7C74749CD2EF"/>
    <pav:createdOn>2014-07-16 10:36:33 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>s supplied for oral administration as scored tablets containing sertraline hydrochloride equivalent to 25, 50, 100, 150 and 200 mg of </ao:prefix>
    <ao:suffix> and the following inactive ingredients: dibasic calcium phosphate dihydrate, hydroxypropyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, talc, and titanium dioxide.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>sertraline</ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6293CB80-DCD6-4620-8C0D-569FB4C95073">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6293CB80-DCD6-4620-8C0D-569FB4C95073"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-16 10:18:56 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> acts as an antagonist at other receptors, but with lower potency. Risperidone has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and haloperidol-</ao:suffix>
    <ao:prefix> is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), α1 and α2 adrenergic, and H1 histaminergic receptors. </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>Risperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95BD0C2B-0FA9-43F6-AC62-608DC7F301DE">
    <pav:createdOn>2014-07-18 14:02:56 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9AA0507C-281E-45C8-9719-03E66F12C069</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DBCB873-26F3-4E6A-9BD4-311369B43736</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-18 14:03:19 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:FC34EFC8-BB07-4B83-AD21-D8DD09AB286D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:079A4E14-C541-4AC8-B876-063FC489849B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C94BECCE-E3E9-4B70-AC23-F715B9D3EEFF</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-17 15:54:46 -0700</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:01F43ADA-D582-470E-9E9C-774668C5EF3D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-17 15:54:41 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:96BAB4C7-6F7A-4EBA-BAC1-134F746F11FA</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD757AC1-7E10-42A9-A8ED-0BD21ADA30A7">
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:createdOn>2014-07-15 14:16:29 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:A156EC26-7CF9-490B-8F02-67A6FCC98E56"/>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41E33AFA-32CF-4F33-A475-CBE51A5010FA">
    <domeo:belongsToSet>urn:domeoserver:annotationset:7BA312DF-BB65-4A90-8B7D-A54425D7C553</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-18 14:20:17 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:1EE1D64B-EDD4-4170-B797-D8F83B927DCE</pav:lineageUri>
    <pav:lastSavedOn>2014-07-18 14:20:41 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EB808AED-F3EE-4633-873E-90372A00493C"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B3DD740-D22B-482C-9A75-48DD8B5632A7">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-16 10:22:55 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2B3DD740-D22B-482C-9A75-48DD8B5632A7"/>
    <ao:suffix> occurred at about 1 hour. Peak concentrations of 9-hydroxyrisperidone occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers. Steady-state concentrations of risperidone are reached in 1 day in extensive metabolizers and w</ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:2CE33325-EF3D-4298-BBCC-82F0A45DA665">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="N9b4e46db0e904596a0f45c6a0ef2ba09"/>
    <pav:lastSavedOn>2014-07-16 17:02:24 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:8ABB5677-3B0A-44AC-B5F0-95374283E66A</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:C966BEAA-709F-4F5C-9638-F94D75B69135"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-16 10:36:03 -0700</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C039DC79-C2B3-4581-A409-2060854712D2"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:C5D9EC69-52E2-48F5-B3D8-867DE23DEC96</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:9DD27DF4-02BD-4CAE-B854-9D4CA6356D04"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-20.txt.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7CAB3CEB-53D4-45C0-BDE2-D01D9FD9219C">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2014-07-15 14:17:20 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:03498850-C0AC-4682-B3F3-91FD27180D38"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D75527AE-44F3-49BF-B7AB-31C1D6E91722">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-18 13:48:39 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2C01868C-4CA4-41F7-878B-4BF3487A2B98"/>
    <pav:lineageUri>urn:domeoserver:annotationset:748BB253-1066-4977-91B2-35D8C6906790</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A7F21A3D-50B3-495E-884A-2C707B40C763</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-18 13:48:05 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F7888D3F-B736-44E1-8FF0-7C578EEDD97E">
    <domeo:belongsToSet>urn:domeoserver:annotationset:E3DA2E5E-FC19-4C22-AF6C-A9CB4B450554</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:66F7DB88-E054-469D-820E-4EDCB75B0F44</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:701B3F36-4375-4CB6-A9F8-C942C7D5632E"/>
    <pav:createdOn>2014-07-16 15:39:41 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-16 15:40:55 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:31B6ED7E-D003-4C21-A285-EBE6FB28E552">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:128DD788-D47E-4F4B-AD6D-B82C77B2F11B"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2AA708F1-622C-4D5D-9D25-2946E06DCDDB">
    <pav:createdOn>2014-07-18 14:05:17 -0700</pav:createdOn>
    <ao:prefix>The </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>2AA708F1-622C-4D5D-9D25-2946E06DCDDB</domeo:uuid>
    <ao:suffix>. (See PRECAUTIONS.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2AA708F1-622C-4D5D-9D25-2946E06DCDDB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD theophylline AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). Theophylline clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of theophylline increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3600E64E-4D3A-48CE-A0E8-33E1B78E99E5">
    <pav:createdOn>2014-07-18 14:23:45 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:3B501E10-7673-4F8E-889F-7048994F6D90"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-18 14:23:49 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A1747CFE-8798-401D-BFC7-1E14B7B3B1B1</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:D0F2204E-5148-4A33-AAD0-599FB1F44EFC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED9173BA-30D7-4181-85F1-37CC30DFF11C">
    <pav:lastSavedOn>2014-07-17 15:59:35 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-17 15:58:55 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DEBE5AF-B171-4BE8-880B-76A2BEE742A6</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:446A1126-39C6-4A5E-8A9C-13D15F81AD8C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B716A719-3E66-4B72-87E0-370D90F3B8F7</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C376F0E-D7D6-4846-B8E9-1C50742E0CD2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-10 11:20:41 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:4B77AEB1-052D-442D-91E6-921DAD259BC6"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A229E325-2C87-4EFC-8114-8F692F9FE147">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/3FD2DBDA-7F24-4B3D-829F-5ECB6A6E2D7B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/62B567F8-EBE4-4BA4-9B68-E81E9E1BCD30"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C20AD1B-8F9C-472D-A102-E6A1F85BDC4E">
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:30F7EA47-3832-4833-A7F4-22FA71A2083F"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-16 10:23:07 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:7EC16932-4B45-4E99-BD42-2FCDF16C4F6D</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-16 10:23:02 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E954CE3-F61D-4171-A4FE-6FAE429FF615">
    <pav:createdOn>2014-07-18 14:07:20 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B480EE53-5881-4650-9D82-D1F972071243</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-18 14:07:26 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:B136901C-38A0-4F12-B35D-BF814374DB34</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:0C8A7DFF-59B1-4852-B9E4-A60D88CD3918"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C69466D9-4AD4-4863-ABBC-AEF76AEF11D6">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Cimetidine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix> (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-10 11:08:09 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C69466D9-4AD4-4863-ABBC-AEF76AEF11D6"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64D0C269-01F6-4340-8315-A41DCAE1D199">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:64D0C269-01F6-4340-8315-A41DCAE1D199"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-15 14:14:03 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix> plus </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F18B18E9-19FE-4C8D-BEE4-1C59CA30430D">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>lithium</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C52DDDDD-59AD-4D62-94B9-F53565B2D800">
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C52DDDDD-59AD-4D62-94B9-F53565B2D800"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-16 15:39:34 -0700</pav:createdOn>
    <ao:suffix> 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers. After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Fluconazole</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2070D1E-ACA9-4A94-BC6D-885BA2DE100C">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E2070D1E-ACA9-4A94-BC6D-885BA2DE100C"/>
    <pav:createdOn>2014-07-18 13:55:43 -0700</pav:createdOn>
    <ao:suffix> dose for at least two weeks. There was a significant increase in zidovudine AUC following the administration of fluconazole. The mean ± SD increase in AUC was 20% ± 32% (range: -27 to 104%). The metabolite, GZDV, to parent drug ratio significantly decre</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>zidovudine</ao:exact>
    <ao:prefix> 200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52926929-04E3-4243-A2C3-5B9100F9FBE1">
    <ao:body rdf:nodeID="N28c4f1a5f2874724adb4efe13b7c3140"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdOn>2014-07-15 14:23:11 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-15 14:30:47 -0700</pav:lastSavedOn>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:040CDB6C-0256-4144-8293-65FE5BE6A8FC"/>
    <pav:previousVersion>urn:domeoserver:annotationset:883587E1-49C1-4EE0-909E-4ADBAE13DD3A</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB1F59F5-F04B-4836-B1C9-90E20E62B91E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B419ACAE-832E-406D-9427-D88D93B6A405"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:AF88B107-1B45-4CD4-A63F-0DC626B375A8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-16 14:07:45 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-16 14:07:53 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C66BBCCE-CA43-44FB-8D97-2084E19C48FF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-15 14:03:13 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-15 14:04:06 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:CE892364-BAE9-432B-976E-743B57F2408B"/>
    <pav:lineageUri>urn:domeoserver:annotation:B3190C68-4AD0-4462-BE08-70DB24E80259</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62C1B60E-3BDC-470D-A027-77547456BB31">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <ao:prefix> oral solution is bioequivalent to </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> tablets.</ao:suffix>
    <pav:createdOn>2014-07-16 10:20:01 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:62C1B60E-3BDC-470D-A027-77547456BB31"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9DE6AF1A-97A2-486C-8C39-E06C073F68E4">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1AA7E714-DDFA-450C-A589-5EA4319B4691"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2690ED3-4A3B-4FA6-84FF-6800464F3D50">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C94BECCE-E3E9-4B70-AC23-F715B9D3EEFF</pav:lineageUri>
    <pav:lastSavedOn>2014-07-17 15:54:46 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-17 15:54:16 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:96BAB4C7-6F7A-4EBA-BAC1-134F746F11FA</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:D1D04FEE-3479-4F04-B0D6-9FC8F29285CE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DAD17BCA-9CFC-4DE8-932B-E68F8A5FAD45">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-18 13:55:49 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:99826AC3-3668-4F74-9E9D-DADD1F7098F0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-18 13:56:04 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:58452268-E11A-438D-ACF7-C32BA04261F1"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:F0DBBACF-FE8B-4884-BCC8-527B11B90A1A</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06A59058-E7B5-4A71-9D10-07FD98051EBF">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:029204D1-F9E2-49AE-8BBC-4F278A048EBD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-16 10:19:19 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:32208944-92E0-40BE-AA45-03DC0663A09C">
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-10 11:14:30 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:7BF5554D-4C3C-4CBD-A76D-4F6E34BF997A</pav:lineageUri>
    <pav:createdOn>2014-07-10 11:10:53 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:3A31AA07-7919-4161-9DEB-01C06D730BF5"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31737AE9-0835-48DB-82BD-A713405999A3">
    <domeo:belongsToSet>urn:domeoserver:annotationset:FF76049E-6B2C-46A9-ACF7-CA565C8087F3</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:C00C2C3C-0648-4779-A135-09D440F1CEA8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-18 13:43:48 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:EFD26771-2076-4B50-83F1-3C5592306D86"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-18 13:43:37 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA792FCD-C812-49FE-9EDF-15DA0F056A53">
    <ao:context rdf:resource="urn:domeoclient:uuid:FE91163B-25D4-45FB-AD96-78A70FE948D6"/>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:2057A694-4518-498B-B065-0F8DC56570A5</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdOn>2014-07-15 14:10:43 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CD3E95AA-5887-4E3B-B181-8C84F1A4D6C5">
    <ao:body rdf:nodeID="Nbb0a682950984f9da10d32492de7e40e"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-10 11:22:24 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D779518E-9AC6-475E-AE81-120556E044A3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:516C333C-B517-4F84-999E-51185DD6E859</pav:previousVersion>
    <pav:lastSavedOn>2014-07-10 11:23:57 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3564DC3A-4069-432B-A29D-98AB86C42DF6">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-18 14:08:08 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:EFDAF0B4-5DB4-4A27-B9EE-3B518A18CDE2</pav:lineageUri>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:body rdf:nodeID="Na108a0ed49e24db6872a67862f1b9bf5"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-18 17:08:09 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B480EE53-5881-4650-9D82-D1F972071243</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:81FD23EC-BBD2-4E95-B296-364F882C43DB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9CAD6283-FE79-428D-A3CE-B664A09583CB">
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdOn>2014-07-15 14:14:03 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:64D0C269-01F6-4340-8315-A41DCAE1D199"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:719101C7-4FC8-4E56-81FA-58D7AC021659">
    <pav:createdOn>2014-07-16 15:40:24 -0700</pav:createdOn>
    <ao:exact>cimetidine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:719101C7-4FC8-4E56-81FA-58D7AC021659"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.</ao:suffix>
    <ao:prefix> AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CDFED240-5630-45F7-B475-A3C10DC429E0">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <domeo:uuid>CDFED240-5630-45F7-B475-A3C10DC429E0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> AUC and a 55% decrease in sildenafil Cmax. Co-administration resulted in a 50% increase in AUC of bosentan. The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing). Concomitant administration o</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CDFED240-5630-45F7-B475-A3C10DC429E0"/>
    <ao:exact>sildenafil</ao:exact>
    <pav:createdOn>2014-07-10 11:20:11 -0700</pav:createdOn>
    <ao:prefix> (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:40C3CB86-AAFD-4D68-AE0D-699574B044BD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>40C3CB86-AAFD-4D68-AE0D-699574B044BD</domeo:uuid>
    <pav:createdOn>2014-07-18 15:17:44 -0700</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> changes of unknown clinical significance</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:40C3CB86-AAFD-4D68-AE0D-699574B044BD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL,</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EEA8D937-1DA8-4F98-9D1E-B48786184636">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-26.txt.html</ao:hasSource>
    <ao:prefix> AUC and Cmax were determined before and after the administration of</ao:prefix>
    <ao:suffix> 200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks. There was a significant increase in cyclosporine AUC, Cmax, Cmin (24-hour conc</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EEA8D937-1DA8-4F98-9D1E-B48786184636"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-18 13:51:15 -0700</pav:createdOn>
    <ao:exact> fluconazole</ao:exact>
    <domeo:uuid>EEA8D937-1DA8-4F98-9D1E-B48786184636</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD7753FF-D1E8-489F-B53D-1F96A5C7118D">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-16 10:21:54 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:0ED84F3F-026A-4100-92FC-0F849E55CAE3</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-16 10:23:07 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B82EA451-7796-4E93-B7B5-692C0393EDDE"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4DD997B-59E6-4FDF-944E-0E3151C25851">
    <pav:createdOn>2014-07-10 11:15:31 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-10 11:15:41 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:A4BD01D1-8101-4C58-92D8-CF144E1497B9"/>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:3F81414E-B149-4B05-925B-18735B554A13</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ADF2DC89-FCCE-47DE-8493-BEC599C898E4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <pav:createdOn>2014-07-16 10:19:32 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:F5EA08DB-0874-466C-8ADD-16FB922B834F"/>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05FDCD78-BAF2-46D7-9D0F-0636684A6834">
    <pav:lastSavedOn>2014-07-18 16:51:47 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:B8452517-26D0-419F-88FD-A818925FDE06</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A59961D-051E-4238-8A44-2BD5D13E656F"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-18 13:51:33 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:D46DAB63-DFCF-4B24-9A25-769A3C80AF51</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F906594B-BBC1-48AF-8F3D-C4A2E2A96B54">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:ACA9D41B-D228-4B02-A61E-CA2C8E027440"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15C80BDC-57FE-49D1-830F-1A9F2C7BCA2C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:15C80BDC-57FE-49D1-830F-1A9F2C7BCA2C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> and its active metabolite decreased by 60% compared to young healthy subjects. Risperidone doses should be reduced in patients with renal disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-15 14:17:46 -0700</pav:createdOn>
    <ao:prefix>Renal Impairment: In patients with moderate to severe renal disease, clearance of the sum of </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A0FB0C6E-5133-4379-A6A1-718CC8383F46">
    <pav:createdOn>2014-07-15 14:15:08 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A0FB0C6E-5133-4379-A6A1-718CC8383F46"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> concentrations than poor metabolizers, the pharmacokinetics of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone</ao:exact>
    <ao:suffix> and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4ae87a8bb30a48c683e11fb5104e796f">
    <domeo:sets rdf:resource="urn:pddi:uuid:3BD41FAC-162E-4141-B15C-C7AD0CAF56A0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A42DE598-1DBE-4AFF-81B2-08991620AD5B">
    <ao:suffix> combined, after single and multiple doses, were similar in extensive and poor metabolizers, with an overall mean elimination half-life of about 20 hours.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-15 14:17:37 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A42DE598-1DBE-4AFF-81B2-08991620AD5B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:prefix> and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:80304B91-FB8B-4EF5-87EC-80F59A689F2A">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:52C23FEF-CB29-459B-934E-EDA40F63DD1E"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:2C25A7F3-8A42-4060-A64C-5C2AB24D4675</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:BE8D3AAD-5714-40E9-8521-B30676F883D5"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-09 16:57:52 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:1FD70F7A-986E-48F8-93F4-DA3377C3E107"/>
    <pav:previousVersion>urn:domeoserver:annotationset:88784842-2713-4D3B-A293-A9498ACCA54A</pav:previousVersion>
    <pav:createdOn>2014-07-09 13:36:31 -0700</pav:createdOn>
    <permissions:permissions rdf:nodeID="N120e4026351a4e2a8d8ba1d3fec36fdc"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-13.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:05BFE4D9-CD9B-4F44-B4A5-28A1E4F90000"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C70E2E47-3AA5-4F01-A8A1-711E946726F5">
    <pav:lastSavedOn>2014-07-10 11:14:30 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-10 11:09:23 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:A4A573A6-4DD9-4D71-9C8C-FC03B750BDC0</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:EF537613-8BA0-4920-9501-06EA08F94E71"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4CE762A1-3B91-4B51-861E-7CFEE91439CF">
    <pav:createdOn>2014-07-09 13:36:31 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4CE762A1-3B91-4B51-861E-7CFEE91439CF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> did not significantly alter steady-state lithium levels or the renal clearance of lithium.</ao:suffix>
    <domeo:uuid>4CE762A1-3B91-4B51-861E-7CFEE91439CF</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>In a placebo-controlled trial in normal volunteers, the administration of two doses of </ao:prefix>
    <ao:exact>sertraline</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-13.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D2018278-5A34-478E-8004-540890604BD3">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>9-hydroxyrisperidone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/679314</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84ED4684-C66A-4CA3-8A17-114128E1557B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdOn>2014-07-10 11:20:31 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:B8AA7B02-72B4-4632-9BDA-34C02C628D9A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:30F7EA47-3832-4833-A7F4-22FA71A2083F">
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-16 10:23:02 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:30F7EA47-3832-4833-A7F4-22FA71A2083F"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF56FD55-EDC5-4596-9E28-37011839842A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>phenytoin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FF56FD55-EDC5-4596-9E28-37011839842A"/>
    <pav:createdOn>2014-07-18 13:48:33 -0700</pav:createdOn>
    <domeo:uuid>FF56FD55-EDC5-4596-9E28-37011839842A</domeo:uuid>
    <ao:prefix> AUC. The mean ± SD increase in </ao:prefix>
    <ao:suffix> AUC was 88% ± 68% (range: 16 to 247%). The absolute magnitude of this interaction is unknown because of the intrinsically nonlinear disposition of phenytoin. (See PRECAUTIONS.)</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5975A18C-9750-49AF-9CBD-E13C8DFBA413">
    <domeo:belongsToSet>urn:domeoclient:uuid:B8452517-26D0-419F-88FD-A818925FDE06</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-18 16:51:47 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:1E1FBE55-6AAA-47B7-B94A-48F3F99E76F0</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:455E5E9F-232E-451B-8C43-9687045AD008"/>
    <pav:createdOn>2014-07-18 13:51:09 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7DF78E91-4010-455D-9300-16EAD7D6AB87">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-15 14:08:33 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A0209F9-EA1A-4BBA-865A-0A0F6CCAF57E"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:9A4FDA77-AC39-4F85-8AE8-81F4B016A81D</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:547CD07E-3BE0-408B-82B7-99021E41003B">
    <pav:createdOn>2014-07-18 14:07:15 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-18 14:07:26 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B480EE53-5881-4650-9D82-D1F972071243</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:A420EA3F-BB84-4220-A684-2224CB4B6C3D"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B136901C-38A0-4F12-B35D-BF814374DB34</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C025BBE5-19A7-4D05-9813-E49F4799CB23">
    <pav:createdOn>2014-07-15 14:18:41 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-15 14:19:34 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CC119E59-51D3-4AAE-87A1-B3FF2D690F31"/>
    <pav:lineageUri>urn:domeoserver:annotation:2BCCD145-6E75-4F42-8F21-C96F2FF41685</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C9C3F3B-D652-4BC5-8BE9-2D01F09D0D62">
    <pav:createdOn>2014-07-16 14:03:15 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:D926C2F6-78D7-4536-8A5A-699F2B8E5B74</pav:lineageUri>
    <pav:lastSavedOn>2014-07-16 14:06:30 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:49A3E368-5986-471F-9A56-C7C0F8072A9E"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ECDDC20F-1C2B-469E-98F0-C0EB9DA754E2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ECDDC20F-1C2B-469E-98F0-C0EB9DA754E2"/>
    <domeo:uuid>ECDDC20F-1C2B-469E-98F0-C0EB9DA754E2</domeo:uuid>
    <ao:prefix> 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in </ao:prefix>
    <ao:suffix> estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%).</ao:suffix>
    <ao:exact>ethinyl </ao:exact>
    <pav:createdOn>2014-07-16 15:32:37 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2808EA87-CFD9-497E-B3D4-336DDC2CF6FF">
    <ao:suffix> concentrations when co-administered with sildenafil (50 mg) to healthy volunteers</ao:suffix>
    <ao:exact>sildenafil</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2808EA87-CFD9-497E-B3D4-336DDC2CF6FF"/>
    <ao:prefix> </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-10 11:08:45 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0676820-4037-444B-AE4D-9C1ED43E28D9">
    <pav:createdOn>2014-07-17 15:59:21 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E0676820-4037-444B-AE4D-9C1ED43E28D9"/>
    <ao:exact> fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTIONS.)</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E0676820-4037-444B-AE4D-9C1ED43E28D9</domeo:uuid>
    <ao:prefix>. There was a mean ± SD reduction in</ao:prefix>
    <ao:hasSource>			http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1D630F4-743B-425E-8FB2-C96DB1D59EEE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D1D630F4-743B-425E-8FB2-C96DB1D59EEE</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D1D630F4-743B-425E-8FB2-C96DB1D59EEE"/>
    <ao:suffix>. However, the administration of</ao:suffix>
    <ao:exact>Fluconazole 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers. After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%)</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>				http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html																													</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-17 15:56:08 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A1A5580F-53D7-4F22-824E-5430565EDBF1">
    <pav:lastSavedOn>2014-07-15 14:04:06 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:25FC3270-77CF-4552-800B-3A6E31592E33"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:11B910BF-1D1A-4CDC-AEE8-7EB159B8DDE1</pav:lineageUri>
    <pav:createdOn>2014-07-15 14:02:44 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2931C8A-EC31-47B6-AE9D-7EFD2AFC6C76">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B716A719-3E66-4B72-87E0-370D90F3B8F7</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:EC1C5E61-FA3B-468A-A86F-BC4B06CEB624"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DEBE5AF-B171-4BE8-880B-76A2BEE742A6</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-17 15:59:35 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-17 15:59:01 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4BD1F108-6B86-46B9-94ED-17733AF67E71">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-18 13:56:04 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:99826AC3-3668-4F74-9E9D-DADD1F7098F0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E34E3E0D-B50B-4B49-B4D0-AD4C76A51252"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-18 13:56:03 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:9A8779B8-6D9E-42E8-A5A7-43649245B924</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EFD26771-2076-4B50-83F1-3C5592306D86">
    <pav:createdOn>2014-07-18 13:43:37 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EFD26771-2076-4B50-83F1-3C5592306D86"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>EFD26771-2076-4B50-83F1-3C5592306D86</domeo:uuid>
    <ao:suffix> increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTIONS.)</ao:suffix>
    <ao:prefix> AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37FB0E70-766B-4459-A183-3C9D1DA69A86">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:37FB0E70-766B-4459-A183-3C9D1DA69A86"/>
    <ao:prefix> and </ao:prefix>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:suffix> [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak binding of risperidone to the enzyme suggests this is unlikely [see 7 DRUG INTERACTIONS].</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-15 14:16:39 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F8B9524-4C64-4996-BBA7-9A2CED8F6A99">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F8B9524-4C64-4996-BBA7-9A2CED8F6A99"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> to</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> [see 7 DRUG INTERACTIONS]. This occurs with quinidine, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of risperidone in patients receiving quinidine have</ao:suffix>
    <ao:exact> 9-hydroxyrisperidone</ao:exact>
    <pav:createdOn>2014-07-15 14:15:32 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E38D9228-C97F-4151-9702-C3C8F519D87E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-15 16:58:25 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:97CA2BFC-4AC9-49DF-A924-849AE4D18CCA</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-15 13:56:25 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:1C00DD3B-AD96-4229-AD96-9CFE64EA4677</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:ED6E68B4-D2C7-419B-A740-99C70A25F570"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4D81A7B-4D7D-4EBA-A2C1-0E5AC4A8CE5C">
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:7AB175A5-BD20-41A8-91C0-16D5DF981557"/>
    <pav:createdOn>2014-07-15 14:17:07 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb7458e4454314e1d99e42e0974e37829">
    <domeo:sets rdf:resource="urn:pddi:uuid:31B6ED7E-D003-4C21-A285-EBE6FB28E552"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ECE81054-6CF5-460C-88CE-88C1E5F148ED">
    <pav:createdOn>2014-07-18 13:43:41 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:C00C2C3C-0648-4779-A135-09D440F1CEA8</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FF76049E-6B2C-46A9-ACF7-CA565C8087F3</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-18 13:43:48 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:61EFE295-187A-4B36-B127-C54D8E2D8B4D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A82BF7D-FCE6-4985-9C4B-E950C1124476">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:E82CAFB0-79BE-4952-A18B-AB34D1AEB9BB</pav:lineageUri>
    <pav:createdOn>2014-07-16 15:36:36 -0700</pav:createdOn>
    <ao:body rdf:nodeID="Nc8416fc4f3ea4933a6f01a66f41df52c"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:05321D03-FF55-4658-854E-AEE6CA65C7B5"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F87EEF0-40A6-43E2-8222-95E7D1335A0B</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-16 18:38:32 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9DF202FF-7B27-4079-825C-68963E1927BA">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9DF202FF-7B27-4079-825C-68963E1927BA"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-16 10:20:36 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> </ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/8A890D90-4AB4-4DD3-A520-217921B71116">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>9-hydroxyrisperidone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/679314</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/DA1E3525-C5D9-473E-8402-BDC110AF5313">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>epoprostenol</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8814</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2360225-A46C-436D-A3D6-1502801E2F92">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:9C850E9D-0903-4A7D-8362-E39D7560ABB0"/>
    <pav:lastSavedOn>2014-07-18 17:26:00 -0400</pav:lastSavedOn>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:nodeID="Nbb3bf637709f4ecebbb5037ba78838fa"/>
    <pav:lineageUri>urn:domeoserver:annotation:AA735FDF-88DE-41B1-8E77-5DAA5722B10D</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A1747CFE-8798-401D-BFC7-1E14B7B3B1B1</domeo:belongsToSet>
    <pav:createdOn>2014-07-18 14:25:59 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B093B77-913B-463D-96DF-69C0A7A14BD4">
    <domeo:uuid>9B093B77-913B-463D-96DF-69C0A7A14BD4</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>No significant interactions were shown with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9.</ao:suffix>
    <pav:createdOn>2014-07-10 11:20:49 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9B093B77-913B-463D-96DF-69C0A7A14BD4"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:exact>tolbutamide</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14470CEA-E989-4566-A704-AC9CEFD39B6E">
    <ao:suffix>and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers.</ao:suffix>
    <ao:prefix>, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:14470CEA-E989-4566-A704-AC9CEFD39B6E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone </ao:exact>
    <pav:createdOn>2014-07-15 14:14:54 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A30AACD8-E9A8-4B2C-9DB3-7E44F147751F">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdOn>2014-07-10 11:20:49 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:9B093B77-913B-463D-96DF-69C0A7A14BD4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC20D454-AAA8-4A81-915D-03526B8FC40B">
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-15 14:08:46 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7B06A286-D3FC-41A8-A621-60C6E027265C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:067DD517-77F6-46CE-952D-88DCC4CCD969</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1D92634-CB40-4585-8260-1917D2119CC7">
    <pav:createdOn>2014-07-15 14:06:52 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:9B307D8B-D2B0-4795-8850-FAAAAC6B5AF4</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-15 14:07:58 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:977E8B6B-E0A2-4EB3-998A-A0DCF25EB2D6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DDF11329-3CD1-4391-B01E-D821B9E4C7F3">
    <pav:lastSavedOn>2014-07-15 14:30:47 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:883587E1-49C1-4EE0-909E-4ADBAE13DD3A</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:00F35F1A-5924-40DE-A59C-C43123E99A77"/>
    <pav:createdOn>2014-07-15 14:22:25 -0700</pav:createdOn>
    <ao:body rdf:nodeID="N6f44278c3a23434aa39d2269beef7853"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:076F37CF-3229-400A-A6F6-EBE2A8FC2F4C">
    <ao:context rdf:resource="urn:domeoclient:uuid:13602CFC-088D-4008-B42C-EA497E316CB4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-16 10:22:41 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:F4C204C3-294D-408E-8ABD-F4E69A7A6099</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-16 10:23:07 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8D0FBEEE-F2C5-4EBC-892B-1E8DE2D584AE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-16 10:20:06 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:10C3FD12-EB69-4E8A-9C52-BB5ED70A7565"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC1C5E61-FA3B-468A-A86F-BC4B06CEB624">
    <ao:hasSource>			http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-17 15:59:01 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EC1C5E61-FA3B-468A-A86F-BC4B06CEB624"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>rifampin</ao:exact>
    <ao:prefix> after 15 days of </ao:prefix>
    <ao:suffix> administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (ran</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>EC1C5E61-FA3B-468A-A86F-BC4B06CEB624</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C906DFD-63EC-472C-AD64-29043E8A58B1">
    <ao:prefix> AUC, Cmax, Cmin (24-hour concentration), and a significant reduction in apparent oral clearance following the administration of</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> fluconazole</ao:exact>
    <domeo:uuid>1C906DFD-63EC-472C-AD64-29043E8A58B1</domeo:uuid>
    <ao:suffix>. The mean ± SD increase in AUC was 92% ± 43% (range: 18 to 147%). The Cmax increased 60% ± 48% (range: -5 to 133%). The Cmin increased 157% ± 96% (range: 33 to 360%). The apparent oral clearance decreased 45% ± 15% (range: -15 to -60%). (See PRECAUTIONS</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-26.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-18 13:51:41 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1C906DFD-63EC-472C-AD64-29043E8A58B1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:A1747CFE-8798-401D-BFC7-1E14B7B3B1B1">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <permissions:permissions rdf:nodeID="N2bcf846e1338444bb4b1ebefe4ee3de0"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:D0F2204E-5148-4A33-AAD0-599FB1F44EFC</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:E2360225-A46C-436D-A3D6-1502801E2F92"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2014-07-18 14:23:36 -0700</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lastSavedOn>2014-07-18 17:26:00 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:9C861997-137E-4C3F-A9A5-BF78640820A1"/>
    <pav:previousVersion>urn:domeoclient:uuid:AA2CF58E-6DB1-4267-8DFC-33DE11331D87</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:3600E64E-4D3A-48CE-A0E8-33E1B78E99E5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2ECA95EB-4370-4C4C-8C95-4A2BE49873EF"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-51.txt.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A252FD3C-4309-4CCB-8491-4B23A2848662">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:A81A4371-A756-421B-8B30-D10382A032D4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:createdOn>2014-07-15 14:14:40 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EF537613-8BA0-4920-9501-06EA08F94E71">
    <ao:prefix> concentrations when co-administered with </ao:prefix>
    <pav:createdOn>2014-07-10 11:09:23 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> (50 mg) to healthy volunteers.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EF537613-8BA0-4920-9501-06EA08F94E71"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>sildenafil</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5DF27E07-C0B9-48CC-97AF-10E8A9830A54">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5DF27E07-C0B9-48CC-97AF-10E8A9830A54"/>
    <ao:suffix> are reached in 5 to 6 days (measured in extensive metabolizers).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> are reached in 1 day in extensive metabolizers and would be expected to reach steady-state in about 5 days in poor metabolizers. Steady-state concentrations of </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <pav:createdOn>2014-07-15 14:07:09 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B234C79-AB11-4626-BB32-A29D819B57BA">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N7290ceb2420f497d8a78e5411fe068db"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-16 14:10:22 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:A7878F85-BB08-493B-BAC8-A9CE6B2E5167</pav:lineageUri>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:F11CBAD8-E220-415C-81B8-EC30E7A34762"/>
    <pav:lastSavedOn>2014-07-16 17:10:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FECBEFAB-2C18-4C64-93DF-19494748E804">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-16 10:19:14 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FECBEFAB-2C18-4C64-93DF-19494748E804"/>
    <ao:suffix> and its major metabolite, 9-hydroxyrisperidone [see 12 CLINICAL PHARMACOLOGY]. Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of risperidone.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <ao:prefix> results from the combined concentrations of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9F2162C5-D2E9-42F5-99DE-E7F470A1AD7C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9F2162C5-D2E9-42F5-99DE-E7F470A1AD7C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix> is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of </ao:prefix>
    <pav:createdOn>2014-07-15 14:09:57 -0700</pav:createdOn>
    <ao:suffix> to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug results fr</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB6A5C23-94A9-4771-82D0-E81F57F7430F">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <ao:suffix> increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours. (See PRECAUTIONS.)</ao:suffix>
    <domeo:uuid>AB6A5C23-94A9-4771-82D0-E81F57F7430F</domeo:uuid>
    <pav:createdOn>2014-07-18 14:03:17 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB6A5C23-94A9-4771-82D0-E81F57F7430F"/>
    <ao:prefix> clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of </ao:prefix>
    <ao:exact>theophylline</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BCC5E7E8-854A-4B02-859A-36A9EC807AF5">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-15 14:16:25 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:F5CF7F61-B7F1-4B7C-AF06-558EB0A245B6"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36A9182C-B7D6-405A-BBF7-D0B654870FAE">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:36A9182C-B7D6-405A-BBF7-D0B654870FAE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of cimetidine 600 mg to 900</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>cimetidine</ao:exact>
    <pav:createdOn>2014-07-17 15:53:45 -0700</pav:createdOn>
    <ao:hasSource>				http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html																													</ao:hasSource>
    <ao:prefix> 400 mg to six healthy male volunteers. After the administration of </ao:prefix>
    <domeo:uuid>36A9182C-B7D6-405A-BBF7-D0B654870FAE</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3051A76E-96A2-4A70-91F9-A241566DEFD1">
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdOn>2014-07-15 14:15:18 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:69BEBC8E-741D-4841-BCB0-771651B22677"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/595576F3-EC50-44DE-92FC-A9FC2111AFB6">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>estradiol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2C03A2F-0DF1-4E82-B58C-1909B3460EAA">
    <ao:context rdf:resource="urn:domeoclient:uuid:3F6F9929-F258-49DD-AEE9-BEC5C27775EF"/>
    <pav:createdOn>2014-07-16 15:40:36 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:9DA9A31B-CA56-4204-B178-1E74EE6E1E6F</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-16 15:40:55 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E3DA2E5E-FC19-4C22-AF6C-A9CB4B450554</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1062598-B310-4CF4-8237-5F8F8F74933F">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-15 14:07:31 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-15 14:07:58 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:2FE06202-CAC5-466E-B0DA-E34428ADAEF3"/>
    <pav:previousVersion>urn:domeoclient:uuid:9B307D8B-D2B0-4795-8850-FAAAAC6B5AF4</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFD4FFA0-934F-4003-A721-60AFD1521572">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CFD4FFA0-934F-4003-A721-60AFD1521572"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> from a tablet is 94% (CV=10%) when compared to a solution.</ao:suffix>
    <ao:prefix> is 70% (CV=25%). The relative oral bioavailability of </ao:prefix>
    <pav:createdOn>2014-07-15 14:03:43 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB5F4799-5045-4FBD-ACF4-AFCEB256A943">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours</ao:exact>
    <pav:createdOn>2014-07-18 13:45:45 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB5F4799-5045-4FBD-ACF4-AFCEB256A943"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <ao:suffix>. (See PRECAUTIONS.</ao:suffix>
    <ao:prefix>Administration of a </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>AB5F4799-5045-4FBD-ACF4-AFCEB256A943</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/B6084BE9-4101-468F-985F-F42789F59869">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>phenytoin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:91F1D915-0F2B-4B98-A86E-D0E424CBADC1">
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:91F1D915-0F2B-4B98-A86E-D0E424CBADC1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:prefix> is 90%, and that of its major metabolite, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix>, is 77%. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in th</ao:suffix>
    <pav:createdOn>2014-07-15 14:08:40 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E3A87903-26B7-471E-B573-E6792F176AFA">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E3A87903-26B7-471E-B573-E6792F176AFA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-18 14:23:40 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy). </ao:suffix>
    <ao:prefix> with </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-51.txt.html</ao:hasSource>
    <domeo:uuid>E3A87903-26B7-471E-B573-E6792F176AFA</domeo:uuid>
    <ao:exact>paroxetine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:32BA85DE-7726-48C4-99FF-A828C5E2713A">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:32BA85DE-7726-48C4-99FF-A828C5E2713A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> in subjects with liver disease were comparable to those in young healthy subjects, the mean free fraction of </ao:prefix>
    <ao:suffix> in plasma was increased by about 35% because of the diminished concentration of both albumin and α1-acid glycoprotein. Risperidone doses should be reduced in patients with liver disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
    <pav:createdOn>2014-07-15 14:18:35 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16CA4CDD-75E6-4B6B-8392-4CE5B648D48E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:891ADA8B-FE3B-424C-BA58-775CE8AC2E75"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C00C2C3C-0648-4779-A135-09D440F1CEA8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-18 13:43:48 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-18 13:43:23 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FF76049E-6B2C-46A9-ACF7-CA565C8087F3</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C850E9D-0903-4A7D-8362-E39D7560ABB0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9C850E9D-0903-4A7D-8362-E39D7560ABB0"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-51.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-18 14:25:59 -0700</pav:createdOn>
    <domeo:uuid>9C850E9D-0903-4A7D-8362-E39D7560ABB0</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:523A8E6B-6F7F-4807-9852-CFA0940BB6CC">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3E222580-6163-4407-B0C4-D0FC6BC85172"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5DCE0D50-99F3-4301-8B36-DE5F9A87ECDD">
    <pav:lineageUri>urn:domeoserver:annotation:9E77CBDC-FE87-4054-9219-455A4C81D84B</pav:lineageUri>
    <pav:lastSavedOn>2014-07-16 14:06:30 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-16 14:03:51 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:8049D373-44B2-4E73-95D6-3445DE0002F8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3A3ADF6-73D6-48FB-AF10-EC6590D40ED9">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <domeo:uuid>A3A3ADF6-73D6-48FB-AF10-EC6590D40ED9</domeo:uuid>
    <ao:suffix> 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD theophylline AUC increased 21% ± 16% (range: -5 to 48%). The Cmax </ao:suffix>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A3A3ADF6-73D6-48FB-AF10-EC6590D40ED9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-18 14:02:49 -0700</pav:createdOn>
    <ao:prefix> (6 mg/kg) before and after the oral administration of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:92E5C2B0-A019-4BC5-BDC7-295AFBB9DF17">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:92E5C2B0-A019-4BC5-BDC7-295AFBB9DF17"/>
    <ao:suffix> increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosi</ao:suffix>
    <ao:prefix> and </ao:prefix>
    <ao:exact>norethindrone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-16 14:04:04 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7443907B-C475-4EA4-B081-8C3D55A1EF69">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdOn>2014-07-15 14:09:39 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:F3519808-15C2-48AA-8344-8BFE8F7E6625</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:0BB528F0-CD4A-4BAC-AA5B-3FF33FCFF9B7"/>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05F3AC40-8EB1-409A-9E01-317E8C07400C">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C</domeo:belongsToSet>
    <pav:createdOn>2014-07-16 14:03:26 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:62B1B85D-E1E5-47D8-A52B-555785D4F8AE</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-16 14:06:30 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:81CA85AD-8F73-41B9-AEC4-5F2B934C9D93"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/ADE2E1DA-D3E9-438C-A1E1-D82219070E28">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4124</dailymed:activeMoietyRxCUI>
    <rdfs:label>ethinyl estradiol</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A4BD01D1-8101-4C58-92D8-CF144E1497B9">
    <ao:suffix>, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A4BD01D1-8101-4C58-92D8-CF144E1497B9"/>
    <domeo:uuid>A4BD01D1-8101-4C58-92D8-CF144E1497B9</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-10 11:15:31 -0700</pav:createdOn>
    <ao:prefix>In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor </ao:prefix>
    <ao:exact>saquinavir</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:831D0F3D-639E-4B91-A3ED-AE0F362D5CE0">
    <ao:suffix> and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compar</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:exact>ethinyl estradiol</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:831D0F3D-639E-4B91-A3ED-AE0F362D5CE0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>compared to similar placebo dosing. The mean AUCs of </ao:prefix>
    <pav:createdOn>2014-07-16 14:03:59 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:892E6482-5108-4155-B6F2-763924AB0616">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:892E6482-5108-4155-B6F2-763924AB0616"/>
    <domeo:uuid>892E6482-5108-4155-B6F2-763924AB0616</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-10 11:17:03 -0700</pav:createdOn>
    <ao:exact>When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC)</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:542B35CF-4581-4FCE-8D90-B315B353F9BE">
    <ao:exact>bosentan</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:542B35CF-4581-4FCE-8D90-B315B353F9BE"/>
    <ao:suffix> (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax. Co-administration resulted in a 50% increase in AUC of bosentan. </ao:suffix>
    <domeo:uuid>542B35CF-4581-4FCE-8D90-B315B353F9BE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:prefix> at steady state (80 mg TID) with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-10 11:20:07 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:380253B1-58A2-45B6-B271-96D870E13796">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:CDFED240-5630-45F7-B475-A3C10DC429E0"/>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <pav:createdOn>2014-07-10 11:20:11 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3B7229C1-BBC3-4F13-A2D8-9C5E932927F8">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C99A2006-8591-4B3F-9788-B075E7E171FD"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C039DC79-C2B3-4581-A409-2060854712D2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2CE33325-EF3D-4298-BBCC-82F0A45DA665</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:3DA2685F-E7CD-44B7-8191-43C3200458E4</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:83325641-7434-4321-A570-829337F41ADF"/>
    <pav:createdOn>2014-07-16 10:36:22 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-16 10:36:38 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:926EB546-FC66-4BEC-B38A-18749E06CCE5">
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-15 14:17:00 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:75978B88-8F19-4550-921C-BCAB17F30E80"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:548F8E3A-F3DF-41D2-B65F-5C14C8EE8007">
    <domeo:belongsToSet>urn:domeoserver:annotationset:FF76049E-6B2C-46A9-ACF7-CA565C8087F3</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-18 13:43:48 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-18 13:43:20 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:35ABEAB8-91E9-4F2D-B158-A3AE422D3EB0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:C00C2C3C-0648-4779-A135-09D440F1CEA8</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6B42267E-6924-4453-B105-2F66C330186C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:6293CB80-DCD6-4620-8C0D-569FB4C95073"/>
    <pav:createdOn>2014-07-16 10:18:56 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F057A8DE-7885-47B0-B2D9-E9C3D877EC02">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-16 15:44:20 -0700</pav:createdOn>
    <ao:suffix>. However, the administration of</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>F057A8DE-7885-47B0-B2D9-E9C3D877EC02</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F057A8DE-7885-47B0-B2D9-E9C3D877EC02"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <ao:exact>Fluconazole 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers. After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%)</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A60BA1DD-61D6-4A5F-906B-D67F0B3C7692">
    <pav:createdOn>2014-07-15 14:15:43 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A60BA1DD-61D6-4A5F-906B-D67F0B3C7692"/>
    <ao:suffix> pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of risperidone in patients receiving quinidine have not been evaluated, but observations in a modest number (N≅70) of poor metabolizers given risperidone </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, giving essentially all recipients a </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/62B567F8-EBE4-4BA4-9B68-E81E9E1BCD30">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>risperidone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0216B801-6401-4E8A-B678-5222EA6AA098">
    <pav:lastSavedOn>2014-07-18 14:03:19 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:9AA0507C-281E-45C8-9719-03E66F12C069</pav:lineageUri>
    <pav:createdOn>2014-07-18 14:03:04 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DBCB873-26F3-4E6A-9BD4-311369B43736</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:427474F1-6F8A-40AF-BCE5-B758B7F7E955"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94A95C57-5A20-472B-87AE-DD634374AADD">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix> do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known enzyme inducers (e.g.,</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-18 15:24:32 -0700</pav:createdOn>
    <domeo:uuid>94A95C57-5A20-472B-87AE-DD634374AADD</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:94A95C57-5A20-472B-87AE-DD634374AADD"/>
    <ao:exact> carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68AD55C4-223A-46C6-896A-87345A781B61">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:46A0754E-C451-439B-B685-374909D4C42D"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-15 14:08:20 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:9D72DC80-EDD2-4049-A453-1997284CCF0D</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:10EA2F12-BD12-4F54-9D90-CD6B3DC5179E">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:542B35CF-4581-4FCE-8D90-B315B353F9BE"/>
    <pav:createdOn>2014-07-10 11:20:07 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0444DBB-743A-42A1-A053-40E5E11BBD66">
    <pav:createdOn>2014-07-16 14:07:50 -0700</pav:createdOn>
    <ao:suffix> treatment.</ao:suffix>
    <ao:exact> fluconazole</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F0444DBB-743A-42A1-A053-40E5E11BBD66"/>
    <ao:prefix> (&lt;5%) in 3 of the 21 subjects after</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:17BE6274-5C33-43EE-85E7-EC723ACF1134">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:DBB0F4E1-DD60-4C7C-94FB-551FD745535F"/>
    <pav:createdOn>2014-07-18 13:55:55 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:B2598027-6899-4DCC-B719-FEB8338FFA83</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:99826AC3-3668-4F74-9E9D-DADD1F7098F0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-18 13:56:04 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:97152B9D-CEAA-4BF5-BCF3-8D56F516DD36">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/165E87BD-01D4-4D78-8A0D-F6089ECEF3AA"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/00222986-6A7D-42B7-950C-C9A90060EA28"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E4FC0A1A-8003-4267-9EC8-5C1F467D2F5F">
    <domeo:uuid>E4FC0A1A-8003-4267-9EC8-5C1F467D2F5F</domeo:uuid>
    <pav:createdOn>2014-07-09 13:36:40 -0700</pav:createdOn>
    <ao:exact>lithium</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E4FC0A1A-8003-4267-9EC8-5C1F467D2F5F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> levels or the renal clearance of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-13.txt.html</ao:hasSource>
    <ao:suffix>.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:70E10DEB-A12F-401E-803F-F6734EDD7985">
    <ao:prefix> and its </ao:prefix>
    <pav:createdOn>2014-07-15 14:18:14 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>active metabolite</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:70E10DEB-A12F-401E-803F-F6734EDD7985"/>
    <ao:suffix> decreased by 60% compared to young healthy subjects. Risperidone doses should be reduced in patients with renal disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:368B4BB2-B03B-4EBF-97A2-1D8357999CE7">
    <ao:suffix>. Consequently, the clinical effect of the drug results from the combined concentrations of risperidone plus 9-hydroxyrisperidone.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:368B4BB2-B03B-4EBF-97A2-1D8357999CE7"/>
    <pav:createdOn>2014-07-15 14:10:17 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, has similar pharmacological activity as </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:862041D3-5963-4DC0-966F-207E3A62BA47">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:748BB253-1066-4977-91B2-35D8C6906790</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:FF56FD55-EDC5-4596-9E28-37011839842A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-18 13:48:39 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-18 13:48:33 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A7F21A3D-50B3-495E-884A-2C707B40C763</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F9B8EE58-CE38-4918-9802-C2CBECEEA050">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-18 13:51:28 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:4E109C84-6323-418A-9404-5FBE487E6AA2"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:8F049889-04A8-49FD-BB22-5FC8DE315EE3</pav:lineageUri>
    <pav:lastSavedOn>2014-07-18 16:51:47 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:B8452517-26D0-419F-88FD-A818925FDE06</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED25013C-406F-45E7-817A-38F31C1C84A1">
    <pav:createdOn>2014-07-15 14:27:09 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ED25013C-406F-45E7-817A-38F31C1C84A1"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BFCAC108-C978-4C7B-A79A-9887A3CA3C6C">
    <pav:createdOn>2014-07-15 14:03:43 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:382E18F6-8A13-40D6-8859-AAB418548244</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-15 14:04:06 -0700</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:CFD4FFA0-934F-4003-A721-60AFD1521572"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/498E6806-6DCA-4705-867A-311AE66F8A32">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <rdfs:label>sertraline</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3F3050AD-E886-4649-8017-65F649BAA9E7">
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-15 14:15:13 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> combined, after single and multiple doses, are similar in extensive and poor metabolizers.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> and </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3F3050AD-E886-4649-8017-65F649BAA9E7"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/929638DA-F799-437F-8033-228CF8F46D12">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>warfarin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A5A2521E-A463-45F1-BFC8-4843561F5EFD">
    <pav:lineageUri>urn:domeoserver:annotationset:9AA0507C-281E-45C8-9719-03E66F12C069</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-18 14:03:17 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DBCB873-26F3-4E6A-9BD4-311369B43736</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB6A5C23-94A9-4771-82D0-E81F57F7430F"/>
    <pav:lastSavedOn>2014-07-18 14:03:19 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:312701AC-EC1C-4292-B01F-44DD40979EEA">
    <pav:lineageUri>urn:domeoserver:annotation:FB36FF68-03E9-4628-8F83-9796F15BD779</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:6684B979-BD2C-446B-B807-178AE44EB6F8"/>
    <pav:createdOn>2014-07-15 14:03:26 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-15 14:04:06 -0700</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A420EA3F-BB84-4220-A684-2224CB4B6C3D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-29.txt.html</ao:hasSource>
    <domeo:uuid>A420EA3F-BB84-4220-A684-2224CB4B6C3D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fluconazole</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A420EA3F-BB84-4220-A684-2224CB4B6C3D"/>
    <ao:prefix> (500 mg single dose) AUC and Cmax following the administration of </ao:prefix>
    <pav:createdOn>2014-07-18 14:07:15 -0700</pav:createdOn>
    <ao:suffix>. There was a mean ± SD increase in tolbutamide AUC of 26% ± 9% (range: 12 to 39%). Tolbutamide Cmax increased 11% ± 9% (range: -6 to 27%). (See PRECAUTIONS.)</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B3F40D13-C4D5-491E-B9BE-818D5A568EC5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>B3F40D13-C4D5-491E-B9BE-818D5A568EC5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> levels or the renal clearance of lithium.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B3F40D13-C4D5-491E-B9BE-818D5A568EC5"/>
    <pav:createdOn>2014-07-09 13:36:36 -0700</pav:createdOn>
    <ao:exact> lithium</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-13.txt.html</ao:hasSource>
    <ao:prefix> did not significantly alter steady-state</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:567E7CC2-49BA-4366-A98A-8E4134A9A74B">
    <pav:lineageUri>urn:domeoserver:annotationset:46F6E8D2-4020-433A-A976-216B25CC416D</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2014-07-18 14:32:24 -0700</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-52.txt.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <permissions:permissions rdf:nodeID="N848ecb80f2af4441b07e9b8f5684ba51"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-18 17:32:28 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:C8A30D50-862D-473B-A05C-42C01434E780"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51770B89-7CCF-409A-A2E9-D4576F9DB59A">
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2014-07-15 14:15:52 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0ABB2266-B2C7-44A9-8367-C5FE4916C02B"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6FED0630-F5B3-4A05-892B-CB86D31FD6DF">
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdOn>2014-07-15 14:16:16 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:541CB376-3C80-4099-9753-CC9C70F09426"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4D3BA7C7-A806-41A4-84AC-38A85FF0F9C2">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdOn>2014-07-15 14:06:36 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:2BB10533-7A8A-4C30-95A1-E3816F2A9980"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-15 14:07:58 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:9B307D8B-D2B0-4795-8850-FAAAAC6B5AF4</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED6E68B4-D2C7-419B-A740-99C70A25F570">
    <ao:prefix>The usual initial dosage of </ao:prefix>
    <pav:createdOn>2014-07-15 13:56:25 -0700</pav:createdOn>
    <ao:exact>acebutolo</ao:exact>
    <ao:suffix>l is 400 mg daily given as 200 mg b.i.d. Dosage should be increased gradually until an optimal clinical response is obtained, generally at 600 to 1200 mg per day. If treatment is to be discontinued, the dosage should be reduced gradually over a period of</ao:suffix>
    <domeo:uuid>ED6E68B4-D2C7-419B-A740-99C70A25F570</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-4.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ED6E68B4-D2C7-419B-A740-99C70A25F570"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AEA36B1F-63F1-4CF9-8B5E-4649C4B9F028">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AEA36B1F-63F1-4CF9-8B5E-4649C4B9F028"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2014-07-15 14:11:08 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:41F53CFC-A1D1-4460-AD5B-0F44E9396C8A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/498E6806-6DCA-4705-867A-311AE66F8A32"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F18B18E9-19FE-4C8D-BEE4-1C59CA30430D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4C14FED-0642-4B44-8AD5-DFA9D02E5B99">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:FE6DEC5A-2EFB-4D44-817D-5B910C9A906D"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-10 11:20:35 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60AE44A7-769C-4774-8E4D-7AF66A2F2EA1">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:37FB0E70-766B-4459-A183-3C9D1DA69A86"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-15 14:16:39 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc57ae467ff874feabe54b93742350fa0">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB6F25A1-6FFC-4CE5-8F5F-AD5806D52477">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-15 14:18:35 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:32BA85DE-7726-48C4-99FF-A828C5E2713A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-15 14:19:34 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:4CAC7ECA-C790-49F7-B709-B23F96D5F2BA</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2AAEA179-90D2-4661-9105-64A780850DEB">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:984705CF-6418-4362-AA0D-0A0DD15065D1"/>
    <pav:lineageUri>urn:domeoserver:annotation:C434D567-7705-4957-9B74-533EB1C6C8C9</pav:lineageUri>
    <pav:createdOn>2014-07-15 14:03:06 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-15 14:04:06 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:12D5CA7C-401C-4376-A246-03585C5F9AC0">
    <pav:createdOn>2014-07-15 14:03:32 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-15 14:04:06 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:3AF5AF5B-6498-4C88-94AC-716E8168CCAC"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:C731C2A5-DBEA-4B3B-ADC8-9CA0828BC185</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C861997-137E-4C3F-A9A5-BF78640820A1">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:D0F2204E-5148-4A33-AAD0-599FB1F44EFC</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A1747CFE-8798-401D-BFC7-1E14B7B3B1B1</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-18 14:23:40 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-18 14:23:49 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:E3A87903-26B7-471E-B573-E6792F176AFA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58452268-E11A-438D-ACF7-C32BA04261F1">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:58452268-E11A-438D-ACF7-C32BA04261F1"/>
    <ao:prefix> dose for at least two weeks. There was a significant increase in zidovudine AUC following the administration of</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. The mean ± SD increase in AUC was 20% ± 32% (range: -27 to 104%). The metabolite, GZDV, to parent drug ratio significantly decreased after the administration of fluconazole, from 7.6 ± 3.6 to 5.7 ± 2.2.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-18 13:55:49 -0700</pav:createdOn>
    <ao:exact> fluconazole</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D707EDCF-5B5D-4AB9-9815-32BDDA05721F">
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-15 14:16:12 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8811156A-F82B-4936-A5FD-E973920A426B"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:446A1126-39C6-4A5E-8A9C-13D15F81AD8C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:446A1126-39C6-4A5E-8A9C-13D15F81AD8C"/>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>			http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <ao:suffix> after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in flucon</ao:suffix>
    <ao:prefix>Administration of a single oral 200 mg dose of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-17 15:58:55 -0700</pav:createdOn>
    <domeo:uuid>446A1126-39C6-4A5E-8A9C-13D15F81AD8C</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8CA72313-3E32-44D6-A336-EDE69F22975A">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:90801A16-10A7-49A8-B684-48F8350FB818</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-15 14:19:34 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-15 14:18:20 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:41C2DB2C-7077-4ABE-8A8A-54A08326A7B8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4DC7A7E5-5253-4EB7-AEC1-2FD55FEF5068">
    <pav:createdOn>2014-07-16 15:35:39 -0700</pav:createdOn>
    <ao:prefix>Oral contraceptives were administered as a</ao:prefix>
    <ao:exact> single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%)</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4DC7A7E5-5253-4EB7-AEC1-2FD55FEF5068"/>
    <ao:suffix> and</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>4DC7A7E5-5253-4EB7-AEC1-2FD55FEF5068</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C54A1798-BD47-4D4C-89DF-B37F5A3AB9F0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-15 14:15:13 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:3F3050AD-E886-4649-8017-65F649BAA9E7"/>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:92F5F5C5-9A9C-4B47-AB81-A514809088C8">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:1EE1D64B-EDD4-4170-B797-D8F83B927DCE</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7BA312DF-BB65-4A90-8B7D-A54425D7C553</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-18 14:20:23 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-18 14:20:41 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:66EB6B71-8574-4EC7-B3B5-BA3D58493C78"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:FF76049E-6B2C-46A9-ACF7-CA565C8087F3">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <pav:previousVersion>urn:domeoclient:uuid:23AC741A-2236-437C-90AA-82B2E00E875C</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2014-07-18 13:43:09 -0700</pav:createdOn>
    <permissions:permissions rdf:nodeID="Nf37c66ab1343427fbf08dea2254da860"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2014-07-18 16:46:22 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:B372AAFD-51DF-43D9-B838-0F98E9692F16"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:548F8E3A-F3DF-41D2-B65F-5C14C8EE8007"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C00C2C3C-0648-4779-A135-09D440F1CEA8</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:16CA4CDD-75E6-4B6B-8392-4CE5B648D48E"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:31737AE9-0835-48DB-82BD-A713405999A3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:30DE360C-B631-4F35-8C09-DC4BC562543A"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:E7893705-3CF7-42B9-9C7F-93F25693DB84"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E68A8F1A-49B1-485B-9508-70DEE10CB0DB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ECE81054-6CF5-460C-88CE-88C1E5F148ED"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E27FBCC-C6F8-42FB-A7DC-B9AA486D3D4F">
    <pav:createdOn>2014-07-15 14:14:47 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix>, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone co</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0E27FBCC-C6F8-42FB-A7DC-B9AA486D3D4F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> rapidly into </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5261237F-686F-41D7-B860-16364A944D37">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5261237F-686F-41D7-B860-16364A944D37"/>
    <pav:createdOn>2014-07-15 14:16:19 -0700</pav:createdOn>
    <ao:suffix>, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs meta</ao:suffix>
    <ao:exact>rifampin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:025B9C60-3F34-47FE-83EE-A415FB50E5FC">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-17 16:00:10 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DEBE5AF-B171-4BE8-880B-76A2BEE742A6</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="Nd5af13157dcc442f9ab08aed0ecbd2b1"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-17 19:00:13 -0400</pav:lastSavedOn>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:3B0E9C37-2753-4F9C-9E67-80E4E93723C9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:BA399F23-8D58-4471-8517-AC275675E0F0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A2FA427B-9D1C-4042-8796-682C2C547E30">
    <pav:lineageUri>urn:domeoserver:annotation:BD6D0955-BF0D-4645-9244-A4A9E38D8457</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-16 14:06:30 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:02EFD3A2-6206-483D-8A82-D5AB320CD4B0"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-16 14:03:34 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29A7AD86-B18C-409C-86E9-985BFF28A757">
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A60BA1DD-61D6-4A5F-906B-D67F0B3C7692"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2014-07-15 14:15:43 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8AD0A979-32CC-4AB1-A507-37A7920B4725">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8AD0A979-32CC-4AB1-A507-37A7920B4725"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>sildenafil</ao:exact>
    <pav:createdOn>2014-07-10 11:20:05 -0700</pav:createdOn>
    <domeo:uuid>8AD0A979-32CC-4AB1-A507-37A7920B4725</domeo:uuid>
    <ao:suffix> at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax. Co-administration resul</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B6D54E8-D781-4B59-A1BC-6120E5CF9015">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-18 14:07:26 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B480EE53-5881-4650-9D82-D1F972071243</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:B136901C-38A0-4F12-B35D-BF814374DB34</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-18 14:07:26 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8C5430EE-8C8A-44B7-9A28-80BDAB1B381C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14655D75-DC23-4E82-84C9-F40B702E4B69">
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:8F5BD518-01AA-46D8-B893-6470B014CC3B"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-15 14:17:13 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0ED8918B-EAC0-44B8-AA42-B78AD724F7BE">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-18 13:51:22 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:B8452517-26D0-419F-88FD-A818925FDE06</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5E5C736D-1CA1-4B67-82D7-01FF596E3F63"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:A9D10DC5-1563-4B76-AF53-88F671A32A18</pav:lineageUri>
    <pav:lastSavedOn>2014-07-18 16:51:47 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/6B3BAFED-E091-412E-B7AB-A9DC8567890B">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8811156A-F82B-4936-A5FD-E973920A426B">
    <pav:createdOn>2014-07-15 14:16:12 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>carbamazepine</ao:exact>
    <ao:suffix>, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolis</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8811156A-F82B-4936-A5FD-E973920A426B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix> do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known enzyme inducers (e.g., </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:99C27DF5-F974-4BCC-AE8D-49CE9212E9D2">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:body rdf:nodeID="N7cf93db10c79492583d4c75f65654088"/>
    <pav:previousVersion>urn:domeoserver:annotationset:883587E1-49C1-4EE0-909E-4ADBAE13DD3A</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-15 14:30:47 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D2EC0D99-6FCE-4978-BE7E-E1C8066C58EF"/>
    <pav:createdOn>2014-07-15 14:25:37 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3DBEE5E-C93B-4DBE-A1E3-317DA19FA203">
    <pav:lineageUri>urn:domeoserver:annotation:08F50372-771E-460E-BD76-88F11A77AEF6</pav:lineageUri>
    <pav:createdOn>2014-07-15 14:09:05 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0C912224-9ADC-4466-B8BD-9A0D37DB3F64"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:99826AC3-3668-4F74-9E9D-DADD1F7098F0">
    <pav:lastSavedOn>2014-07-18 16:59:52 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N96899bab291e497894144588b6f80b94"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-18 13:55:33 -0700</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:17BE6274-5C33-43EE-85E7-EC723ACF1134"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F6C87C3C-DE3E-4C1E-A1AE-B620C6D1B31E"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:688A40AF-929E-4DEA-858A-D3762D3C014B"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4BD1F108-6B86-46B9-94ED-17733AF67E71"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:35CDD2E7-70B2-4586-B719-AE865BE6C293"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:C084ABD9-9B0C-479B-B9AC-42D7E6E50879</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:82AC5ADA-B8CE-47A9-AA99-E7187ABEFACA</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:DAD17BCA-9CFC-4DE8-932B-E68F8A5FAD45"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9A5182DA-4DAC-48D6-946F-8283D026674F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:844AAE28-6A60-487D-810E-79FA4BF0CAB5">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:1EE1D64B-EDD4-4170-B797-D8F83B927DCE</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7BA312DF-BB65-4A90-8B7D-A54425D7C553</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:C0577481-DCD6-4058-A293-BB8EFDB9B578"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-18 14:20:30 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-18 14:20:41 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E68A8F1A-49B1-485B-9508-70DEE10CB0DB">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FF76049E-6B2C-46A9-ACF7-CA565C8087F3</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:C00C2C3C-0648-4779-A135-09D440F1CEA8</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:616A7F11-F942-4085-A069-8C230D26C0CF"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-18 13:43:30 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-18 13:43:48 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:114FB83A-C60C-42F5-AB92-9462558A06FC">
    <pav:lastSavedOn>2014-07-10 11:17:08 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <ao:body rdf:nodeID="N8969333cf9ad45839f5627c08be5f100"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <pav:createdOn>2014-07-10 11:17:03 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:DBBBAD55-D12B-4890-A2AF-85D3C85A7BEF</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:892E6482-5108-4155-B6F2-763924AB0616"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EE597E16-26DA-463C-A72C-1CA155D4131A">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:590959F7-F15A-4306-BE23-1D37D8B0C281"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A96A53F5-6219-428F-A3F8-43699BB234C3">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A96A53F5-6219-428F-A3F8-43699BB234C3"/>
    <domeo:uuid>A96A53F5-6219-428F-A3F8-43699BB234C3</domeo:uuid>
    <ao:prefix>In 13 normal male volunteers, there was significant increase in </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> (500 mg single dose) AUC and Cmax following the administration of fluconazole. There was a mean ± SD increase in tolbutamide AUC of 26% ± 9% (range: 12 to 39%). Tolbutamide Cmax increased 11% ± 9% (range: -6 to 27%). (See PRECAUTIONS.)</ao:suffix>
    <pav:createdOn>2014-07-18 14:07:10 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>tolbutamide</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-29.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E6D4B4B-5988-41DE-96F1-703204EEF5AF">
    <ao:prefix> (250 mg) or </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-10 11:20:50 -0700</pav:createdOn>
    <ao:suffix> (40 mg), both of which are metabolized by CYP2C9.</ao:suffix>
    <ao:exact>warfarin</ao:exact>
    <domeo:uuid>5E6D4B4B-5988-41DE-96F1-703204EEF5AF</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5E6D4B4B-5988-41DE-96F1-703204EEF5AF"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B7BF01C6-A444-43C9-8592-E7548AF045AB">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> [see 7 DRUG INTERACTIONS]. This occurs with</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B7BF01C6-A444-43C9-8592-E7548AF045AB"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-15 14:28:14 -0700</pav:createdOn>
    <ao:suffix>. The therapeutic benefits and adverse effects of</ao:suffix>
    <ao:exact> quinidine, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79C3BE8E-51D8-473A-AC88-0ADB7AE9D239">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-15 14:19:34 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-15 14:18:14 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:70E10DEB-A12F-401E-803F-F6734EDD7985"/>
    <pav:lineageUri>urn:domeoserver:annotation:D3256BE2-E89D-49FD-813F-D726CC19F915</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51D42CFA-4CB2-4B55-9EFE-A1109484AC25">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:DE86A623-45C7-446E-BC44-389610395DA9"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-16 15:32:30 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:7AE68AC7-9B47-4954-8C65-45A6F0DC80C2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F87EEF0-40A6-43E2-8222-95E7D1335A0B</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-16 15:33:06 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE1313C3-E1E7-419F-9B99-0AFA7CE149F5">
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> in 24 healthy male volunteers</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FE1313C3-E1E7-419F-9B99-0AFA7CE149F5"/>
    <ao:prefix> </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-16 15:40:52 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:00F35F1A-5924-40DE-A59C-C43123E99A77">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:00F35F1A-5924-40DE-A59C-C43123E99A77"/>
    <ao:prefix> displaces each other from plasma binding sites. High therapeutic concentrations of</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-15 14:26:34 -0700</pav:createdOn>
    <ao:suffix>, changes of unknown clinical significance</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact> sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL</ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:026A9D62-B81B-44DD-A18F-6776E5D0E1A2">
    <ao:suffix> do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma c</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:026A9D62-B81B-44DD-A18F-6776E5D0E1A2"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> have not been evaluated, but observations in a modest number (N≅70) of poor metabolizers given</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact> risperidone</ao:exact>
    <pav:createdOn>2014-07-15 14:16:07 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE91163B-25D4-45FB-AD96-78A70FE948D6">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FE91163B-25D4-45FB-AD96-78A70FE948D6"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix> </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-15 14:10:43 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F6C87C3C-DE3E-4C1E-A1AE-B620C6D1B31E">
    <pav:lineageUri>urn:domeoserver:annotation:E4E42703-FD7D-4D0A-BA90-920A2D4F880E</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:34E48324-D870-4398-B241-2FAE6690C98C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-18 13:55:37 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-18 13:56:04 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:99826AC3-3668-4F74-9E9D-DADD1F7098F0</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:318D970E-E791-465D-B650-869C74523D2C">
    <ao:context rdf:resource="urn:domeoclient:uuid:0E27FBCC-C6F8-42FB-A7DC-B9AA486D3D4F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-15 14:14:47 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E960B89C-B215-4093-9AF7-C100D8D48511">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-18 13:48:28 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-18 13:48:39 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:748BB253-1066-4977-91B2-35D8C6906790</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:45DF7FF1-EC0B-4049-BA97-01C05E9D3DFE"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A7F21A3D-50B3-495E-884A-2C707B40C763</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:372E2DC2-9D30-4E6B-AD72-5B085AE1A42F">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:3FD0B464-381E-48E3-8E4B-CFFB6EAA6EDF</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:C51A06F1-DF50-4438-A801-D1307CBA609A"/>
    <pav:createdOn>2014-07-18 13:49:30 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A7F21A3D-50B3-495E-884A-2C707B40C763</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N206740cac061446a9314da6018bbb24e"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-18 16:49:32 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/E0D97E91-2E7D-4932-BF6E-D14381A9B58A">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Fluconazole</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:085B00A2-6C6B-488C-9382-36A86ADDE1DE">
    <ao:exact>estradiol</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:085B00A2-6C6B-488C-9382-36A86ADDE1DE"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> or levonorgestrel AUC after the administration of 50 mg of fluconazole. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%).</ao:suffix>
    <domeo:uuid>085B00A2-6C6B-488C-9382-36A86ADDE1DE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-16 15:32:41 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0623A94E-6CBD-441E-92B8-16C280BD8650">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-16 10:20:13 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:41D4DAFD-01A3-4F08-82F4-AB8B59CEEB2B"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:7BA312DF-BB65-4A90-8B7D-A54425D7C553">
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:41E33AFA-32CF-4F33-A475-CBE51A5010FA"/>
    <permissions:permissions rdf:nodeID="N1a0d77abee6649ccb442d12b8a80ff31"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:92F5F5C5-9A9C-4B47-AB81-A514809088C8"/>
    <pav:previousVersion>urn:domeoclient:uuid:51A184F8-19CA-4489-AB8F-9AF92E4BE5BE</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:17162313-6A55-4157-B495-83AA9CF1A26A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3A410142-DDEC-496D-86F6-76E692FBA77E"/>
    <pav:createdOn>2014-07-18 14:20:17 -0700</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-50.txt.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:1EE1D64B-EDD4-4170-B797-D8F83B927DCE</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:844AAE28-6A60-487D-810E-79FA4BF0CAB5"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2014-07-18 17:22:23 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:029204D1-F9E2-49AE-8BBC-4F278A048EBD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>9-hydroxyrisperidone </ao:exact>
    <ao:suffix> [see 12 CLINICAL PHARMACOLOGY]. Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of risperidone.</ao:suffix>
    <ao:prefix> and its major metabolite, </ao:prefix>
    <pav:createdOn>2014-07-16 10:19:19 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:029204D1-F9E2-49AE-8BBC-4F278A048EBD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:240CE9DC-DA1D-48D6-946F-B8B1FEC89249">
    <domeo:uuid>240CE9DC-DA1D-48D6-946F-B8B1FEC89249</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:240CE9DC-DA1D-48D6-946F-B8B1FEC89249"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>[see 7 DRUG INTERACTIONS]. It would also be possible for</ao:suffix>
    <ao:exact> carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-18 15:25:36 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C676DD4-0D35-4578-AF3F-F66853FF712A">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-18 14:07:26 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A96A53F5-6219-428F-A3F8-43699BB234C3"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-18 14:07:10 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B480EE53-5881-4650-9D82-D1F972071243</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:B136901C-38A0-4F12-B35D-BF814374DB34</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4148B6C7-21F7-44D9-9466-BC519FF61DF1">
    <pav:createdOn>2014-07-18 13:48:11 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:hasSource>
    <ao:exact>phenytoin</ao:exact>
    <ao:suffix> dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in </ao:suffix>
    <domeo:uuid>4148B6C7-21F7-44D9-9466-BC519FF61DF1</domeo:uuid>
    <ao:prefix> AUC was determined after 4 days of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4148B6C7-21F7-44D9-9466-BC519FF61DF1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A01C077-1FE2-4DD4-96E1-C475228628A9">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8A01C077-1FE2-4DD4-96E1-C475228628A9"/>
    <pav:createdOn>2014-07-16 10:21:21 -0700</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFF4DD39-5FB5-46B5-9868-D724A30FB42C">
    <pav:lineageUri>urn:domeoserver:annotationset:9AA0507C-281E-45C8-9719-03E66F12C069</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:16AE9675-2124-48E2-984A-6251D41F39B6"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DBCB873-26F3-4E6A-9BD4-311369B43736</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-18 14:03:12 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-18 14:03:19 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:B480EE53-5881-4650-9D82-D1F972071243">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1B6D54E8-D781-4B59-A1BC-6120E5CF9015"/>
    <pav:createdOn>2014-07-18 14:07:10 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-18 17:08:08 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:346C4DA6-A4F5-4B6F-AADB-4E76B1FDE36F</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B136901C-38A0-4F12-B35D-BF814374DB34</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:3564DC3A-4069-432B-A29D-98AB86C42DF6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:9E954CE3-F61D-4171-A4FE-6FAE429FF615"/>
    <domeo:deleted>false</domeo:deleted>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:8C676DD4-0D35-4578-AF3F-F66853FF712A"/>
    <permissions:permissions rdf:nodeID="Nd7745f40ec2646208daa7c8066853639"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-29.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:547CD07E-3BE0-408B-82B7-99021E41003B"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C730C18-D51E-4ABD-B037-60F8C4579F49">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9C730C18-D51E-4ABD-B037-60F8C4579F49"/>
    <ao:exact> ethinyl estradio</ao:exact>
    <domeo:uuid>9C730C18-D51E-4ABD-B037-60F8C4579F49</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> AUC after the administration of 50 mg of fluconazole. The mean increase in</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>l AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%).</ao:suffix>
    <pav:createdOn>2014-07-16 15:32:56 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B656CB9-304A-4F35-9AAE-0A055011F03C">
    <ao:prefix> was about 21 hours (CV=20%) in extensive metabolizers and 30 hours (CV=25%) in poor metabolizers. The pharmacokinetics of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7B656CB9-304A-4F35-9AAE-0A055011F03C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-15 14:17:31 -0700</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> and 9-hydroxyrisperidone combined, after single and multiple doses, were similar in extensive and poor metabolizers, with an overall mean elimination half-life of about 20 hours.</ao:suffix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BED0BB6E-5962-4714-A49A-2DB5A1787334">
    <pav:createdOn>2014-07-15 14:09:52 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:8288AD6F-5E38-44AB-8425-B5F017B96EB1</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:55703ACD-B978-421D-82AE-69E7022573D6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:54821DEB-AB64-414E-803A-23F9B9CF1CE7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>9-hydroxyrisperidone </ao:exact>
    <ao:suffix> [see 12 CLINICAL PHARMACOLOGY]. Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of risperidone.</ao:suffix>
    <ao:prefix> and its major metabolite, </ao:prefix>
    <pav:createdOn>2014-07-15 14:03:20 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:54821DEB-AB64-414E-803A-23F9B9CF1CE7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B372AAFD-51DF-43D9-B838-0F98E9692F16">
    <domeo:belongsToSet>urn:domeoserver:annotationset:FF76049E-6B2C-46A9-ACF7-CA565C8087F3</domeo:belongsToSet>
    <ao:body rdf:nodeID="N7e2b9f953ad64ab7a9585b40f92bdb85"/>
    <pav:createdOn>2014-07-18 13:45:45 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB5F4799-5045-4FBD-ACF4-AFCEB256A943"/>
    <pav:lineageUri>urn:domeoserver:annotation:7D45B6D7-391F-41FC-9D7B-0B3F18F4A9B7</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-18 16:46:22 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>expertstudy Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7130A96C-7BF2-4DBE-A880-248C420268E9">
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-15 14:16:55 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:570B84EB-A83D-4275-82DA-1B306C0F0E33"/>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14EF1296-9281-4C53-B309-5C368E7DBD5D">
    <ao:prefix> flucon</ao:prefix>
    <pav:createdOn>2014-07-16 14:03:38 -0700</pav:createdOn>
    <ao:suffix>e dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:14EF1296-9281-4C53-B309-5C368E7DBD5D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>azol</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC5E4603-2CB7-4D28-ABE9-54E9294FD8DC">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FC5E4603-2CB7-4D28-ABE9-54E9294FD8DC"/>
    <ao:prefix> are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma concentrations of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-15 14:06:47 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> occurred at about 1 hour. Peak concentrations of 9-hydroxyrisperidone occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers. Steady-state concentrations of risperidone are reached in 1 day in extensive metabolizers and w</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:52DE006C-2A48-4A64-83D4-EE312E42B8E6">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4E844D74-03C0-41B6-B571-7703666D11BA"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:24886D93-A995-41A8-9E66-1BF6DF77E9D2">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-15 14:07:58 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:DEA7496B-9CAF-4929-AD2C-2B22EB0C5A6B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdOn>2014-07-15 14:06:27 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:9B307D8B-D2B0-4795-8850-FAAAAC6B5AF4</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:73C19DFA-F31A-4286-BFC2-5C8757F59492">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:C586DBB5-BE53-48E7-ACD5-8863ACBCD5CE</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-16 14:03:46 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-16 14:06:30 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:3E2E0F2D-3281-4126-8A9C-921B0A849990"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9A899E70-DA16-4FA1-A716-CEF8414FF84E">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:03C138A3-3A62-41DC-8535-D728778DDD42"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C8A7DFF-59B1-4852-B9E4-A60D88CD3918">
    <ao:suffix> AUC of 26% ± 9% (range: 12 to 39%). Tolbutamide Cmax increased 11% ± 9% (range: -6 to 27%). (See PRECAUTIONS.)</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0C8A7DFF-59B1-4852-B9E4-A60D88CD3918"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-18 14:07:20 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>. There was a mean ± SD increase in </ao:prefix>
    <domeo:uuid>0C8A7DFF-59B1-4852-B9E4-A60D88CD3918</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-29.txt.html</ao:hasSource>
    <ao:exact>tolbutamide</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:797BAFBC-5256-4C7D-9ACC-064403D70DDB">
    <pav:createdOn>2014-07-15 14:08:51 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:FBBE65E6-567D-48EE-99B9-B5E8C8480685"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:602391D0-01F6-4A8E-A578-660F21D18E55</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B73CF3F-C910-4D04-9121-43AA38BE7F2F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> were determined from a single intravenous dose of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-18 14:02:43 -0700</pav:createdOn>
    <domeo:uuid>5B73CF3F-C910-4D04-9121-43AA38BE7F2F</domeo:uuid>
    <ao:exact>aminophylline</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5B73CF3F-C910-4D04-9121-43AA38BE7F2F"/>
    <ao:suffix> (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53F2EA0B-B02F-4D15-A55E-843D837795E4">
    <ao:prefix> plus </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma concentrations of risperidone occurred at about 1 hour. Peak concentrations of 9-hydroxyrisp</ao:suffix>
    <pav:createdOn>2014-07-15 14:06:41 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:53F2EA0B-B02F-4D15-A55E-843D837795E4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:702BE5BD-B486-4EEB-9B0C-8C790AAA768A">
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A239FA7-0EC5-40B4-BB98-C16757BB8044"/>
    <pav:createdOn>2014-07-10 11:19:20 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D779518E-9AC6-475E-AE81-120556E044A3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D779518E-9AC6-475E-AE81-120556E044A3"/>
    <ao:suffix>. The effect of</ao:suffix>
    <domeo:uuid>D779518E-9AC6-475E-AE81-120556E044A3</domeo:uuid>
    <pav:createdOn>2014-07-10 11:22:24 -0700</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations. Therefore, the slight decrease of sildenafil exposure in the presence of epoprostenol is not considered clinically relevant</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BEEF40B4-6424-4E52-8991-9FA7249F61E5">
    <pav:createdOn>2014-07-16 10:19:56 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> oral solution is bioequivalent to risperidone tablets.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Pharmacokinetic studies showed that </ao:prefix>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BEEF40B4-6424-4E52-8991-9FA7249F61E5"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB5A75B5-09F1-40D7-97B6-D21EA870EF66">
    <pav:createdOn>2014-07-15 14:09:12 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance.</ao:suffix>
    <ao:prefix> (10 mcg/mL), and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>carbamazepine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CB5A75B5-09F1-40D7-97B6-D21EA870EF66"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na603c9495bc34faaba77d3cd645dbad8">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:446899E9-2BB7-4629-AA6E-75AF9EC38F08">
    <pav:lineageUri>urn:domeoserver:annotation:2A77ED44-7A24-44A3-804A-12F4E3277AA5</pav:lineageUri>
    <pav:createdOn>2014-07-15 14:08:40 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:91F1D915-0F2B-4B98-A86E-D0E424CBADC1"/>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6f44278c3a23434aa39d2269beef7853">
    <domeo:sets rdf:resource="urn:pddi:uuid:52DE006C-2A48-4A64-83D4-EE312E42B8E6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1A443CA-B8D4-4A28-825B-B97ECDEC88D7">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:368B4BB2-B03B-4EBF-97A2-1D8357999CE7"/>
    <pav:createdOn>2014-07-15 14:10:17 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:8F1DE52D-E566-44A5-B267-A501CC18ABA0</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C0577481-DCD6-4058-A293-BB8EFDB9B578">
    <pav:createdOn>2014-07-18 14:20:30 -0700</pav:createdOn>
    <ao:suffix> alone at steady state. If anticholinergic effects are seen, the dose of procyclidine should be reduced.</ao:suffix>
    <ao:prefix> (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to </ao:prefix>
    <ao:exact>procyclidine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C0577481-DCD6-4058-A293-BB8EFDB9B578"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-50.txt.html</ao:hasSource>
    <domeo:uuid>C0577481-DCD6-4058-A293-BB8EFDB9B578</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/608E1DA9-C778-41BB-AF19-BEB866893872">
    <rdfs:label>fluconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A4632682-84C0-4DFD-915D-D1C3B235F095">
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2014-07-15 14:16:07 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:026A9D62-B81B-44DD-A18F-6776E5D0E1A2"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F5CF7F61-B7F1-4B7C-AF06-558EB0A245B6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>phenobarbital</ao:exact>
    <ao:prefix>, and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F5CF7F61-B7F1-4B7C-AF06-558EB0A245B6"/>
    <ao:suffix>) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-15 14:16:25 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8F6DECD-B84A-439C-AB5B-FD0E059E3FAC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>carbamazepine</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-15 14:31:21 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B8F6DECD-B84A-439C-AB5B-FD0E059E3FAC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7E6B698-CDF9-4B67-A4F6-CC3D84C50315">
    <ao:prefix> in patients receiving </ao:prefix>
    <ao:suffix> have not been evaluated, but observations in a modest number (N≅70) of poor metabolizers given risperidone do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known enzyme inducers (e.g., carbamazep</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E7E6B698-CDF9-4B67-A4F6-CC3D84C50315"/>
    <ao:exact>quinidine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-15 14:15:56 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:920B7836-2155-4EE5-9028-A6274B846CBA">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:15C80BDC-57FE-49D1-830F-1A9F2C7BCA2C"/>
    <pav:lineageUri>urn:domeoserver:annotation:38E5099A-2116-42B9-B051-715C68299A81</pav:lineageUri>
    <pav:lastSavedOn>2014-07-15 14:19:34 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-15 14:17:46 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EF340BC-FC51-443A-B404-48D9728F2E15">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-16 14:04:04 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:857E22AD-F64E-4FA6-B3BC-CE9046AD4CDA</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:92E5C2B0-A019-4BC5-BDC7-295AFBB9DF17"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-16 14:06:30 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A8134EE-D8E3-447B-9EB9-2CB597651AB4">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-15 14:06:47 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:FC5E4603-2CB7-4D28-ABE9-54E9294FD8DC"/>
    <pav:previousVersion>urn:domeoclient:uuid:9B307D8B-D2B0-4795-8850-FAAAAC6B5AF4</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:lastSavedOn>2014-07-15 14:07:58 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0B7730D3-D7F2-4D65-B79F-6DB4ADEC18E6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0B7730D3-D7F2-4D65-B79F-6DB4ADEC18E6"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers.</ao:suffix>
    <pav:createdOn>2014-07-15 14:15:02 -0700</pav:createdOn>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>and higher </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F6BE9E0C-96F1-4A3F-BE0A-413829714A90">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:97152B9D-CEAA-4BF5-BCF3-8D56F516DD36"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A8C9B71B-88CF-40BB-B2E7-05BB8108A261">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A8C9B71B-88CF-40BB-B2E7-05BB8108A261"/>
    <pav:createdOn>2014-07-16 15:32:46 -0700</pav:createdOn>
    <ao:exact>levonorgestrel</ao:exact>
    <ao:prefix> or </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>A8C9B71B-88CF-40BB-B2E7-05BB8108A261</domeo:uuid>
    <ao:suffix> AUC after the administration of 50 mg of fluconazole. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%).</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9F493B28-AE3A-4E32-85C4-AE2C806F7BDA">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-15 14:02:34 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <ao:prefix>The mechanism of action of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix>, as with other drugs used to treat schizophrenia, is unknown. However, it has been proposed that the drug’s therapeutic activity in schizophrenia is mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9F493B28-AE3A-4E32-85C4-AE2C806F7BDA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4BDAA007-22DC-4E1D-8BB3-46728661C2F1">
    <pav:createdOn>2014-07-18 14:05:17 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="Ncc330724a0384cd1b0213dd420f7a7a5"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lastSavedOn>2014-07-18 17:05:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2AA708F1-622C-4D5D-9D25-2946E06DCDDB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DBCB873-26F3-4E6A-9BD4-311369B43736</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:0E7FAAC6-D462-439E-8A8E-930827B202EC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C9D98AB8-FCA0-4A14-92DD-EBD32CC6776E">
    <ao:context rdf:resource="urn:domeoclient:uuid:D166220A-E6E2-4ECF-B03B-AF573EEAE31B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-10 11:20:24 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE1BA765-A716-44E9-BE81-971BDF21154E">
    <pav:lastSavedOn>2014-07-18 16:51:47 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-18 13:51:15 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:EEA8D937-1DA8-4F98-9D1E-B48786184636"/>
    <pav:lineageUri>urn:domeoserver:annotation:A333DBF9-EA93-491F-AA00-B054BE6A4C4E</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:B8452517-26D0-419F-88FD-A818925FDE06</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3ABC05DD-EC5F-4576-86DC-D8C25A0E287D">
    <ao:exact>In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3ABC05DD-EC5F-4576-86DC-D8C25A0E287D"/>
    <pav:createdOn>2014-07-10 11:24:33 -0700</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>3ABC05DD-EC5F-4576-86DC-D8C25A0E287D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/3FD2DBDA-7F24-4B3D-829F-5ECB6A6E2D7B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>quinidine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82FFD7F0-AC94-462F-BA86-70CFD849B686">
    <pav:createdOn>2014-07-15 14:03:20 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:54821DEB-AB64-414E-803A-23F9B9CF1CE7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-15 14:04:06 -0700</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:73404969-6C7F-414E-BB3E-BABBFAA2C784</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:025EF8CC-8100-4ED5-A590-368E009133CC">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="Nb3abecc880d44776a0136433625b58e0"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3443022F-68AE-4016-8363-C6C96EE0AE69"/>
    <pav:createdOn>2014-07-10 11:21:39 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A156EC26-7CF9-490B-8F02-67A6FCC98E56">
    <ao:prefix>) with </ao:prefix>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A156EC26-7CF9-490B-8F02-67A6FCC98E56"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak b</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-15 14:16:29 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B230469B-00AA-4A73-A839-6D9826213D36">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:96BAB4C7-6F7A-4EBA-BAC1-134F746F11FA</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-17 15:54:46 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:36A9182C-B7D6-405A-BBF7-D0B654870FAE"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C94BECCE-E3E9-4B70-AC23-F715B9D3EEFF</pav:lineageUri>
    <pav:createdOn>2014-07-17 15:53:45 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2BB10533-7A8A-4C30-95A1-E3816F2A9980">
    <pav:createdOn>2014-07-15 14:06:36 -0700</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> plus 9-hydroxyrisperidone are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma concentrations of risperidone occurred at about 1 hour. Peak conce</ao:suffix>
    <ao:prefix>, and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2BB10533-7A8A-4C30-95A1-E3816F2A9980"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31F660CD-C617-4D06-85AD-7A9D8F2EDEEC">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:F247102D-970B-4569-BFF9-4021B0D33CE0"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-10 11:20:13 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E9DA4784-7755-4859-B2A0-96322779CF59">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-20.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-16 14:02:20 -0700</pav:createdOn>
    <ao:prefix> is supplied for oral administration as scored tablets containing </ao:prefix>
    <ao:suffix>equivalent to 25, 50, 100, 150 and 200 mg of </ao:suffix>
    <ao:exact>sertraline hydrochloride </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E9DA4784-7755-4859-B2A0-96322779CF59</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E9DA4784-7755-4859-B2A0-96322779CF59"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F247102D-970B-4569-BFF9-4021B0D33CE0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F247102D-970B-4569-BFF9-4021B0D33CE0"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-10 11:20:13 -0700</pav:createdOn>
    <ao:exact>sildenafil</ao:exact>
    <ao:prefix> AUC and a 55% decrease in </ao:prefix>
    <domeo:uuid>F247102D-970B-4569-BFF9-4021B0D33CE0</domeo:uuid>
    <ao:suffix> Cmax. Co-administration resulted in a 50% increase in AUC of bosentan. The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing). Concomitant administration of potent CYP3A inducers is expected t</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:30DE360C-B631-4F35-8C09-DC4BC562543A">
    <ao:context rdf:resource="urn:domeoclient:uuid:005571AF-9B7B-4186-B036-1D92080F00CA"/>
    <pav:createdOn>2014-07-18 13:43:09 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C00C2C3C-0648-4779-A135-09D440F1CEA8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-18 13:43:48 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FF76049E-6B2C-46A9-ACF7-CA565C8087F3</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ADFEE70E-EDC2-4D08-90AB-0ABAFD52BC6F">
    <pav:lineageUri>urn:domeoserver:annotation:8E83F562-4A5B-4C25-9BBD-C2D4037787C2</pav:lineageUri>
    <pav:createdOn>2014-07-15 14:04:00 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-15 14:04:06 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:CC9D7EB3-FEB5-450C-959B-F7BCBAC26F3C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/68169CA6-EEA6-4C01-BAD6-EB46996FEBC2">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11413</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>zidovudine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63FB79CC-576B-4FFD-A109-FF63DAE371C0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-15 14:19:34 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:B0997699-FE17-48DB-97D8-9BA9ABDD0C90"/>
    <pav:lineageUri>urn:domeoserver:annotation:DE64D465-1597-4221-A9B1-89F08D7235B8</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-15 14:18:48 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0EC9718-8100-4840-9F10-BFE3FC7823F2">
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdOn>2014-07-15 14:15:37 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:0846F768-2376-4051-A905-427746D087A6"/>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3A410142-DDEC-496D-86F6-76E692FBA77E">
    <domeo:belongsToSet>urn:domeoserver:annotationset:7BA312DF-BB65-4A90-8B7D-A54425D7C553</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N88da97ef264a460a9efb9622919ea667"/>
    <pav:createdOn>2014-07-18 14:22:23 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5D12662E-B4E8-4D82-82D8-C7038995144A"/>
    <pav:lastSavedOn>2014-07-18 17:22:23 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:0D4D8D25-063B-40EF-AFCD-BAC6B8FA59D2</pav:lineageUri>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:069D387B-708F-4C78-BA75-2E62415C81C9">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-16 10:20:36 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9DF202FF-7B27-4079-825C-68963E1927BA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F7635891-9395-4AA7-B1C6-22B3D89F0719">
    <domeo:uuid>F7635891-9395-4AA7-B1C6-22B3D89F0719</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F7635891-9395-4AA7-B1C6-22B3D89F0719"/>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers</ao:suffix>
    <pav:createdOn>2014-07-17 15:54:34 -0700</pav:createdOn>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>				http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html																													</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6395774E-A61F-4CC3-AC03-4A9A97F402CB">
    <ao:context rdf:resource="urn:domeoclient:uuid:1EC63B9B-4ECA-4533-97EA-FF3CFF05DB75"/>
    <pav:createdOn>2014-07-16 10:18:44 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:02EFD3A2-6206-483D-8A82-D5AB320CD4B0">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:prefix>. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment,</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:02EFD3A2-6206-483D-8A82-D5AB320CD4B0"/>
    <pav:createdOn>2014-07-16 14:03:34 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>ole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 </ao:suffix>
    <ao:exact> fluconaz</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0ABB2266-B2C7-44A9-8367-C5FE4916C02B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <ao:prefix> pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-15 14:15:52 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0ABB2266-B2C7-44A9-8367-C5FE4916C02B"/>
    <ao:suffix> in patients receiving quinidine have not been evaluated, but observations in a modest number (N≅70) of poor metabolizers given risperidone do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known e</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ABA94567-EA53-40B6-AF02-E6FC02E40AD6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:D6D403B6-0AB7-4752-BF22-C8CEC77D1E23</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-16 15:40:52 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E3DA2E5E-FC19-4C22-AF6C-A9CB4B450554</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:FE1313C3-E1E7-419F-9B99-0AFA7CE149F5"/>
    <pav:lastSavedOn>2014-07-16 15:40:55 -0700</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DADF82D0-0BE9-4691-8522-E52C0C20266C">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>Risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> acts as an antagonist at other receptors, but with lower potency. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DADF82D0-0BE9-4691-8522-E52C0C20266C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-16 10:19:02 -0700</pav:createdOn>
    <ao:suffix> has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and haloperidol-sensitive sigma site, and no affinity (when tested at concentrations &gt;10-5 M) </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6DC754D9-968C-4DBC-BC8E-28DCC1DD36A3">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6DC754D9-968C-4DBC-BC8E-28DCC1DD36A3"/>
    <ao:prefix> and </ao:prefix>
    <ao:exact>ritonavir</ao:exact>
    <domeo:uuid>6DC754D9-968C-4DBC-BC8E-28DCC1DD36A3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-10 11:20:46 -0700</pav:createdOn>
    <ao:suffix>, both of which are CYP3A substrates.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F5B727AA-1FE7-4EF4-9422-5C712EBAD08C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/689</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>aminophylline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1AC6F60-3C7C-4BEB-9095-25D25890AC79">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>sildenafil</ao:exact>
    <domeo:uuid>C1AC6F60-3C7C-4BEB-9095-25D25890AC79</domeo:uuid>
    <ao:prefix> was 28%, resulting in about 22% lower mean average steady state concentrations. Therefore, the slight decrease of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C1AC6F60-3C7C-4BEB-9095-25D25890AC79"/>
    <ao:suffix> exposure in the presence of epoprostenol is not considered clinically relevant. The effect of sildenafil on epoprostenol pharmacokinetics is not known.</ao:suffix>
    <pav:createdOn>2014-07-10 11:20:29 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E2E0F2D-3281-4126-8A9C-921B0A849990">
    <ao:prefix>dosing resulted in small increases in the mean AUCs of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3E2E0F2D-3281-4126-8A9C-921B0A849990"/>
    <pav:createdOn>2014-07-16 14:03:46 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cau</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:exact>ethinyl estradiol</ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0AE1727A-ACA3-43E1-8A12-B8F0F479A3DF">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:75FA9873-2FCB-4682-B059-2B0DDAB0A8C0"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:B716A719-3E66-4B72-87E0-370D90F3B8F7</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-17 15:59:35 -0700</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DEBE5AF-B171-4BE8-880B-76A2BEE742A6</domeo:belongsToSet>
    <pav:createdOn>2014-07-17 15:59:27 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2174191-CE1D-4EF2-8DD5-03008A9706DE">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdOn>2014-07-15 14:07:02 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A1CC34D-A3D8-43C2-AC0E-2F3EF96927DD"/>
    <pav:lastSavedOn>2014-07-15 14:07:58 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:9B307D8B-D2B0-4795-8850-FAAAAC6B5AF4</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8F4A61A4-B256-44BA-A917-3B5D6CDEEC4F">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:32A0FE11-022B-463B-8705-7B1DFD8D84DC"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:977E8B6B-E0A2-4EB3-998A-A0DCF25EB2D6">
    <ao:prefix> occurred at about 1 hour. Peak concentrations of </ao:prefix>
    <ao:suffix> occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers. Steady-state concentrations of risperidone are reached in 1 day in extensive metabolizers and would be expected to reach steady-state in about 5 days in poor metabol</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:977E8B6B-E0A2-4EB3-998A-A0DCF25EB2D6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <pav:createdOn>2014-07-15 14:06:52 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DCA6DB56-8ED4-4BF0-9368-16ACBA6F82AE">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-16 14:07:50 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:F0444DBB-743A-42A1-A053-40E5E11BBD66"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-16 14:07:53 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:42447E7A-991B-4E48-9BA8-E5C03F8FFFAC</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8EE5491-20E0-446F-BE4F-48D8F8CDCAB9">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:026B20A4-1022-4C15-ACEE-79151F28992D</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:A21EC03A-3C43-4CAE-9D75-32F08D9599AA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-16 14:06:30 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-16 14:03:39 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F87C43FC-DD9B-42FA-953B-C8C25AA48C91">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:9B307D8B-D2B0-4795-8850-FAAAAC6B5AF4</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-15 14:07:09 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:5DF27E07-C0B9-48CC-97AF-10E8A9830A54"/>
    <pav:lastSavedOn>2014-07-15 14:07:58 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D12662E-B4E8-4D82-82D8-C7038995144A">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5D12662E-B4E8-4D82-82D8-C7038995144A"/>
    <domeo:uuid>5D12662E-B4E8-4D82-82D8-C7038995144A</domeo:uuid>
    <ao:suffix>. If anticholinergic effects are seen, the dose of</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-18 14:22:23 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-50.txt.html</ao:hasSource>
    <ao:exact>Daily oral dosing of immediate-release paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0846F768-2376-4051-A905-427746D087A6">
    <pav:createdOn>2014-07-15 14:15:37 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0846F768-2376-4051-A905-427746D087A6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> [see 7 DRUG INTERACTIONS]. This occurs with </ao:prefix>
    <ao:suffix>, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of risperidone in patients receiving quinidine have not been evaluated, but observations in a modest numb</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>quinidine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2EC0D99-6FCE-4978-BE7E-E1C8066C58EF">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D2EC0D99-6FCE-4978-BE7E-E1C8066C58EF"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone a</ao:exact>
    <pav:createdOn>2014-07-15 14:26:58 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix>t 50 ng/m</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05BFE4D9-CD9B-4F44-B4A5-28A1E4F90000">
    <pav:lastSavedOn>2014-07-09 13:39:37 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:2C25A7F3-8A42-4060-A64C-5C2AB24D4675</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-09 13:36:36 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:80304B91-FB8B-4EF5-87EC-80F59A689F2A</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:B3F40D13-C4D5-491E-B9BE-818D5A568EC5"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4E9DA8F-91C3-4A6F-9726-C8A51040AAC3">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C4E9DA8F-91C3-4A6F-9726-C8A51040AAC3"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:suffix> </ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-16 10:21:01 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C54C358E-1731-4D93-820E-2F87B9D286FE">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D2062C41-A719-4900-9B45-2632D5CEE604"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/2CB7BD6B-AF06-43CD-9905-C06E37B34FC9"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ADE68C3A-6684-4E35-B3C0-F519065A2D66">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-15 14:06:21 -0700</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> oral solution is bioequivalent to</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ADE68C3A-6684-4E35-B3C0-F519065A2D66"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:24229507-32A8-4A26-89C0-59655390DA1A">
    <ao:context rdf:resource="urn:domeoclient:uuid:0B7730D3-D7F2-4D65-B79F-6DB4ADEC18E6"/>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:createdOn>2014-07-15 14:15:02 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C0FAFB3-9734-473A-85E5-980D1051DADD">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:47F91319-FBBC-4D96-B4A4-0705F95D9E7C"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdOn>2014-07-15 14:16:36 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8AA7B02-72B4-4632-9BDA-34C02C628D9A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B8AA7B02-72B4-4632-9BDA-34C02C628D9A"/>
    <ao:suffix> is not considered clinically relevant. The effect of sildenafil on epoprostenol pharmacokinetics is not known.</ao:suffix>
    <ao:exact>epoprostenol</ao:exact>
    <domeo:uuid>B8AA7B02-72B4-4632-9BDA-34C02C628D9A</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-10 11:20:31 -0700</pav:createdOn>
    <ao:prefix> exposure in the presence of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C966BEAA-709F-4F5C-9638-F94D75B69135">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-16 10:36:33 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:ED0BE9B7-B4C4-4EBF-AAFA-BF4510B72413</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2CE33325-EF3D-4298-BBCC-82F0A45DA665</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-16 10:36:38 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:EDA74310-A0B5-4356-940A-7C74749CD2EF"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1b471d49d3eb44f6ba9b021f2038d6c9">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33374D0E-AF28-4161-ACC9-7713697436CB">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-10 11:20:50 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:5E6D4B4B-5988-41DE-96F1-703204EEF5AF"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75FA9873-2FCB-4682-B059-2B0DDAB0A8C0">
    <ao:hasSource>			http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:75FA9873-2FCB-4682-B059-2B0DDAB0A8C0"/>
    <pav:createdOn>2014-07-17 15:59:27 -0700</pav:createdOn>
    <ao:suffix> increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTIONS.)</ao:suffix>
    <domeo:uuid>75FA9873-2FCB-4682-B059-2B0DDAB0A8C0</domeo:uuid>
    <ao:prefix> AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/276A1818-8600-415C-BF4E-E95E1BB0E0CC">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F11E81F-1EDB-4EA8-8E4A-47D93E06FFF2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-15 14:15:32 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:7F8B9524-4C64-4996-BBA7-9A2CED8F6A99"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DBB0F4E1-DD60-4C7C-94FB-551FD745535F">
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DBB0F4E1-DD60-4C7C-94FB-551FD745535F"/>
    <pav:createdOn>2014-07-18 13:55:55 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:hasSource>
    <ao:suffix> to parent drug ratio significantly decreased after the administration of fluconazole, from 7.6 ± 3.6 to 5.7 ± 2.2.</ao:suffix>
    <ao:exact>GZDV,</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>. The mean ± SD increase in AUC was 20% ± 32% (range: -27 to 104%). The metabolite, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC34EFC8-BB07-4B83-AD21-D8DD09AB286D">
    <ao:prefix> 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD theophylline AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). Theophylline clearance decreased 16% ± 11 % (range: -32 to 5%).</ao:suffix>
    <domeo:uuid>FC34EFC8-BB07-4B83-AD21-D8DD09AB286D</domeo:uuid>
    <ao:exact>theophylline</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FC34EFC8-BB07-4B83-AD21-D8DD09AB286D"/>
    <pav:createdOn>2014-07-18 14:02:56 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B501E10-7673-4F8E-889F-7048994F6D90">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3B501E10-7673-4F8E-889F-7048994F6D90"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>3B501E10-7673-4F8E-889F-7048994F6D90</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>. Any dose adjustment should be guided by clinical effect (tolerability and efficacy). </ao:suffix>
    <pav:createdOn>2014-07-18 14:23:45 -0700</pav:createdOn>
    <ao:exact>paroxetine</ao:exact>
    <ao:prefix> significantly decreased plasma levels of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-51.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D590AF4F-FC05-41EA-8CBC-29156060B437">
    <pav:createdOn>2014-07-17 15:53:34 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:96BAB4C7-6F7A-4EBA-BAC1-134F746F11FA</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C94BECCE-E3E9-4B70-AC23-F715B9D3EEFF</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:C9AAECF8-1252-4F78-95C3-766B0DC2CF93"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-17 15:54:46 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C7811B96-6935-4053-BDA0-233B88584EB2">
    <ao:exact>fluconazole</ao:exact>
    <ao:hasSource>				http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html																													</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C7811B96-6935-4053-BDA0-233B88584EB2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>C7811B96-6935-4053-BDA0-233B88584EB2</domeo:uuid>
    <pav:createdOn>2014-07-17 15:54:08 -0700</pav:createdOn>
    <ao:suffix> AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of flucon</ao:suffix>
    <ao:prefix>fluconazole AUC and Cmax. There was a mean ± SD decrease in </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55703ACD-B978-421D-82AE-69E7022573D6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:55703ACD-B978-421D-82AE-69E7022573D6"/>
    <ao:exact>Risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-15 14:09:52 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>Metabolism and Drug Interactions: </ao:prefix>
    <ao:suffix> is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, h</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:01F43ADA-D582-470E-9E9C-774668C5EF3D">
    <ao:exact> fluconazole</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:01F43ADA-D582-470E-9E9C-774668C5EF3D"/>
    <ao:hasSource>				http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html																													</ao:hasSource>
    <ao:suffix> in 24 healthy male volunteers.</ao:suffix>
    <ao:prefix> 200 mg) did not affect the bioavailability or pharmacokinetics of</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>01F43ADA-D582-470E-9E9C-774668C5EF3D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-17 15:54:41 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:49A3E368-5986-471F-9A56-C7C0F8072A9E">
    <ao:prefix>A third study evaluated the potential interaction of once weekly dosing of</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:49A3E368-5986-471F-9A56-C7C0F8072A9E"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> 300 mg to 21 normal females taking an oral contraceptive containing ethinyl estradiol and norethindrone. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, flucona</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-16 14:03:15 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:exact> fluconazole</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD319A5A-0B87-457E-BF99-76BC4728CC77">
    <pav:lineageUri>urn:domeoserver:annotationset:C94BECCE-E3E9-4B70-AC23-F715B9D3EEFF</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-17 15:53:41 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:96BAB4C7-6F7A-4EBA-BAC1-134F746F11FA</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:E03B1442-AB3D-475E-AEE8-EFD5DC37D96C"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-17 15:54:46 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7247E1B1-4BA1-4DE0-AA64-CA56899212F6">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-15 14:19:12 -0700</pav:createdOn>
    <ao:suffix> drug products.</ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix>harmacokinetic information for pediatric patients with schizophrenia, 13to 17 years of age, bipolar mania, 10 to 17 years old, and irritability associated with autistic disorder,5 to 16 years of age, is approved for Janssen Pharmaceuticals Corporation’s </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7247E1B1-4BA1-4DE0-AA64-CA56899212F6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:728539A9-7322-4281-848B-5507BB82A585">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:728539A9-7322-4281-848B-5507BB82A585"/>
    <ao:suffix> with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy). </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-51.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Co-administration of </ao:prefix>
    <pav:createdOn>2014-07-18 14:23:36 -0700</pav:createdOn>
    <domeo:uuid>728539A9-7322-4281-848B-5507BB82A585</domeo:uuid>
    <ao:exact>fosamprenavir/ritonavir</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:540A603C-5624-405F-9660-D636865AE01B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-10 11:20:15 -0700</pav:createdOn>
    <ao:prefix> Cmax. Co-administration resulted in a 50% increase in AUC of </ao:prefix>
    <ao:exact>bosentan</ao:exact>
    <ao:suffix>. The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing). Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:540A603C-5624-405F-9660-D636865AE01B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>540A603C-5624-405F-9660-D636865AE01B</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:12CCDE72-9FC0-4264-A3F2-C533F792F613">
    <pav:lastSavedOn>2014-07-15 14:04:06 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-15 14:02:53 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:A7E2E6B0-6F82-4961-8B6D-923A4E0BC5E9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:A853DC31-3688-4537-B866-1E714F554B83</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7E2E6B0-6F82-4961-8B6D-923A4E0BC5E9">
    <ao:suffix>e acts as an antagonist at other receptors, but with lower potency. Risperidone has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and haloperidol</ao:suffix>
    <pav:createdOn>2014-07-15 14:02:53 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A7E2E6B0-6F82-4961-8B6D-923A4E0BC5E9"/>
    <ao:prefix> is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), α1 and α2 adrenergic, and H1 histaminergic receptors. </ao:prefix>
    <ao:exact>Risperidon</ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ACA9D41B-D228-4B02-A61E-CA2C8E027440">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/30725548-E65C-4611-B944-3E83F4ECA098"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/54E13418-11DC-4671-AB00-7B464BF4A389"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9E905EC-FD3B-44E6-9603-8C4B7B645A61">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <pav:createdOn>2014-07-16 10:21:01 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:2F716A41-B68F-48AE-B5C1-E31F1704C565</pav:previousVersion>
    <pav:lastSavedOn>2014-07-16 10:21:09 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:C4E9DA8F-91C3-4A6F-9726-C8A51040AAC3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7838B265-7A04-40B9-A395-37C612A69AEA">
    <pav:lineageUri>urn:domeoserver:annotation:92855478-6BBF-4E59-B790-71252579DF43</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F87EEF0-40A6-43E2-8222-95E7D1335A0B</domeo:belongsToSet>
    <pav:createdOn>2014-07-16 15:35:39 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-16 18:38:32 -0400</pav:lastSavedOn>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:4DC7A7E5-5253-4EB7-AEC1-2FD55FEF5068"/>
    <ao:body rdf:nodeID="Na1a527ecca324f69b45c2b668b1b37c1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F68205D1-C26C-4CDF-8BC6-B801BDEFE695">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:31106440-9B03-40EC-87ED-9D0BFE935266"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E8921F3A-7792-4582-AEB4-1956E549C6E3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-15 14:13:56 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix>. Consequently, the clinical effect of the drug results from the combined concentrations of </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> plus 9-hydroxyrisperidone.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E8921F3A-7792-4582-AEB4-1956E549C6E3"/>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:616A7F11-F942-4085-A069-8C230D26C0CF">
    <ao:suffix> AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTIONS.)</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:616A7F11-F942-4085-A069-8C230D26C0CF"/>
    <ao:prefix>. There was a mean ± SD reduction in </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>616A7F11-F942-4085-A069-8C230D26C0CF</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-18 13:43:30 -0700</pav:createdOn>
    <ao:exact>fluconazole</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A1CC34D-A3D8-43C2-AC0E-2F3EF96927DD">
    <ao:prefix> occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers. Steady-state concentrations of </ao:prefix>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A1CC34D-A3D8-43C2-AC0E-2F3EF96927DD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-15 14:07:02 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> are reached in 1 day in extensive metabolizers and would be expected to reach steady-state in about 5 days in poor metabolizers. Steady-state concentrations of 9-hydroxyrisperidone are reached in 5 to 6 days (measured in extensive metabolizers).</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/6CA51826-BC17-4C41-9533-7687E5BBFB21">
    <rdfs:label>levonorgestrel</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6373</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D9907CFF-B778-4B29-8773-70DE74FE7759">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> at 10 ng/mL and </ao:prefix>
    <pav:createdOn>2014-07-15 14:09:46 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D9907CFF-B778-4B29-8773-70DE74FE7759"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> at 50 ng/mL, changes of unknown clinical significance.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83325641-7434-4321-A570-829337F41ADF">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:83325641-7434-4321-A570-829337F41ADF"/>
    <pav:createdOn>2014-07-16 10:36:22 -0700</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> i</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-20.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Sertraline hydrochloride</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A2215D32-FF99-4DC9-90B9-5C350C098EEB">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:A478A219-F6F2-4E61-B58F-0E374B4C9D0D</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdOn>2014-07-15 14:11:08 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AEA36B1F-63F1-4CF9-8B5E-4649C4B9F028"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/4F35C443-9DBC-4CC5-A6B5-6AC7F37CD815">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>cimetidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:74592674-5629-4C4B-8931-FFAA6830CB3B">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6176C4B3-F970-4A01-84A9-4E5517225598"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6491BF48-AC35-48FA-A8D2-102002F8E57E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6491BF48-AC35-48FA-A8D2-102002F8E57E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers</ao:exact>
    <domeo:uuid>6491BF48-AC35-48FA-A8D2-102002F8E57E</domeo:uuid>
    <ao:prefix>. However, the </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>				http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html																													</ao:hasSource>
    <pav:createdOn>2014-07-17 15:56:45 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:85B5BEBE-D146-414B-A979-B9CEBE9C57E6">
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdOn>2014-07-15 14:15:08 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:A0FB0C6E-5133-4379-A6A1-718CC8383F46"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A688F7D2-43BF-4838-A9A1-339829ADA43A">
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:21CD752E-6211-4C49-B6F0-F912F29E4F0E"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdOn>2014-07-15 14:14:29 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:10C3FD12-EB69-4E8A-9C52-BB5ED70A7565">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:10C3FD12-EB69-4E8A-9C52-BB5ED70A7565"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>Plasma concentrations of </ao:prefix>
    <ao:suffix>, its major metabolite, 9-hydroxyrisperidone, and risperidone plus 9-hydroxyrisperidone are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma conce</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone</ao:exact>
    <pav:createdOn>2014-07-16 10:20:06 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:34A66F13-B248-4FD8-A3CE-7AAAC40B7ACC">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-15 14:07:58 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:75D8DE94-F5D4-4DC6-BC3F-9344C057C003"/>
    <pav:previousVersion>urn:domeoclient:uuid:9B307D8B-D2B0-4795-8850-FAAAAC6B5AF4</pav:previousVersion>
    <pav:createdOn>2014-07-15 14:07:26 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA483938-DFFC-4F6C-85C3-FED68E6D4DE8">
    <pav:lineageUri>urn:domeoserver:annotation:5F7DE49C-385D-4D24-A536-4D51C78BC17D</pav:lineageUri>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-15 14:09:57 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:9F2162C5-D2E9-42F5-99DE-E7F470A1AD7C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF8175E8-F52D-4CE3-9DE9-BAE3E2CE04A1">
    <pav:lineageUri>urn:domeoserver:annotation:8BB0959D-8DED-4C4F-8D65-ACFF43731ED4</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-15 14:10:02 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:47D397AD-5153-40DA-83B8-C0A45725E6BC"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF7B07B6-2BD9-490B-95BF-D760C5399474">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AF7B07B6-2BD9-490B-95BF-D760C5399474"/>
    <pav:createdOn>2014-07-10 11:10:37 -0700</pav:createdOn>
    <ao:prefix>When a single 100 mg dose of</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix>sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1EC63B9B-4ECA-4533-97EA-FF3CFF05DB75">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1EC63B9B-4ECA-4533-97EA-FF3CFF05DB75"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), α1 and α2 adrenergic, and H1 histaminergic receptors. Risperidone acts as an antagonist at other receptors, but with</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-16 10:18:44 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A671621-83D0-48B3-B249-7E1ECC849539">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:7AE68AC7-9B47-4954-8C65-45A6F0DC80C2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F87EEF0-40A6-43E2-8222-95E7D1335A0B</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-16 15:33:06 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-16 15:32:46 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A8C9B71B-88CF-40BB-B2E7-05BB8108A261"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/A854A7DE-A8FE-498F-9B31-F34790052689">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/679314</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <rdfs:label>9-hydroxyrisperidone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5153D183-17EE-480B-9FF3-A9FB70E3CB26">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-16 15:33:06 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:7AE68AC7-9B47-4954-8C65-45A6F0DC80C2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:9C730C18-D51E-4ABD-B037-60F8C4579F49"/>
    <pav:createdOn>2014-07-16 15:32:56 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F87EEF0-40A6-43E2-8222-95E7D1335A0B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F4E4C204-187C-449E-9023-BF663418A548">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:666583ED-95C0-4F25-8463-3174C806F5FF"/>
    <pav:createdOn>2014-07-10 11:20:33 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/20605659-64E0-42A7-BDB2-B4AA5CBC2059">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>fosamprenavir/ritonavir</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:98825CF8-1CA0-489D-A1C4-2239A4A1278A">
    <pav:createdOn>2014-07-15 14:10:55 -0700</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:98825CF8-1CA0-489D-A1C4-2239A4A1278A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9DD27DF4-02BD-4CAE-B854-9D4CA6356D04">
    <pav:lineageUri>urn:domeoserver:annotation:EDB609C2-D0B7-41E7-83D5-9E2646CB8E4E</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:E9DA4784-7755-4859-B2A0-96322779CF59"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-16 14:02:20 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2CE33325-EF3D-4298-BBCC-82F0A45DA665</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-16 17:02:25 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2EFDE02B-EB81-4773-A923-937E941963E2">
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:9006A3C1-1FFE-448B-887C-2F101EC30804"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:572B1D44-A4E2-4B1D-93B4-24E5BB651905</pav:lineageUri>
    <pav:createdOn>2014-07-16 15:46:07 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="Nc5cd4c6515824de28e080fb3ec02d4e9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E3DA2E5E-FC19-4C22-AF6C-A9CB4B450554</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-16 18:46:13 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:785FC8A2-DE5D-4084-8BEC-107690A111CB">
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:DADF82D0-0BE9-4691-8522-E52C0C20266C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-16 10:19:02 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25FC3270-77CF-4552-800B-3A6E31592E33">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:25FC3270-77CF-4552-800B-3A6E31592E33"/>
    <pav:createdOn>2014-07-15 14:02:44 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), α1 and α2 adrenergic, and H1 histaminergic receptors. Risperidone acts as an antagonist at other receptors, but with</ao:suffix>
    <ao:exact>Risperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8900088E-395F-4576-960E-1B67ECCA0A65">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-15 14:16:48 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:DB032524-38CD-456B-A44B-C425DFD76D47"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76E5F11A-7EC2-4412-BCB7-E9B0542040DE">
    <pav:createdOn>2014-07-15 14:09:12 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:CB5A75B5-09F1-40D7-97B6-D21EA870EF66"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:AF2632B4-B087-439E-B33B-C14D3A0BCF9B</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA399F23-8D58-4471-8517-AC275675E0F0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BA399F23-8D58-4471-8517-AC275675E0F0"/>
    <ao:suffix>. (See PRECAUTIONS.</ao:suffix>
    <domeo:uuid>BA399F23-8D58-4471-8517-AC275675E0F0</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-17 16:00:10 -0700</pav:createdOn>
    <ao:hasSource>			http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <ao:exact>Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1453C795-84C1-4C48-AF84-AEEE18ED1682">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-15 14:09:01 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:D65EE4FB-C2D2-4BA1-977B-5D3CB6873FE9"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:BE4E6E88-B736-4374-9FE7-02AECE79780F</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23BAF555-C96E-4707-8EBA-34BCE14B71F5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:23BAF555-C96E-4707-8EBA-34BCE14B71F5"/>
    <domeo:uuid>23BAF555-C96E-4707-8EBA-34BCE14B71F5</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-18 13:43:13 -0700</pav:createdOn>
    <ao:suffix> administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (ran</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> after 15 days of </ao:prefix>
    <ao:exact>rifampin</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E109C84-6323-418A-9404-5FBE487E6AA2">
    <ao:exact>cyclosporine</ao:exact>
    <pav:createdOn>2014-07-18 13:51:28 -0700</pav:createdOn>
    <ao:suffix> dose for at least 6 weeks. There was a significant increase in cyclosporine AUC, Cmax, Cmin (24-hour concentration), and a significant reduction in apparent oral clearance following the administration of fluconazole. The mean ± SD increase in AUC was 92</ao:suffix>
    <ao:prefix> therapy for at least 6 months and on a stable </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4E109C84-6323-418A-9404-5FBE487E6AA2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-26.txt.html</ao:hasSource>
    <domeo:uuid>4E109C84-6323-418A-9404-5FBE487E6AA2</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.1alpha-050">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <foafx:build>050</foafx:build>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <foafx:version>2.1alpha</foafx:version>
    <foafx:homepage></foafx:homepage>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:977A2BC8-0744-472F-9FA2-CCF897431CA1">
    <ao:context rdf:resource="urn:domeoclient:uuid:D7826928-4C32-427A-B946-D947EB2451B5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-10 11:15:15 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-10 11:15:41 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:3F81414E-B149-4B05-925B-18735B554A13</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A5182DA-4DAC-48D6-946F-8283D026674F">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:EEEDCB2D-0F2D-42A1-AF30-23CDE2191AB4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-18 13:55:33 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:99826AC3-3668-4F74-9E9D-DADD1F7098F0</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-18 13:56:04 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:B87CC34F-8B98-4E82-835E-39A3B10EA5E5</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3443022F-68AE-4016-8363-C6C96EE0AE69">
    <pav:createdOn>2014-07-10 11:21:39 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. Co-administration resulted in a 50% increase in AUC of</ao:suffix>
    <domeo:uuid>3443022F-68AE-4016-8363-C6C96EE0AE69</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3443022F-68AE-4016-8363-C6C96EE0AE69"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F42BBCFB-733A-404A-8BEB-B260F9A5A30B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>sildenafil</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/136411</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:590959F7-F15A-4306-BE23-1D37D8B0C281">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/52C813E5-0F7C-4C85-B289-60F729DEBDA0"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F42BBCFB-733A-404A-8BEB-B260F9A5A30B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35CDD2E7-70B2-4586-B719-AE865BE6C293">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:E2070D1E-ACA9-4A94-BC6D-885BA2DE100C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-18 13:55:43 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:99826AC3-3668-4F74-9E9D-DADD1F7098F0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-18 13:56:04 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:FD41E7F4-0BFF-4655-AF6A-DB36A69B65D2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:91E13B1F-608F-46DC-825E-D1031BD8EE6D">
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:8AD0A979-32CC-4AB1-A507-37A7920B4725"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-10 11:20:05 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:427474F1-6F8A-40AF-BCE5-B758B7F7E955">
    <domeo:uuid>427474F1-6F8A-40AF-BCE5-B758B7F7E955</domeo:uuid>
    <ao:exact>theophylline</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:427474F1-6F8A-40AF-BCE5-B758B7F7E955"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <ao:prefix> AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD </ao:prefix>
    <ao:suffix> AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). Theophylline clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of theophylline increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours. (See PRECAUTIO</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-18 14:03:04 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48E274BA-EE97-464C-9512-861F9207381F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:883587E1-49C1-4EE0-909E-4ADBAE13DD3A</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:nodeID="Nd890d2ed54f14b4db89d414b2d5e51ea"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3D2F7357-CD2E-446B-8A85-437E7D90CAA9"/>
    <pav:lastSavedOn>2014-07-15 14:30:47 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-15 14:24:15 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>expertstudy Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/4702EA7F-D817-4188-B0B3-15F9D82CDDBA">
    <rdfs:label>procyclidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6176C4B3-F970-4A01-84A9-4E5517225598">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/A854A7DE-A8FE-498F-9B31-F34790052689"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/929638DA-F799-437F-8033-228CF8F46D12"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18EE2CB9-3D4F-42B6-A49D-245BF6C564CA">
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <pav:createdOn>2014-07-16 10:19:09 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B09717CD-B9B4-417C-B2AA-D11A10E5FE3E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/B54D2CA7-6597-43FB-AC52-34E959AFBD56">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>carbamazepine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:274D4FB3-81D3-46CA-BE6A-31286B260E56">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:A33A59D0-2BD7-42C9-87D9-CB819AC41E8C</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-15 14:10:55 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:98825CF8-1CA0-489D-A1C4-2239A4A1278A"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4A4923A-11E7-4579-931D-08B5995E3BC1">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B4A4923A-11E7-4579-931D-08B5995E3BC1"/>
    <ao:prefix>e acts as an antagonist at other receptors, but with lower potency. </ao:prefix>
    <ao:exact>Risperidone</ao:exact>
    <pav:createdOn>2014-07-15 14:02:59 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and haloperidol-sensitive sigma site, and no affinity (when tested at concentrations &gt;10-5 M) </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CC8EDBDD-A7A3-41E7-8775-C12B2FD8C92B">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1FFE9DE2-04AD-4E77-8218-3B3AECFFDAA7"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/AC9A1D27-44BD-40B7-A83D-E484627AE823">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/136411</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>sildenafil</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/54E13418-11DC-4671-AB00-7B464BF4A389">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C30B0B1-5EC7-4866-B5F3-AA2CB04C9143">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>1C30B0B1-5EC7-4866-B5F3-AA2CB04C9143</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1C30B0B1-5EC7-4866-B5F3-AA2CB04C9143"/>
    <pav:createdOn>2014-07-10 11:20:26 -0700</pav:createdOn>
    <ao:exact>epoprostenol</ao:exact>
    <ao:suffix> was 28%, resulting in about 22% lower mean average steady state concentrations. Therefore, the slight decrease of sildenafil exposure in the presence of epoprostenol is not considered clinically relevant. The effect of sildenafil on epoprostenol pharmac</ao:suffix>
    <ao:prefix> (80 mg tid) bioavailability due to co-administration of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:701B3F36-4375-4CB6-A9F8-C942C7D5632E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:701B3F36-4375-4CB6-A9F8-C942C7D5632E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> 400 mg to six healthy male volunteers. After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14</ao:suffix>
    <ao:prefix> 100 mg was administered as a single oral dose alone and two hours after a single dose of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <ao:exact>cimetidine</ao:exact>
    <pav:createdOn>2014-07-16 15:39:41 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:541CB376-3C80-4099-9753-CC9C70F09426">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:541CB376-3C80-4099-9753-CC9C70F09426"/>
    <pav:createdOn>2014-07-15 14:16:16 -0700</pav:createdOn>
    <ao:prefix>, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>phenytoin</ao:exact>
    <ao:suffix>, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5CE6135C-97A9-4B21-9915-11E87A1697A5">
    <pav:createdOn>2014-07-15 14:18:55 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A8C40C51-0B43-4493-80CC-949EA671E491"/>
    <pav:lineageUri>urn:domeoserver:annotation:9EEF5EF6-F6F0-436C-A2A1-B786DCDF7C27</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-15 14:19:34 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94220E4B-2D94-4374-8F09-2F8CAACF7723">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-18 18:26:41 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-18 15:25:36 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:17EFB5BA-9EFA-4D0C-BB82-D8BBB7EA6411</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:body rdf:nodeID="N688de982838d496897f93f18e250c517"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:240CE9DC-DA1D-48D6-946F-B8B1FEC89249"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3F707B16-9AC0-4A46-A0C5-ED7358D7F764">
    <ao:context rdf:resource="urn:domeoclient:uuid:D31038BF-BD20-49DC-B15A-84202B180FA2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdOn>2014-07-10 11:19:20 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D2F7357-CD2E-446B-8A85-437E7D90CAA9">
    <ao:exact>sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3D2F7357-CD2E-446B-8A85-437E7D90CAA9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-15 14:26:41 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6c1edeae53834f0b85d46ff0eac3ef13">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9AF357DC-FE46-4BA4-BC30-1C0C4232273D">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C52DDDDD-59AD-4D62-94B9-F53565B2D800"/>
    <pav:createdOn>2014-07-16 15:39:34 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:0E4C899A-6757-4D55-8BFC-FEDC7728D34C</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E3DA2E5E-FC19-4C22-AF6C-A9CB4B450554</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-16 15:40:55 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F5BD518-01AA-46D8-B893-6470B014CC3B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8F5BD518-01AA-46D8-B893-6470B014CC3B"/>
    <pav:createdOn>2014-07-15 14:17:13 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>The apparent half-life of </ao:prefix>
    <ao:suffix> was 3 hours (CV=30%) in extensive metabolizers and 20 hours (CV=40%) in poor metabolizers. The apparent half-life of 9-hydroxyrisperidone was about 21 hours (CV=20%) in extensive metabolizers and 30 hours (CV=25%) in poor metabolizers. The pharmacokinet</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B06A286-D3FC-41A8-A621-60C6E027265C">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7B06A286-D3FC-41A8-A621-60C6E027265C"/>
    <pav:createdOn>2014-07-15 14:08:46 -0700</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <ao:suffix> nor 9-hydroxyrisperidone displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidon</ao:suffix>
    <ao:prefix>, is 77%. Neither </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FCAC7AB3-7719-4C9B-8378-64BF0D2B4AD2">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:4148B6C7-21F7-44D9-9466-BC519FF61DF1"/>
    <pav:createdOn>2014-07-18 13:48:11 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A7F21A3D-50B3-495E-884A-2C707B40C763</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-18 13:48:39 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:748BB253-1066-4977-91B2-35D8C6906790</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A5A82A3B-FE45-46DE-9048-8E85995D8F43">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-15 14:11:14 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:C8EFF1C4-C4FB-4CBB-A08A-C7EA79DBA43E</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-15 14:09:46 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D9907CFF-B778-4B29-8773-70DE74FE7759"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60698783-AF86-402C-ADB4-1162CCD89EBA">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>60698783-AF86-402C-ADB4-1162CCD89EBA</domeo:uuid>
    <pav:createdOn>2014-07-16 14:09:37 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>study evaluated the potential interaction of once weekly dosing of fluconazole 300 mg to 21 normal females taking an oral contraceptive containing ethinyl estradiol and norethindrone. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosing. The individual AUC values of norethindrone decreased very slightly (&lt;5%) in 3 of the 21 subjects after fluconazole treatment</ao:exact>
    <ao:prefix>A third </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:60698783-AF86-402C-ADB4-1162CCD89EBA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:45DF7FF1-EC0B-4049-BA97-01C05E9D3DFE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>phenytoin</ao:exact>
    <ao:prefix>200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:hasSource>
    <ao:suffix> AUC. The mean ± SD increase in phenytoin AUC was 88% ± 68% (range: 16 to 247%). The absolute magnitude of this interaction is unknown because of the intrinsically nonlinear disposition of phenytoin. (See PRECAUTIONS.)</ao:suffix>
    <pav:createdOn>2014-07-18 13:48:28 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:45DF7FF1-EC0B-4049-BA97-01C05E9D3DFE"/>
    <domeo:uuid>45DF7FF1-EC0B-4049-BA97-01C05E9D3DFE</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FDDEE9D3-D4C2-40CB-BC92-305777AFD63E">
    <pav:lineageUri>urn:domeoserver:annotation:D2DBCC4A-ADA3-42C3-8C46-57DBF12F00B7</pav:lineageUri>
    <pav:createdOn>2014-07-15 14:18:29 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A61CD8E1-11C9-4016-9EA7-411997F38BC7"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-15 14:19:34 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E03B1442-AB3D-475E-AEE8-EFD5DC37D96C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>cimetidine</ao:exact>
    <domeo:uuid>E03B1442-AB3D-475E-AEE8-EFD5DC37D96C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E03B1442-AB3D-475E-AEE8-EFD5DC37D96C"/>
    <ao:suffix> 400 mg to six healthy male volunteers. After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14</ao:suffix>
    <ao:hasSource>				http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html																													</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-17 15:53:41 -0700</pav:createdOn>
    <ao:prefix> 100 mg was administered as a single oral dose alone and two hours after a single dose of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB99EE39-D6AF-4C66-A7BF-D1186DCE23D6">
    <ao:prefix> administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in</ao:prefix>
    <ao:hasSource>			http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact> fluconazole</ao:exact>
    <domeo:uuid>DB99EE39-D6AF-4C66-A7BF-D1186DCE23D6</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DB99EE39-D6AF-4C66-A7BF-D1186DCE23D6"/>
    <pav:createdOn>2014-07-17 15:59:07 -0700</pav:createdOn>
    <ao:suffix> AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole hal</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf37c66ab1343427fbf08dea2254da860">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E5C736D-1CA1-4B67-82D7-01FF596E3F63">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>5E5C736D-1CA1-4B67-82D7-01FF596E3F63</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5E5C736D-1CA1-4B67-82D7-01FF596E3F63"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-26.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-18 13:51:22 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks. There was a significant increase in cyclosporine AUC, Cmax, Cmin (24-hour concentration), and a significant reduction in apparent oral clearance following the administ</ao:suffix>
    <ao:exact>cyclosporine</ao:exact>
    <ao:prefix> 200 mg daily for 14 days in eight renal transplant patients who had been on </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2BE90FDD-0DF8-4A0A-9B1E-B84B43D68582">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0409A564-F79B-4C83-9844-E9D65A082622"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46A0754E-C451-439B-B685-374909D4C42D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> ri</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:46A0754E-C451-439B-B685-374909D4C42D"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>spe</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-15 14:08:20 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na108a0ed49e24db6872a67862f1b9bf5">
    <domeo:sets rdf:resource="urn:pddi:uuid:F6BE9E0C-96F1-4A3F-BE0A-413829714A90"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:046CE425-7371-402F-A18F-6913B0C03124">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-17 15:56:45 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-17 18:56:48 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:nodeID="N9f12a6c9b6704173b79173d062dbe5ed"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:96BAB4C7-6F7A-4EBA-BAC1-134F746F11FA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:4D55F9FA-B792-4C06-8530-A362B2C70BA5</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:6491BF48-AC35-48FA-A8D2-102002F8E57E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75D8DE94-F5D4-4DC6-BC3F-9344C057C003">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>. Thus, </ao:prefix>
    <ao:suffix> can be given with or without meals.</ao:suffix>
    <pav:createdOn>2014-07-15 14:07:26 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:75D8DE94-F5D4-4DC6-BC3F-9344C057C003"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/52C813E5-0F7C-4C85-B289-60F729DEBDA0">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>ritonavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86ABDA54-6350-41E2-93E1-1353431A082D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-10 11:20:29 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:C1AC6F60-3C7C-4BEB-9095-25D25890AC79"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2C83F977-3681-48B0-B3C1-D84A60204AF3">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9C571DAA-DD40-49B9-9828-24A46A158061"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C912224-9ADC-4466-B8BD-9A0D37DB3F64">
    <ao:exact>warfarin</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0C912224-9ADC-4466-B8BD-9A0D37DB3F64"/>
    <pav:createdOn>2014-07-15 14:09:05 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> (100 mcg/mL), </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AAA6478C-E7E4-4D30-9F06-AA094434B620">
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-15 14:15:56 -0700</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E7E6B698-CDF9-4B67-A4F6-CC3D84C50315"/>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2bcf846e1338444bb4b1ebefe4ee3de0">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:03C138A3-3A62-41DC-8535-D728778DDD42">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/6CA51826-BC17-4C41-9533-7687E5BBFB21"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/17338360-FF55-4D91-8F6A-612551EEFC58"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2A636FF-8FE8-44E9-B454-573E4E7470FA">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-15 14:04:06 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:9F493B28-AE3A-4E32-85C4-AE2C806F7BDA"/>
    <pav:lineageUri>urn:domeoserver:annotation:61CDF0ED-4B77-4286-ACD0-B0B8D2D03F7C</pav:lineageUri>
    <pav:createdOn>2014-07-15 14:02:34 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D8773E33-77FB-4402-ABAD-8048CB22BB84">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-18 13:48:39 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A7F21A3D-50B3-495E-884A-2C707B40C763</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:748BB253-1066-4977-91B2-35D8C6906790</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-18 13:48:22 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D0DA49DD-64B6-4DB4-8411-726DBD8A6893"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47F91319-FBBC-4D96-B4A4-0705F95D9E7C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:47F91319-FBBC-4D96-B4A4-0705F95D9E7C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> may cause a decrease in the combined plasma concentrations of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-15 14:16:36 -0700</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <ao:suffix> and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak binding of risperidone to the enzyme suggests this is unlikely [see 7 DRUG </ao:suffix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E0194D4-524A-4E69-B161-52FB98ED36C2">
    <pav:createdOn>2014-07-10 11:20:21 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:46F4178C-1487-4F57-A6D9-06D0CE8BE565"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9DE1789-19F9-43BC-B292-659F900EA6EB">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:6A83C9D2-32BF-47FE-8FCD-DD0E108CBF21</pav:lineageUri>
    <pav:createdOn>2014-07-10 11:10:42 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:587BEAE7-8AE9-4452-8478-FF400284EBF7"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-10 11:14:30 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC119E59-51D3-4AAE-87A1-B3FF2D690F31">
    <ao:prefix> in plasma was increased by about 35% because of the diminished concentration of both albumin and α1-acid glycoprotein. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-15 14:18:41 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CC119E59-51D3-4AAE-87A1-B3FF2D690F31"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> doses should be reduced in patients with liver disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
    <ao:exact>Risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F620DDE8-4C9B-4A5E-8FA3-1F42BF3BD963">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>sulfamethazine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:666583ED-95C0-4F25-8463-3174C806F5FF">
    <pav:createdOn>2014-07-10 11:20:33 -0700</pav:createdOn>
    <ao:prefix> is not considered clinically relevant. The effect of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>sildenafil</ao:exact>
    <domeo:uuid>666583ED-95C0-4F25-8463-3174C806F5FF</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> on epoprostenol pharmacokinetics is not known.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:666583ED-95C0-4F25-8463-3174C806F5FF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16AE9675-2124-48E2-984A-6251D41F39B6">
    <ao:suffix> clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of theophylline increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours. (See PRECAUTIONS.)</ao:suffix>
    <ao:exact>Theophylline</ao:exact>
    <ao:prefix> AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <domeo:uuid>16AE9675-2124-48E2-984A-6251D41F39B6</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16AE9675-2124-48E2-984A-6251D41F39B6"/>
    <pav:createdOn>2014-07-18 14:03:12 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:34BFAD74-FE4D-4E30-8ACE-10002901EAA2">
    <pav:createdOn>2014-07-16 10:18:37 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4CE774DD-EF4B-488F-AD09-38B151FCAC2F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0BB528F0-CD4A-4BAC-AA5B-3FF33FCFF9B7">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0BB528F0-CD4A-4BAC-AA5B-3FF33FCFF9B7"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-15 14:09:39 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F2AF7A08-3EE5-4851-BC7F-4DF99BFE382A">
    <ao:context rdf:resource="urn:domeoclient:uuid:3CE58974-7E1B-4366-B479-80D2CA8B6A5B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-16 10:19:26 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:612ABB21-3ECF-401B-9B38-AA1A866FE000">
    <ao:suffix> produced no genotoxic effects in a battery of 5 in vitro and 2 in vivo assays that included the following: Bacterial mutation assay, mouse lymphoma mutation assay, unscheduled DNA synthesis assay, and tests for cytogenetic aberrations in vivo in mouse b</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-52.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:612ABB21-3ECF-401B-9B38-AA1A866FE000"/>
    <pav:createdOn>2014-07-18 14:32:24 -0700</pav:createdOn>
    <domeo:uuid>612ABB21-3ECF-401B-9B38-AA1A866FE000</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Paroxetine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9AA1C371-A08E-41E5-AC8E-B7624054B9FF">
    <ao:suffix>. Extensive CYP 2D6 metabolizers convert risperidone rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations t</ao:suffix>
    <ao:prefix>r drugs. CYP 2D6 is subject to genetic polymorphism (about 6% to 8% of Caucasians, and a very low percentage of Asians, have little or no activity and are “poor metabolizers”) and to inhibition by a variety of substrates and some non-substrates, notably </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9AA1C371-A08E-41E5-AC8E-B7624054B9FF"/>
    <ao:exact>quinidine</ao:exact>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-15 14:14:23 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:701FB70F-31F1-4E69-B54F-77820E603E4C">
    <ao:context rdf:resource="urn:domeoclient:uuid:A3A3ADF6-73D6-48FB-AF10-EC6590D40ED9"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-18 14:02:49 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DBCB873-26F3-4E6A-9BD4-311369B43736</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9AA0507C-281E-45C8-9719-03E66F12C069</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-18 14:03:19 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N96899bab291e497894144588b6f80b94">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7527009-01DC-4E9A-8438-D89D172BDEAA">
    <domeo:uuid>A7527009-01DC-4E9A-8438-D89D172BDEAA</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>The pharmacokinetics of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A7527009-01DC-4E9A-8438-D89D172BDEAA"/>
    <pav:createdOn>2014-07-18 14:02:36 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <ao:suffix> were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>theophylline</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE6DEC5A-2EFB-4D44-817D-5B910C9A906D">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix> pharmacokinetics is not known.</ao:suffix>
    <ao:exact>epoprostenol</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FE6DEC5A-2EFB-4D44-817D-5B910C9A906D"/>
    <ao:prefix> on </ao:prefix>
    <domeo:uuid>FE6DEC5A-2EFB-4D44-817D-5B910C9A906D</domeo:uuid>
    <pav:createdOn>2014-07-10 11:20:35 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4B77AEB1-052D-442D-91E6-921DAD259BC6">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4B77AEB1-052D-442D-91E6-921DAD259BC6"/>
    <pav:createdOn>2014-07-10 11:20:41 -0700</pav:createdOn>
    <ao:suffix> (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates.</ao:suffix>
    <ao:exact>sildenafil</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>4B77AEB1-052D-442D-91E6-921DAD259BC6</domeo:uuid>
    <ao:prefix>In a study of healthy volunteers, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N120e4026351a4e2a8d8ba1d3fec36fdc">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52A12616-29C9-4323-A81B-949195D51273">
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:2E5CE73B-BFD4-4E35-9A07-D5E37A9E87AE</pav:previousVersion>
    <pav:lastSavedOn>2014-07-15 14:17:25 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:E455E1D2-B393-4131-81F1-25CAC07249AA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2014-07-15 14:15:27 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0F043D82-C59E-477B-8CC6-ED534D6C8664">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F929AFAD-20F2-46BB-9E7C-A915CD8E65D0"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D65EE4FB-C2D2-4BA1-977B-5D3CB6873FE9">
    <ao:exact>sulfamethazine</ao:exact>
    <ao:prefix> displaces each other from plasma binding sites. High therapeutic concentrations of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D65EE4FB-C2D2-4BA1-977B-5D3CB6873FE9"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance.</ao:suffix>
    <pav:createdOn>2014-07-15 14:09:01 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A61CD8E1-11C9-4016-9EA7-411997F38BC7">
    <ao:suffix> in subjects with liver disease were comparable to those in young healthy subjects, the mean free fraction of risperidone in plasma was increased by about 35% because of the diminished concentration of both albumin and α1-acid glycoprotein. Risperidone d</ao:suffix>
    <pav:createdOn>2014-07-15 14:18:29 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A61CD8E1-11C9-4016-9EA7-411997F38BC7"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Hepatic Impairment: While the pharmacokinetics of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB808AED-F3EE-4633-873E-90372A00493C">
    <ao:exact>paroxetine</ao:exact>
    <domeo:uuid>EB808AED-F3EE-4633-873E-90372A00493C</domeo:uuid>
    <ao:prefix>Daily oral dosing of immediate-release </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-50.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-18 14:20:17 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EB808AED-F3EE-4633-873E-90372A00493C"/>
    <ao:suffix> (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state. If anticholinergic effects are seen, the dose of procycli</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4B8784BF-1D41-417E-A20C-C9B069D76FAA">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C54C358E-1731-4D93-820E-2F87B9D286FE"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/A04865E8-787E-4761-9CCC-B05D3C433330">
    <rdfs:label>sildenafil</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/136411</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82C41618-75F7-4A21-9E13-4028DB75BB70">
    <ao:exact>Fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>82C41618-75F7-4A21-9E13-4028DB75BB70</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:82C41618-75F7-4A21-9E13-4028DB75BB70"/>
    <ao:prefix> increased 32% ± 17% (range: 16 to 72%). </ao:prefix>
    <ao:hasSource>			http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-17 15:59:32 -0700</pav:createdOn>
    <ao:suffix> half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTIONS.)</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N206740cac061446a9314da6018bbb24e">
    <domeo:sets rdf:resource="urn:pddi:uuid:8F4A61A4-B256-44BA-A917-3B5D6CDEEC4F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1D04FEE-3479-4F04-B0D6-9FC8F29285CE">
    <pav:createdOn>2014-07-17 15:54:16 -0700</pav:createdOn>
    <ao:exact>cimetidine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D1D04FEE-3479-4F04-B0D6-9FC8F29285CE"/>
    <ao:hasSource>				http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html																													</ao:hasSource>
    <ao:suffix> 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.</ao:suffix>
    <ao:prefix> AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D1D04FEE-3479-4F04-B0D6-9FC8F29285CE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:65491747-3FED-4091-AB6D-7A1B627B89AD">
    <ao:suffix> and ritonavir, both of which are CYP3A substrates.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:65491747-3FED-4091-AB6D-7A1B627B89AD"/>
    <domeo:uuid>65491747-3FED-4091-AB6D-7A1B627B89AD</domeo:uuid>
    <ao:exact>saquinavir</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-10 11:20:45 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3CE58974-7E1B-4366-B479-80D2CA8B6A5B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3CE58974-7E1B-4366-B479-80D2CA8B6A5B"/>
    <ao:prefix>[see 12 CLINICAL PHARMACOLOGY]. Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>.</ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <pav:createdOn>2014-07-16 10:19:26 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81CA85AD-8F73-41B9-AEC4-5F2B934C9D93">
    <ao:exact>norethindrone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-16 14:03:26 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:81CA85AD-8F73-41B9-AEC4-5F2B934C9D93"/>
    <ao:prefix> and </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:suffix>. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9006A3C1-1FFE-448B-887C-2F101EC30804">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9006A3C1-1FFE-448B-887C-2F101EC30804"/>
    <ao:exact>administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>. However, the </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>9006A3C1-1FFE-448B-887C-2F101EC30804</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-07-16 15:46:07 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DEA7496B-9CAF-4929-AD2C-2B22EB0C5A6B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DEA7496B-9CAF-4929-AD2C-2B22EB0C5A6B"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-15 14:06:27 -0700</pav:createdOn>
    <ao:suffix>, its major metabolite, 9-hydroxyrisperidone, and risperidone plus 9-hydroxyrisperidone are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma conce</ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Plasma concentrations of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A5B87F1-0D90-49BD-B71F-1710FF095850">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:9AA0507C-281E-45C8-9719-03E66F12C069</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-18 14:03:19 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DBCB873-26F3-4E6A-9BD4-311369B43736</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-18 14:02:43 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5B73CF3F-C910-4D04-9121-43AA38BE7F2F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:665D54F7-737F-4E41-85AF-4DB192AB7A15">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:6DC754D9-968C-4DBC-BC8E-28DCC1DD36A3"/>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-10 11:20:46 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nce83eb0cbafd4be08363841226135913">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71649D2A-6308-46A5-9322-DFC56F36E8F3">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-16 15:40:17 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:D4F68DB2-7686-4E60-9A9D-F764E3A0DF93"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E3DA2E5E-FC19-4C22-AF6C-A9CB4B450554</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-16 15:40:55 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:3427BB2C-A91E-4C2F-9AEF-7451962FB2E7</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4B04F76-068F-4446-8605-4EDC1E4CB4F3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <pav:createdOn>2014-07-15 14:07:21 -0700</pav:createdOn>
    <ao:prefix>Food Effect: Food does not affect either the rate or extent of absorption of </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D4B04F76-068F-4446-8605-4EDC1E4CB4F3"/>
    <ao:suffix>. Thus, risperidone can be given with or without meals.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E5AC3B8B-F69B-4482-815F-54FC3F75312F">
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2BFC2FB6-6BE9-4822-A245-973533533023</pav:previousVersion>
    <pav:lastSavedOn>2014-07-10 11:21:41 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:65491747-3FED-4091-AB6D-7A1B627B89AD"/>
    <pav:createdOn>2014-07-10 11:20:45 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:17162313-6A55-4157-B495-83AA9CF1A26A">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-18 14:20:41 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7BA312DF-BB65-4A90-8B7D-A54425D7C553</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:1EE1D64B-EDD4-4170-B797-D8F83B927DCE</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-18 14:20:39 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:11E6A1FA-CF90-4170-B074-E4E3C8C8288D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D31038BF-BD20-49DC-B15A-84202B180FA2">
    <ao:prefix>i</ao:prefix>
    <ao:exact>l</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D31038BF-BD20-49DC-B15A-84202B180FA2"/>
    <domeo:uuid>D31038BF-BD20-49DC-B15A-84202B180FA2</domeo:uuid>
    <pav:createdOn>2014-07-10 11:19:20 -0700</pav:createdOn>
    <ao:suffix>denafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax. Co-administratio</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5415B79F-FEAF-4999-A78E-2C1039116F7C">
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2014-07-15 14:07:58 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:9B307D8B-D2B0-4795-8850-FAAAAC6B5AF4</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:D0A91F52-6752-4FEC-A801-601958619292"/>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-15 14:07:38 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D2E85468-7CF7-4CD4-BDCA-9028642087EE">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/B54D2CA7-6597-43FB-AC52-34E959AFBD56"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D2018278-5A34-478E-8004-540890604BD3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3AF5AF5B-6498-4C88-94AC-716E8168CCAC">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3AF5AF5B-6498-4C88-94AC-716E8168CCAC"/>
    <ao:prefix> is well absorbed. The absolute oral bioavailability of</ao:prefix>
    <ao:exact> risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.</ao:suffix>
    <pav:createdOn>2014-07-15 14:03:32 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F69E5920-13F7-4233-8E5C-355591D43752">
    <pav:createdOn>2014-07-18 13:51:41 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:B8452517-26D0-419F-88FD-A818925FDE06</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-18 16:51:47 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:2F75FC7D-FA23-4713-836C-9481CAAF5C89</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:1C906DFD-63EC-472C-AD64-29043E8A58B1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47D397AD-5153-40DA-83B8-C0A45725E6BC">
    <ao:prefix> to </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug results from the combined concentr</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:47D397AD-5153-40DA-83B8-C0A45725E6BC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-15 14:10:02 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3776F388-42AA-4941-B8F9-416DFC230546">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E3DA2E5E-FC19-4C22-AF6C-A9CB4B450554</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:036BDAF2-5EB1-43A8-9A15-54EECB844D12</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-16 15:39:46 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-16 15:40:55 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6501B61D-9F1D-47DB-B93C-A2B799BFACF1"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:887773A9-6D1A-46C3-A7F4-E2255F7FBE67">
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lastSavedOn>2014-07-16 18:46:13 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:8D624D14-9F33-4059-A979-A132EC3D7292</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E3DA2E5E-FC19-4C22-AF6C-A9CB4B450554</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-16 15:44:20 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="N1cd4484c34ff4788a1e07d601d1dd58a"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F057A8DE-7885-47B0-B2D9-E9C3D877EC02"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D74FA7C5-5531-44B7-99F1-8D9CCAA862A7">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:25F38526-D98C-49CE-873D-4D75248FDE0A"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90386835-AD59-4BAA-A860-3003ABCAF86C">
    <pav:lineageUri>urn:domeoserver:annotationset:75FC1225-8399-469B-AE9D-7F697713E6AC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:ADE68C3A-6684-4E35-B3C0-F519065A2D66"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-15 14:07:58 -0700</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:9B307D8B-D2B0-4795-8850-FAAAAC6B5AF4</pav:previousVersion>
    <pav:createdOn>2014-07-15 14:06:21 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D2062C41-A719-4900-9B45-2632D5CEE604">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>carbamazepine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94AD2935-8FE6-4D3D-847A-A1AC66E35692">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:2808EA87-CFD9-497E-B3D4-336DDC2CF6FF"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-10 11:08:45 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:F1857E03-2545-40CD-AA96-12B6719617BF</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lastSavedOn>2014-07-10 11:14:30 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5280B7DB-AA4C-46FE-AB43-85E58C828264">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-18 14:03:19 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:9AA0507C-281E-45C8-9719-03E66F12C069</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:A7527009-01DC-4E9A-8438-D89D172BDEAA"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DBCB873-26F3-4E6A-9BD4-311369B43736</domeo:belongsToSet>
    <pav:createdOn>2014-07-18 14:02:36 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B82EA451-7796-4E93-B7B5-692C0393EDDE">
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B82EA451-7796-4E93-B7B5-692C0393EDDE"/>
    <pav:createdOn>2014-07-16 10:21:54 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>hydroxyrisperidone </ao:exact>
    <ao:prefix>9-</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4CD0874F-AA43-4C04-958D-6CFBFA68EC61">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7247E1B1-4BA1-4DE0-AA64-CA56899212F6"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-15 14:19:12 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-15 14:19:34 -0700</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:93D5917A-205E-46B0-9DE7-4C1529BDE33E</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DD78A8D5-89E1-46CD-BC97-037DB330DF6D">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-15 14:06:32 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DD78A8D5-89E1-46CD-BC97-037DB330DF6D"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:prefix>, its major metabolite, </ao:prefix>
    <ao:suffix>, and risperidone plus 9-hydroxyrisperidone are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma concentrations of risperidone occurred at about 1</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95E933E3-09F5-4362-96D4-CF14B045A370">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C94BECCE-E3E9-4B70-AC23-F715B9D3EEFF</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:F7635891-9395-4AA7-B1C6-22B3D89F0719"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-17 15:54:34 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-17 15:54:46 -0700</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:96BAB4C7-6F7A-4EBA-BAC1-134F746F11FA</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FBA60B3A-004D-4687-B7EC-56E7B9D4A78B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/276A1818-8600-415C-BF4E-E95E1BB0E0CC"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/0DCDA0D5-A5B2-483F-AFDF-50EAB4D41396"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e143046812afe0146812ce85a0000">
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:email>ningyifan1212@163.com</foafx:email>
    <foafx:homepage></foafx:homepage>
    <foafx:title>expert1</foafx:title>
    <foafx:lastname>1</foafx:lastname>
    <foafx:firstname>expert</foafx:firstname>
    <foafx:name>expert1</foafx:name>
    <rdfs:label>expert1</rdfs:label>
    <foafx:middlename></foafx:middlename>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/78CA8426-F17B-4F98-AB2F-F77F74181051">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83395</dailymed:activeMoietyRxCUI>
    <rdfs:label>saquinavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/2CB7BD6B-AF06-43CD-9905-C06E37B34FC9">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>risperidone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/0E179D30-7DE3-4459-A1C5-69426205C386">
    <rdfs:label>cimetidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:801BF977-34B8-44B2-9E5A-A5D9E2906430">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:801BF977-34B8-44B2-9E5A-A5D9E2906430"/>
    <pav:createdOn>2014-07-10 10:59:54 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> is an inhibitor of cGMP specific phosphodiesterase type-5 (PDE5) in the smooth muscle of the pulmonary vasculature, where PDE5 is responsible for degradation of cGMP. </ao:prefix>
    <ao:suffix>, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with pulmonary hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemi</ao:suffix>
    <ao:exact>Sildenafil</ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne0807a27b7434b0d86f8c7e840db2a2e">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D897A818-DCCA-4D6F-9782-6DA45BBFD745">
    <rdfs:label>fluconazole</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EFED6610-75EB-4165-827C-237B7D245279">
    <pav:createdOn>2014-07-10 10:59:54 -0700</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:801BF977-34B8-44B2-9E5A-A5D9E2906430"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-10 11:00:22 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:BE290CA3-79BD-411A-BE2E-69AA4D19607D</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6F6FACEE-5C35-4020-BE6D-26958BA10CA6">
    <pav:lastSavedOn>2014-07-17 15:54:46 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:C7811B96-6935-4053-BDA0-233B88584EB2"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:96BAB4C7-6F7A-4EBA-BAC1-134F746F11FA</domeo:belongsToSet>
    <pav:createdOn>2014-07-17 15:54:08 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C94BECCE-E3E9-4B70-AC23-F715B9D3EEFF</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2FE06202-CAC5-466E-B0DA-E34428ADAEF3">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2FE06202-CAC5-466E-B0DA-E34428ADAEF3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-15 14:07:31 -0700</pav:createdOn>
    <ao:prefix>Distribution: </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> is rapidly distributed. The volume of distribution is 1 to 2 L/kg. In plasma, risperidone is bound to albumin and α1-acid glycoprotein. The plasma protein binding of risperidone is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%. Nei</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>Risperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc5cd4c6515824de28e080fb3ec02d4e9">
    <domeo:sets rdf:resource="urn:pddi:uuid:F906594B-BBC1-48AF-8F3D-C4A2E2A96B54"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:58CDDE97-D8B0-4830-BB7A-AAE058957A70">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F0AE4B90-85AC-42C7-B80E-8A27A4B6E455"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3C55FE98-387B-4122-94EC-ABF9B03F8B03">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B3A2FE9F-B6D1-4F2D-8EB2-E8EA69DEC037"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:570B84EB-A83D-4275-82DA-1B306C0F0E33">
    <ao:prefix> to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak binding of </ao:prefix>
    <ao:suffix> to the enzyme suggests this is unlikely [see 7 DRUG INTERACTIONS].</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:570B84EB-A83D-4275-82DA-1B306C0F0E33"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-15 14:16:55 -0700</pav:createdOn>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:787C8DA7-E4FF-4344-8E03-827399F78206">
    <pav:lastSavedOn>2014-07-16 15:33:06 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F87EEF0-40A6-43E2-8222-95E7D1335A0B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:085B00A2-6C6B-488C-9382-36A86ADDE1DE"/>
    <pav:createdOn>2014-07-16 15:32:41 -0700</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:7AE68AC7-9B47-4954-8C65-45A6F0DC80C2</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B09717CD-B9B4-417C-B2AA-D11A10E5FE3E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-16 10:19:09 -0700</pav:createdOn>
    <ao:prefix>The clinical effect from </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B09717CD-B9B4-417C-B2AA-D11A10E5FE3E"/>
    <ao:exact>risperidone</ao:exact>
    <ao:suffix> results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone [see 12 CLINICAL PHARMACOLOGY]. Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/17338360-FF55-4D91-8F6A-612551EEFC58">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluconazole</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9b4e46db0e904596a0f45c6a0ef2ba09">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:287EB7AD-1FB2-4E91-A01C-FFE1A2CB547D">
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-18 15:17:44 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-18 18:26:41 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:40C3CB86-AAFD-4D68-AE0D-699574B044BD"/>
    <pav:lineageUri>urn:domeoserver:annotation:2C6B5082-4151-4204-A301-043C0F3C9951</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:nodeID="N4ae87a8bb30a48c683e11fb5104e796f"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>expertstudy Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E34E3E0D-B50B-4B49-B4D0-AD4C76A51252">
    <ao:exact> fluconazole</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E34E3E0D-B50B-4B49-B4D0-AD4C76A51252"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-18 13:56:03 -0700</pav:createdOn>
    <ao:prefix> to parent drug ratio significantly decreased after the administration of</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:hasSource>
    <ao:suffix>, from 7.6 ± 3.6 to 5.7 ± 2.2.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F929AFAD-20F2-46BB-9E7C-A915CD8E65D0">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/EDAB886F-D798-49C1-A0C4-ED5754179815"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/EC076291-AAD4-470B-AEA2-F25F4E7DC70B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:040CDB6C-0256-4144-8293-65FE5BE6A8FC">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-15 14:26:47 -0700</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:040CDB6C-0256-4144-8293-65FE5BE6A8FC"/>
    <ao:exact>warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:005571AF-9B7B-4186-B036-1D92080F00CA">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:005571AF-9B7B-4186-B036-1D92080F00CA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in flucon</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Administration of a single oral 200 mg dose of </ao:prefix>
    <pav:createdOn>2014-07-18 13:43:09 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <ao:exact>fluconazole</ao:exact>
    <domeo:uuid>005571AF-9B7B-4186-B036-1D92080F00CA</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D8D8ADB4-7CA8-48E1-AC8A-2DBE43F6BB49">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluconazole</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A81A4371-A756-421B-8B30-D10382A032D4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>. Extensive CYP 2D6 metabolizers convert </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A81A4371-A756-421B-8B30-D10382A032D4"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of rispe</ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-15 14:14:40 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:80054AD6-BA25-42F5-A7DD-E6D78015E9FA">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FBA60B3A-004D-4687-B7EC-56E7B9D4A78B"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/0A391966-16D3-4D0D-ACE8-794D85C254DC">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/75207</dailymed:activeMoietyRxCUI>
    <rdfs:label>bosentan</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/0F60CDA1-1EF3-48A8-B482-B23A5151B7B7">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <rdfs:label>risperidone</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3D1C555-823A-42D3-975B-C6C42C41329E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A3D1C555-823A-42D3-975B-C6C42C41329E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-18 13:57:27 -0700</pav:createdOn>
    <domeo:uuid>A3D1C555-823A-42D3-975B-C6C42C41329E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:hasSource>
    <ao:exact>zidovudine concentrations were determined on two occasions (before and following fluconazole 200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable zidovudine dose for at least two weeks. There was a significant increase in zidovudine AUC following the administration of fluconazole. The mean ± SD increase in AUC was 20% ± 32% (range: -27 to 104%). The metabolite, GZDV, to parent drug ratio significantly decreased after the administration of fluconazole, from 7.6 ± 3.6 to 5.7 ± 2.2</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F8EED65F-31D9-41A0-9BB4-436FCBA969FA">
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-15 14:19:21 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9AEC1350-B38C-47B6-8956-CA137F414E0B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-15 14:19:34 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:98EDA90E-C90D-4D63-98A6-D0E5B5AB1A9D</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/5DE2E202-6D4F-4F94-96E7-9AC3DF505EFC">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/EC076291-AAD4-470B-AEA2-F25F4E7DC70B">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>warfarin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05321D03-FF55-4658-854E-AEE6CA65C7B5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <ao:exact> single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%)</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:05321D03-FF55-4658-854E-AEE6CA65C7B5"/>
    <pav:createdOn>2014-07-16 15:36:36 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>05321D03-FF55-4658-854E-AEE6CA65C7B5</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:96BAB4C7-6F7A-4EBA-BAC1-134F746F11FA">
    <permissions:permissions rdf:nodeID="Ne0807a27b7434b0d86f8c7e840db2a2e"/>
    <pav:lastSavedOn>2014-07-17 18:56:48 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:C94BECCE-E3E9-4B70-AC23-F715B9D3EEFF</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:079A4E14-C541-4AC8-B876-063FC489849B"/>
    <pav:createdOn>2014-07-17 15:53:34 -0700</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:B230469B-00AA-4A73-A839-6D9826213D36"/>
    <ao:annotatesResource>				http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html																													</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:0FE2C318-FF67-459F-9092-2EF6E04B1472"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:046CE425-7371-402F-A18F-6913B0C03124"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:D590AF4F-FC05-41EA-8CBC-29156060B437"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BD319A5A-0B87-457E-BF99-76BC4728CC77"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B2690ED3-4A3B-4FA6-84FF-6800464F3D50"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>urn:domeoserver:annotationset:2D3D9594-163C-4299-854D-3987A43B7DCF</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:95E933E3-09F5-4362-96D4-CF14B045A370"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6F6FACEE-5C35-4020-BE6D-26958BA10CA6"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812ce85a0000"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E455E1D2-B393-4131-81F1-25CAC07249AA">
    <pav:createdOn>2014-07-15 14:15:27 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E455E1D2-B393-4131-81F1-25CAC07249AA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> to 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. This occurs with quinidine, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of risperidone in patients </ao:suffix>
    <ao:exact> risperidone</ao:exact>
    <ao:prefix>could be subject to two kinds of drug-drug interactions. First, inhibitors of CYP 2D6 interfere with conversion of</ao:prefix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D4B9A038-2770-4F91-9562-10173A7F2D34">
    <rdfs:label>cimetidine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd7745f40ec2646208daa7c8066853639">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D3C6A443-5788-4C8E-B4F0-D1A386132459">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <rdfs:label>carbamazepine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C99A2006-8591-4B3F-9788-B075E7E171FD">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D8D8ADB4-7CA8-48E1-AC8A-2DBE43F6BB49"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F995B9BA-3282-4734-8DF3-ADABDFFE80DD"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd5af13157dcc442f9ab08aed0ecbd2b1">
    <domeo:sets rdf:resource="urn:pddi:uuid:3B7229C1-BBC3-4F13-A2D8-9C5E932927F8"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/165E87BD-01D4-4D78-8A0D-F6089ECEF3AA">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81DA2C24-D202-4991-9DC6-FFA54776B4D2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-16 10:20:01 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:62C1B60E-3BDC-470D-A027-77547456BB31"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4CE774DD-EF4B-488F-AD09-38B151FCAC2F">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-16 10:18:37 -0700</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, as with other drugs used to treat schizophrenia, is unknown. However, it has been proposed that the drug’s therapeutic activity in schizophrenia is mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4CE774DD-EF4B-488F-AD09-38B151FCAC2F"/>
    <ao:prefix>The mechanism of action of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/09FCD917-E332-4552-87D1-A1B73168DBA1">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>sulfamethazine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FBBE65E6-567D-48EE-99B9-B5E8C8480685">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FBBE65E6-567D-48EE-99B9-B5E8C8480685"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <pav:createdOn>2014-07-15 14:08:51 -0700</pav:createdOn>
    <ao:suffix> displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydro</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> nor </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/5D96455B-66E9-4C54-AEED-0EA46BBFE77A">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>9-hydroxyrisperidone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/679314</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB032524-38CD-456B-A44B-C425DFD76D47">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak binding of risperidone to the enzyme suggests this is unlikely [see 7 DRUG INTERACTIONS].</ao:suffix>
    <pav:createdOn>2014-07-15 14:16:48 -0700</pav:createdOn>
    <ao:prefix> [see 7 DRUG INTERACTIONS]. It would also be possible for </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DB032524-38CD-456B-A44B-C425DFD76D47"/>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd890d2ed54f14b4db89d414b2d5e51ea">
    <domeo:sets rdf:resource="urn:pddi:uuid:CC8EDBDD-A7A3-41E7-8775-C12B2FD8C92B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C5430EE-8C8A-44B7-9A28-80BDAB1B381C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-29.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> Cmax increased 11% ± 9% (range: -6 to 27%). (See PRECAUTIONS.)</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8C5430EE-8C8A-44B7-9A28-80BDAB1B381C"/>
    <pav:createdOn>2014-07-18 14:07:26 -0700</pav:createdOn>
    <ao:exact>Tolbutamide</ao:exact>
    <domeo:uuid>8C5430EE-8C8A-44B7-9A28-80BDAB1B381C</domeo:uuid>
    <ao:prefix> AUC of 26% ± 9% (range: 12 to 39%). </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/FE3925A8-8E3B-4F19-B5AB-889AF933932B">
    <rdfs:label>erythromycin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4053</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6501B61D-9F1D-47DB-B93C-A2B799BFACF1">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-16 15:39:46 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6501B61D-9F1D-47DB-B93C-A2B799BFACF1"/>
    <ao:exact>cimetidine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of cimetidine 600 mg to 900</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> 400 mg to six healthy male volunteers. After the administration of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:49AC02A4-8391-4B23-ADA4-A757C853CF17">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F8EAECE2-30A6-49BF-883F-70A7B4280D18"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:742BAEF2-5B32-4F05-87AD-ACC7F302B35E">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/A3473ECA-4411-4CF5-A4E8-ABE5F8CA6A53"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F5B727AA-1FE7-4EF4-9422-5C712EBAD08C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:316356DA-5EB5-42EB-9878-F3A3E1BDA4E9">
    <ao:prefix> 300 mg to 21 normal females taking an oral contraceptive containing </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:316356DA-5EB5-42EB-9878-F3A3E1BDA4E9"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>ethinyl estradiol</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-16 14:03:22 -0700</pav:createdOn>
    <ao:suffix> and norethindrone. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and nore</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8A30D50-862D-473B-A05C-42C01434E780">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:5543F979-9AD2-451B-BEB4-B0DD8D480F71</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-18 14:32:24 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:612ABB21-3ECF-401B-9B38-AA1A866FE000"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:567E7CC2-49BA-4366-A98A-8E4134A9A74B</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-18 17:32:28 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9f12a6c9b6704173b79173d062dbe5ed">
    <domeo:sets rdf:resource="urn:pddi:uuid:D74FA7C5-5531-44B7-99F1-8D9CCAA862A7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:43443A66-1162-4BDC-88F9-4CB789CFAF8B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-10 11:25:13 -0700</pav:createdOn>
    <ao:body rdf:nodeID="N5165f3fe946a4004985133c00cd13833"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4A892E21-8734-4284-A9E5-E434991F2B9C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-10 14:25:16 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:56E0D923-5115-443D-9DA6-488B28B808F8</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41134D12-A312-4FDD-ADEA-5285A0740BFA">
    <pav:lastSavedOn>2014-07-16 10:23:07 -0700</pav:lastSavedOn>
    <pav:createdOn>2014-07-16 10:22:00 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:FBE4D752-3492-405C-8C46-E0FAC0507DD3"/>
    <pav:lineageUri>urn:domeoserver:annotation:8A513507-73B4-452F-947A-B7973A3A467C</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:65B1AF5D-CC49-4B9F-BACA-07320E9834D7">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:49FCC0DB-01A0-4D81-BC7E-4E5BA9BCB5A0"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/A3473ECA-4411-4CF5-A4E8-ABE5F8CA6A53">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluconazole</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1a0d77abee6649ccb442d12b8a80ff31">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C820B82D-AF0E-4A71-9E65-5AB73DFE5206">
    <pav:lineageUri>urn:domeoserver:annotation:B06DA6C0-E42B-45A0-999E-F9ABDA68454E</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:15A537D1-5648-41B2-8BFA-0D0BA3DF4393</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C69466D9-4AD4-4863-ABBC-AEF76AEF11D6"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-10 11:08:09 -0700</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-10 11:14:30 -0700</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2ECA95EB-4370-4C4C-8C95-4A2BE49873EF">
    <pav:lineageUri>urn:domeoserver:annotationset:D0F2204E-5148-4A33-AAD0-599FB1F44EFC</pav:lineageUri>
    <pav:createdOn>2014-07-18 14:23:36 -0700</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-18 14:23:49 -0700</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A1747CFE-8798-401D-BFC7-1E14B7B3B1B1</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:728539A9-7322-4281-848B-5507BB82A585"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/30725548-E65C-4611-B944-3E83F4ECA098">
    <rdfs:label>cimetidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A0073BE0-0C00-42AF-8C67-EADDD1F4519E">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0B393FF7-1BB4-4312-85CF-8C8D73B22BB7"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35ABEAB8-91E9-4F2D-B158-A3AE422D3EB0">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-18 13:43:20 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:35ABEAB8-91E9-4F2D-B158-A3AE422D3EB0"/>
    <ao:prefix> administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in </ao:prefix>
    <domeo:uuid>35ABEAB8-91E9-4F2D-B158-A3AE422D3EB0</domeo:uuid>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole hal</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F8EAECE2-30A6-49BF-883F-70A7B4280D18">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/ADE2E1DA-D3E9-438C-A1E1-D82219070E28"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/FA53ED44-367B-4D92-8F10-3F967033E9F0"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A892E21-8734-4284-A9E5-E434991F2B9C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4A892E21-8734-4284-A9E5-E434991F2B9C"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-10 11:25:13 -0700</pav:createdOn>
    <domeo:uuid>4A892E21-8734-4284-A9E5-E434991F2B9C</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AA5B502F-CF57-4C65-81A8-140217111073">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-15 14:19:34 -0700</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:F31130A8-92DE-4A3D-BCA1-C17226A873C5</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-15 14:17:37 -0700</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A42DE598-1DBE-4AFF-81B2-08991620AD5B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F995B9BA-3282-4734-8DF3-ADABDFFE80DD">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>rifampin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/83246816-D7FF-44ED-AF9B-04CDD30DDA0F">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluconazole</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21CD752E-6211-4C49-B6F0-F912F29E4F0E">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>debrisoquin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-15 14:14:29 -0700</pav:createdOn>
    <ao:prefix>CYP 2D6, also called </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:21CD752E-6211-4C49-B6F0-F912F29E4F0E"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> hydroxylase, is the enzyme responsible for metabolism of many neuroleptics, antidepressants, antiarrhythmics, and other drugs. CYP 2D6 is subject to genetic polymorphism (about 6% to 8% of Caucasians, and a very low percentage of Asians, have little or </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DE86A623-45C7-446E-BC44-389610395DA9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>DE86A623-45C7-446E-BC44-389610395DA9</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DE86A623-45C7-446E-BC44-389610395DA9"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <ao:prefix>Oral contraceptives were administered as a single dose both before and after the oral administration of </ao:prefix>
    <ao:suffix> 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and</ao:suffix>
    <ao:exact>fluconazole</ao:exact>
    <pav:createdOn>2014-07-16 15:32:30 -0700</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:387A1EFC-40FD-4ED2-A90C-E9AE2D14E77B">
    <ao:prefix>l AUC was 6% (range: -47 to 108%) and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> AUC increased 17% (range: -33 to 141%).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>levonorgestrel</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:387A1EFC-40FD-4ED2-A90C-E9AE2D14E77B"/>
    <domeo:uuid>387A1EFC-40FD-4ED2-A90C-E9AE2D14E77B</domeo:uuid>
    <pav:createdOn>2014-07-16 15:33:03 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/0DCDA0D5-A5B2-483F-AFDF-50EAB4D41396">
    <rdfs:label>norethindrone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7514</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6684B979-BD2C-446B-B807-178AE44EB6F8">
    <ao:suffix> is well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6684B979-BD2C-446B-B807-178AE44EB6F8"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-15 14:03:26 -0700</pav:createdOn>
    <ao:exact>Risperidone</ao:exact>
    <ao:prefix>Absorption: </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B7CDA6B5-18B6-4EB0-A176-5FA6DF4BD169">
    <pav:lastSavedOn>2014-07-16 14:06:30 -0700</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:E3BDCAAC-7613-4A30-B9AE-3E150C9C0E1D</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C2A39432-076D-421D-8007-22690EDA5A0C</domeo:belongsToSet>
    <pav:createdOn>2014-07-16 14:03:59 -0700</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:831D0F3D-639E-4B91-A3ED-AE0F362D5CE0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:61CB1DA8-A104-4CBC-A3C7-E8898B001ECF">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A229E325-2C87-4EFC-8114-8F692F9FE147"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B419ACAE-832E-406D-9427-D88D93B6A405">
    <ao:exact>norethindrone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B419ACAE-832E-406D-9427-D88D93B6A405"/>
    <ao:prefix>individual AUC values of </ao:prefix>
    <ao:suffix> decreased very slightly</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-16 14:07:45 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:34E48324-D870-4398-B241-2FAE6690C98C">
    <pav:createdOn>2014-07-18 13:55:37 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> 200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable zidovudine dose for at least two weeks. There was a significant increase in zidovudine AUC following the administration of fluconazole. The mean ± SD increase in AUC was 20</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:34E48324-D870-4398-B241-2FAE6690C98C"/>
    <ao:prefix> concentrations were determined on two occasions (before and following </ao:prefix>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N848ecb80f2af4441b07e9b8f5684ba51">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EEEDCB2D-0F2D-42A1-AF30-23CDE2191AB4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-18 13:55:33 -0700</pav:createdOn>
    <ao:prefix>Plasma </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:hasSource>
    <ao:suffix> concentrations were determined on two occasions (before and following fluconazole 200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable zidovudine dose for at least two weeks. There was a significant increase in zidovudine AUC</ao:suffix>
    <ao:exact>zidovudine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EEEDCB2D-0F2D-42A1-AF30-23CDE2191AB4"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9C571DAA-DD40-49B9-9828-24A46A158061">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/AC9A1D27-44BD-40B7-A83D-E484627AE823"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/DA1E3525-C5D9-473E-8402-BDC110AF5313"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50B64AB9-5E00-4F5D-BE7F-9B8CE91BCF2A">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-16 10:19:14 -0700</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6FFFF211-BFDC-4E16-968C-A296868530C4</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-16 10:20:50 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:FECBEFAB-2C18-4C64-93DF-19494748E804"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C8D7FDC6-6816-4BD4-BC7F-88ABDCC37D79</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C91DD2D9-B8D7-4C80-85A1-EE73345B059A">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:7B656CB9-304A-4F35-9AAE-0A055011F03C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:F6A08558-747B-4489-8846-8F2B5DE155ED</pav:lineageUri>
    <pav:createdOn>2014-07-15 14:17:31 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-15 14:19:34 -0700</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/4AF09D72-39A6-4BC4-A512-26DBDD3392E4">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/136411</dailymed:activeMoietyRxCUI>
    <rdfs:label>sildenafil</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3e33944b1b3747898ec3a325c6c1ffbe">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A49ECAF-CE5A-41FF-B8D4-43B060247DBA">
    <pav:lastSavedOn>2014-07-17 15:59:35 -0700</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:82C41618-75F7-4A21-9E13-4028DB75BB70"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DEBE5AF-B171-4BE8-880B-76A2BEE742A6</domeo:belongsToSet>
    <pav:createdOn>2014-07-17 15:59:32 -0700</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:B716A719-3E66-4B72-87E0-370D90F3B8F7</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/3A85B371-E653-4667-9F67-A08A4188190B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>rifampin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B0997699-FE17-48DB-97D8-9BA9ABDD0C90">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B0997699-FE17-48DB-97D8-9BA9ABDD0C90"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone</ao:exact>
    <ao:suffix> and 9-hydroxyrisperidone was decreased, and elimination half-lives were prolonged compared to young healthy subjects. Dosing should be modified accordingly in the elderly patients [see 2 DOSAGE AND ADMINISTRATION].</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-15 14:18:48 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix>Elderly: In healthy elderly subjects, renal clearance of both </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7A0B21EC-9B42-45A6-939E-5702AED058B8">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:41F53CFC-A1D1-4460-AD5B-0F44E9396C8A"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3dbb2b829465456a87b87065d29aa30b">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A0209F9-EA1A-4BBA-865A-0A0F6CCAF57E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A0209F9-EA1A-4BBA-865A-0A0F6CCAF57E"/>
    <pav:createdOn>2014-07-15 14:08:33 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), an</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N28c4f1a5f2874724adb4efe13b7c3140">
    <domeo:sets rdf:resource="urn:pddi:uuid:0F043D82-C59E-477B-8CC6-ED534D6C8664"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:32A0FE11-022B-463B-8705-7B1DFD8D84DC">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D897A818-DCCA-4D6F-9782-6DA45BBFD745"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/B6084BE9-4101-468F-985F-F42789F59869"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0B393FF7-1BB4-4312-85CF-8C8D73B22BB7">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/4702EA7F-D817-4188-B0B3-15F9D82CDDBA"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/EB5D25E9-EAE4-4A5C-BDE0-2EDF1AA4D125"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:65047D28-4B70-4701-B243-A146C45926A7">
    <pav:lastSavedOn>2014-07-15 14:04:06 -0700</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B6A462D-57EA-4BBD-87E1-A0EC2FAF5196</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:B4A4923A-11E7-4579-931D-08B5995E3BC1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:78CEB220-43DA-4746-897F-A8FFEDD2BDD8</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-15 14:02:59 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N147c3273815e49bd9a16ba3fe2d02f2e">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/EB5D25E9-EAE4-4A5C-BDE0-2EDF1AA4D125">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D0DA49DD-64B6-4DB4-8411-726DBD8A6893">
    <ao:exact>fluconazole </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> (oral </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D0DA49DD-64B6-4DB4-8411-726DBD8A6893"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-18 13:48:22 -0700</pav:createdOn>
    <ao:suffix> 200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in phenytoin AUC. The mean ± SD increase in phenytoin AUC was 88% ± 68% (range: 16 to 247%). The absolute magnitude of this interaction is unknown because of the in</ao:suffix>
    <domeo:uuid>D0DA49DD-64B6-4DB4-8411-726DBD8A6893</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A239FA7-0EC5-40B4-BB98-C16757BB8044">
    <ao:prefix>In a study of healthy male volunteers, co-administration of </ao:prefix>
    <domeo:uuid>7A239FA7-0EC5-40B4-BB98-C16757BB8044</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A239FA7-0EC5-40B4-BB98-C16757BB8044"/>
    <ao:exact>s</ao:exact>
    <ao:suffix>ildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax. Co-administrat</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-10 11:19:20 -0700</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7AB175A5-BD20-41A8-91C0-16D5DF981557">
    <pav:createdOn>2014-07-15 14:17:07 -0700</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7AB175A5-BD20-41A8-91C0-16D5DF981557"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> and its metabolites are eliminated via the urine and, to a much lesser extent, via the feces. As illustrated by a mass balance study of a single 1 mg oral dose of 14C-</ao:prefix>
    <ao:suffix>administered as solution to three healthy male volunteers, total recovery of radioactivity at 1 week was 84%, including 70% in the urine and 14% in the feces.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9AEC1350-B38C-47B6-8956-CA137F414E0B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-15 14:19:21 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9AEC1350-B38C-47B6-8956-CA137F414E0B"/>
    <ao:suffix> due to gender (whether corrected for body weight or not) or race.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Race and Gender Effects: No specific pharmacokinetic study was conducted to investigate race and gender effects, but a population pharmacokinetic analysis did not identify important differences in the disposition of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3601F178-6758-48FF-9A7C-218ADE3838A3">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/37773057-2593-4F89-A721-5933D9C73741"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/0A391966-16D3-4D0D-ACE8-794D85C254DC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4ACE7F4B-F57E-4417-9D3D-B18148E82D1E">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812ce85a0000</pav:createdBy>
    <pav:createdOn>2014-07-18 13:48:18 -0700</pav:createdOn>
    <pav:lastSavedOn>2014-07-18 13:48:39 -0700</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A7F21A3D-50B3-495E-884A-2C707B40C763</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:748BB253-1066-4977-91B2-35D8C6906790</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:BAF30A3C-A239-441C-8B34-9AC0EFD5ED8E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nab58d95e62b24227af3808cbbec530c8">
    <domeo:sets rdf:resource="urn:pddi:uuid:61CB1DA8-A104-4CBC-A3C7-E8898B001ECF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B3A2FE9F-B6D1-4F2D-8EB2-E8EA69DEC037">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/FE3925A8-8E3B-4F19-B5AB-889AF933932B"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/A04865E8-787E-4761-9CCC-B05D3C433330"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1cd4484c34ff4788a1e07d601d1dd58a">
    <domeo:sets rdf:resource="urn:pddi:uuid:2A85543D-D428-4598-B706-98C5E81EE7F2"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/37773057-2593-4F89-A721-5933D9C73741">
    <rdfs:label>sildenafil</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/136411</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:49FCC0DB-01A0-4D81-BC7E-4E5BA9BCB5A0">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/68169CA6-EEA6-4C01-BAD6-EB46996FEBC2"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/608E1DA9-C778-41BB-AF19-BEB866893872"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B3D0F9C9-FF6E-49C9-83A0-E46C52456757">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/1FC51968-9D21-44A1-9E75-B063933AF89E"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D3E8CE76-944F-40F2-AF66-51EBF76481A9"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:128DD788-D47E-4F4B-AD6D-B82C77B2F11B">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/0E179D30-7DE3-4459-A1C5-69426205C386"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/E0D97E91-2E7D-4932-BF6E-D14381A9B58A"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3E222580-6163-4407-B0C4-D0FC6BC85172">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D3C6A443-5788-4C8E-B4F0-D1A386132459"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/5D96455B-66E9-4C54-AEED-0EA46BBFE77A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5cac53e0585347c0b0bdd3b1e50e4054">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/1FC51968-9D21-44A1-9E75-B063933AF89E">
    <rdfs:label>risperidone</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:25F38526-D98C-49CE-873D-4D75248FDE0A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/83246816-D7FF-44ED-AF9B-04CDD30DDA0F"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D4B9A038-2770-4F91-9562-10173A7F2D34"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5165f3fe946a4004985133c00cd13833">
    <domeo:sets rdf:resource="urn:pddi:uuid:EE597E16-26DA-463C-A72C-1CA155D4131A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1AA7E714-DDFA-450C-A589-5EA4319B4691">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/5DE2E202-6D4F-4F94-96E7-9AC3DF505EFC"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/20605659-64E0-42A7-BDB2-B4AA5CBC2059"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/EDAB886F-D798-49C1-A0C4-ED5754179815">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>risperidone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F0D97621-1E50-45F0-BAA1-F81268B95E28">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluconazole</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F0AE4B90-85AC-42C7-B80E-8A27A4B6E455">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/595576F3-EC50-44DE-92FC-A9FC2111AFB6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F0D97621-1E50-45F0-BAA1-F81268B95E28"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:44695E00-3FB6-4D5F-B815-8E3CED70A3F6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3601F178-6758-48FF-9A7C-218ADE3838A3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8969333cf9ad45839f5627c08be5f100">
    <domeo:sets rdf:resource="urn:pddi:uuid:3C55FE98-387B-4122-94EC-ABF9B03F8B03"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:11E6A1FA-CF90-4170-B074-E4E3C8C8288D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-18 14:20:39 -0700</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:11E6A1FA-CF90-4170-B074-E4E3C8C8288D"/>
    <ao:prefix> alone at steady state. If anticholinergic effects are seen, the dose of </ao:prefix>
    <domeo:uuid>11E6A1FA-CF90-4170-B074-E4E3C8C8288D</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-50.txt.html</ao:hasSource>
    <ao:suffix> should be reduced.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>procyclidine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0409A564-F79B-4C83-9844-E9D65A082622">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/3A85B371-E653-4667-9F67-A08A4188190B"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/6B3BAFED-E091-412E-B7AB-A9DC8567890B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne6b5e89703e34cad809c689b3bc9b8fb">
    <domeo:sets rdf:resource="urn:pddi:uuid:65B1AF5D-CC49-4B9F-BACA-07320E9834D7"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbaa1a9bdc6384b75b8d0824504b16b4d">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbb3bf637709f4ecebbb5037ba78838fa">
    <domeo:sets rdf:resource="urn:pddi:uuid:9DE6AF1A-97A2-486C-8C39-E06C073F68E4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1FFE9DE2-04AD-4E77-8218-3B3AECFFDAA7">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/09FCD917-E332-4552-87D1-A1B73168DBA1"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/8A890D90-4AB4-4DD3-A520-217921B71116"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N88da97ef264a460a9efb9622919ea667">
    <domeo:sets rdf:resource="urn:pddi:uuid:A0073BE0-0C00-42AF-8C67-EADDD1F4519E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2A85543D-D428-4598-B706-98C5E81EE7F2">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:22097E52-FDC1-4F33-B19C-C5FBE58E871D"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/FA53ED44-367B-4D92-8F10-3F967033E9F0">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:22097E52-FDC1-4F33-B19C-C5FBE58E871D">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/2440B2BA-E703-439E-9D9D-F871F0C7006D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/4F35C443-9DBC-4CC5-A6B5-6AC7F37CD815"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4E844D74-03C0-41B6-B571-7703666D11BA">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/0F60CDA1-1EF3-48A8-B482-B23A5151B7B7"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F620DDE8-4C9B-4A5E-8FA3-1F42BF3BD963"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3BD41FAC-162E-4141-B15C-C7AD0CAF56A0">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B3D0F9C9-FF6E-49C9-83A0-E46C52456757"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na24e8708a58d43cb8b5041c765dc28d9">
    <domeo:sets rdf:resource="urn:pddi:uuid:4B8784BF-1D41-417E-A20C-C9B069D76FAA"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncc330724a0384cd1b0213dd420f7a7a5">
    <domeo:sets rdf:resource="urn:pddi:uuid:FC0B6A3C-A2F8-4ACD-9832-BF13C7065BAE"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N688de982838d496897f93f18e250c517">
    <domeo:sets rdf:resource="urn:pddi:uuid:523A8E6B-6F7F-4807-9852-CFA0940BB6CC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nad0f4c7de3ab4d7eb27614e2b129af81">
    <domeo:sets rdf:resource="urn:pddi:uuid:3363C787-8AF1-4899-903A-F4812DD65C36"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7e2b9f953ad64ab7a9585b40f92bdb85">
    <domeo:sets rdf:resource="urn:pddi:uuid:2BE90FDD-0DF8-4A0A-9B1E-B84B43D68582"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0daa61040cdc45c8ac598b175b7a935e">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncf9ea80f1b4c494fb4d5b7042d73e55e">
    <domeo:sets rdf:resource="urn:pddi:uuid:F68205D1-C26C-4CDF-8BC6-B801BDEFE695"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb3abecc880d44776a0136433625b58e0">
    <domeo:sets rdf:resource="urn:pddi:uuid:44695E00-3FB6-4D5F-B815-8E3CED70A3F6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4f2e2d3050024dbe8dbe521893735c39">
    <domeo:sets rdf:resource="urn:pddi:uuid:49AC02A4-8391-4B23-ADA4-A757C853CF17"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7290ceb2420f497d8a78e5411fe068db">
    <domeo:sets rdf:resource="urn:pddi:uuid:80054AD6-BA25-42F5-A7DD-E6D78015E9FA"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N963671e9e79045288f7a0196105f6283">
    <domeo:sets rdf:resource="urn:pddi:uuid:7A0B21EC-9B42-45A6-939E-5702AED058B8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc8416fc4f3ea4933a6f01a66f41df52c">
    <domeo:sets rdf:resource="urn:pddi:uuid:9A899E70-DA16-4FA1-A716-CEF8414FF84E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na1a527ecca324f69b45c2b668b1b37c1">
    <domeo:sets rdf:resource="urn:pddi:uuid:58CDDE97-D8B0-4830-BB7A-AAE058957A70"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbb0a682950984f9da10d32492de7e40e">
    <domeo:sets rdf:resource="urn:pddi:uuid:2C83F977-3681-48B0-B3C1-D84A60204AF3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7cf93db10c79492583d4c75f65654088">
    <domeo:sets rdf:resource="urn:pddi:uuid:74592674-5629-4C4B-8931-FFAA6830CB3B"/>
  </rdf:Description>
</rdf:RDF>
